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Abstract

The general aim of the work was to explore the design and synthesis
of n e w ligands which could have potential to mimic the action of
neurotransmitters at the dopaminergic or serotonergic receptor sites.

The first part of the project involved studies on the design and
development of medium-ring cyclophane-based potential prodrugs which
could be ultimately converted to an endogenous ligand, dopamine.

A

photochemical route to the w-cyclophane lactams was improved and
extended.

N e w chloroacetamides and derivatives were prepared for

photochemical investigation.

Photolysis of (40) gave rise to a new m-

cyclophane analogue (64) in good yield whose structure was confirmed by
X-ray crystallography. In addition, a range of other w-cyclophanes (65), (66)
and (67) were obtained from the photolysis of chloroacetamides (42), (44)
and (46) respectively. Photolysis of other new chloroacetamide derivatives
(52), (53), (54), (57), (58), (59), (60), (61) and (63), however, did not result in
the formation of m-cyclophane lactams. Benzazepinone analogues or nonheterocyclic products were obtained instead. Mechanistic pathways for the
products were indicated.

The usefulness of the photochemical approach to medium ring
heterocycles was further extended.

Photolysis of N-chloroacetamide

derivatives, 3-chloroacetyl-7,8-dimethoxy-4,5-dihydro-lH-3-bezazepin-2
(3H)-one (86) in aqueous acetonitrile gave lla-hydroxy-8,9-dimethoxy5,6,11,lla-tetrahydrooxazolo[2,3-b][3]benzazepin-2-(2H)-one (87) in good
yield. This representative of a new heterocyclic system could be converted
into the lla-ethoxy derivative (88) by recrystallization from ethanol. The
structure of (88) was confirmed by X-ray crystallography.

IX

W o r k w a s also conducted to develop methods to modify the
bridging chain of the m-cyclophane derivatives as part of the potential
prodrug studies. Further to this effort, some n e w chemistry associated
with approaches to fused indole systems from the m-cyclophane precursors
w a s uncovered.

Reaction of cyclophane lactams (8) and (64) with N -

bromosuccinimide

in the

presence

of

a

catalytic

amount

of

azobisisobutyronitrile led to n e w seven m e m b e r e d ring fused indolic
derivatives (104-112) via C-N intramolecular cyclisation. The reaction,
however, did not proceed with N-protected lactam functionality in the
bridging ring. Alternative C-C cyclisation in (8) by using boron tribromide
gave the previously reported imine (102) which, in turn, w a s used to
prepare the n e w tricyclic chloroacetamide derivatives (119), (120) and (121)
for photochemical investigation. Ultraviolet irradiation of the silylated
eneamide (121) afforded a benzopyran chloroacetamide derivative (122) in
low yield.

The second part of this project was involved with the design and
development of non-natural ligands for serotonergic sites and was carried
out under a scientific exchange program at the Universite of Orleans
(France). A n e w series of 3,4-dihydro-3-amino-2H-benzopyran derivatives
with various C5-substituents, (146), (143), (145), (137), (158), (159), (160), (141)
and (178) were successfully prepared. The substituents were introduced via
palladium-mediated cross-coupling reactions. The effect of these different
groups in the 5-position on the interactions with 5HTiA-and 5HT7-subtype
receptors was evaluated. In vitro studies, carried out by the pharmaceutical
company SERVIER indicated that these derivatives are very active agonists
while the ketones (145) and (160) are more potent than the lead
compounds at the serotonergic receptor sites. In an extension of this work,

X

an azido derivative, (69) was also synthesised for future photo-affinity
labelling of the above receptors.
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CHAPTER 1
General Introduction
1.1 Background
It has been shown, by histological studies, that there is always a gap
between the nerve ending and the target tissue, and if a signal from the
nerve is to reach the target this gap must be crossed.1'3 Observations of the
effects of poisons on animals led to the idea that nerves m a y communicate
with other cells by releasing small quantities of chemicals at their junction1
and, in fact, this is h o w a signal is transferred from one cell to another.
The first evidence for the actual release of a chemical in response to
activation of nerves was provided by Otto Loewi.1 H e showed that when the
vagus nerve to the heart of a frog was stimulated a substance wras released
into the perfusion fluid and the heart was slowed. If the perfusion fluid was
passed into a second heart which was free of nervous stimulation, then this
heart also was slowed. H e concluded that a chemical which was released,
after stimulation of the vagus nerve, slowed the heart. This chemical passed
into the perfusion fluid and acted to slow the second heart. To demonstrate
this process in m a n y organs and tissues, more refined techniques were
subsequently introduced.

The process has been called neurochemical

transmission,

chemicals

and

the

released

have

been

named

neurotransmitters.
Neurotransmitters act at targets close to the nerve from which they
are released. Neurotransmitters and hormones (which m a y also act at sites
quite distant from the site of release) are classes of information known as
primary messengers. These messengers are recognised by target cells via a
specialised mechanisms which allow transferring the message from the
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outer surface of the cell, into the cell. The recognition site is called the
receptor.
Receptors are, in fact, proteins found in the membrane which can
selectively bind messenger molecules and transduce the chemical signal into
a response in the target cell.
There are two types of precursor which are used as sources of
neurotransmitters. A transmitter m a y be synthesised in the nerve terminal
from which it is released. There is an active transport mechanism in the cell
membrane which carries the precursor from the extracellular space into the
nerve.

Tryptophan uptake into 5-hydroxytryptamine neurones is an

example of such a precursor- uptake system. Increased precursor availability
is the basis of some forms of therapy. In some neurones, the transmitter is
not synthesised in the nerve terminal.

A

larger precursor m a y be

synthesised in the nerve-cell body and then carried by axonal transport to
the nerve terminal. At the nerve terminal, there is an enzymatic process
which causes the large precursor to break d o w n into a smaller molecule
which is then released. It has been reported that peptides are brought to
nerve terminals via this mechanism. The only drugs which can modify the
availability of these precursors are actually the inhibitors of the axonal
transport.
The following criteria by which it is established that a substance can
act as a neurotransmitter have been reported.1
1) The substance must be synthesised and stored within the neurone from
which it is released.

Enzymes and substances must be present in the

neurone.
2) Calcium-dependent release must be shown to occur, with all transmitters,
following physiological stimulation of the appropriate neuronal pathway.
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3) A synthetic neuorotransmitter applied exogenously must mimic the
actions of the true transmitter in response to physiological or electrical
stimulation.

It must behave identically in every other regard to the

endogenous neurotransmitter.
4) There must be a rapid termination of the action of a released
neurotransmitter. The exogenously applied substance must be inactivated
by the same mechanism as the true neurotransmitter.

1.2 Neurochemical Transmission
A neurone is the basic unit of the nervous system and can be divided
structurally into three parts (1) the dendrites and the cell body, (2) the axon,
and (3) the axon terminals. The junction between two nerve cells is called a
synapse.
Neurones can be divided into three classes: Afferent neurones,
efferent neurones and interneurones. Afferent and efferent neurones lie
largely outside the skull or vertebral column while interneurones

lie

within the C N S .
The process of transferring information from one end of a neurone to
the other end (synaptic cleft) is electrical. The peripheral endings of the
afferent neurones have receptors. They are either specialised peripheral
endings of afferent neurones or separate cells intimately connected to
afferent neurone endings that convert the energy presented by the
environment 1 into the electrochemical energy of an action potential.
W h e n the receptor is activated by a stimulus (Figure 1), the
permeability properties of the receptor m e m b r a n e changes to permit the
m o v e m e n t of ions across the membrane. With the increased permeability
sodium ions m o v e into the cell and potassium ions from inside the cell
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move out to the plasma. This is because the concentration of potassium in
intra-cellular fluid is higher and the concentration of the sodium is lower
than in the extracellular fluid.
The effect of this increased membrane permeability is a net diffusion
of a small number of potassium ions and the simultaneous movement of a
large number of sodium ions. This is probably because the sodium is a
smaller ion than the potassium. The result is the movement of positive
charges into the cell leading to a decrease in membrane potential or
depolarisation2, since the inside of a resting neurone is about 70 m V
negative with respect to the outside.
The depolarisation initiates an action potential which then propagates
along the neurone axon to the axon terminal (presynaptic axon), which is in
conjunction with the interneurones cell body (postsynaptic cell). This is
where a synaptic transmission takes place (Figure 1.1). The information
carried by the action potential is then transmitted across the synaptic cleft bv
means of a chemical agent.
W h e n an action potential in the presynaptic neurone reaches the
axon terminal and depolarises the synaptic knob, small quantities of
chemical transmitters are released from the synaptic knob into the synaptic
cleft. These chemical transmitters are identified largely by histochemical
fluorescence techniques, as well as by

electron microscopy

and

spectrophotoflurometry3.
The transmitter then diffuses across the synaptic cleft and combines
with the reactive site of the postsynaptic cell lying right under the
subsynaptic membrane, and changes its permeability properties. Here the
effect of the chemical transmitter-reactive site combination is to increase the
permeability of the subsynaptic membrane to positively charged ions. The
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net m o v e m e n t of positive ions is into the neurone and that depolarises the

postsynaptic cell. This potential change is called the excitatory postsynaptic
potential (EPSP).

synaptic vesicles
carrying chemical transmitters

direction of conduction
of action potential

presynaptic axon

synaptic knob

\
postsynaptic cell

Figure 1.1 A synapse

However, some chemical transmitters can combine with the receptor
site of the postsynaptic neurone, causing an increase in the permeability of
the subsynaptic membrane to potassium and chloride ions, but the sodium

ion permeability is not affected2. Potassium ions, as discussed, diffuse into
the extracellular fluid. The inside of the neurone then becomes more
negative with respect to the outside. This increased negativity
(hyperpolarisation) is an inhibitory postsynaptic potential (IPSP). The
transmittance of the concerned information is then inhibited as a result of
feed back originating primarily from an increased effect of EPSP.
This type of feed back, in which the increased output of a system leads
to an inhibitory effect, is known as negative feed back (Figure 1.2).
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Figure 1.2 Components of a biological nervous control system

1.3 Ligands to Mimic the Action of Neurotransmitters
Transfer of information from the neurone to a neuro-effector tissue,
as discussed so far, is achieved by means of release of chemicals from the
nerve terminal. The chemical diffuses across the synaptic cleft between the
nerve terminal and the neuro-effector tissue and combines with the
recognition site (the receptor). This process of chemical neurotransmission
is susceptible to the action of drugs at several stages of the sequence and the
synthesis of such potential medicinal agents is the subject of this thesis.

1.3.1 Endogenous Ligand Derived from an Administered Precursor
During the past few decades, it has been repeatedly reported that the
c o m m o n l y used processes of delivering therapeutic agents to the sites of
their action within the body are generally inefficient and unreliable.4 M u c h
attention has been focussed on approaches which aim at enhancing the
efficacy and reducing the toxicity and unwanted effects of drugs by
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controlling their absorption, blood levels, metabolism, distribution and
cellular uptake.
Prodrug design comprises an area of drug delivery and consequently
an improvement in drug efficacy.4 This implies an efficient and selective
delivery and transport of a drug substance to the site of action. A prodrug is
a

pharmacologically

inactive

compound

which

undergoes

biotransformation, facilitated by enzymes specific to an area, in order to
release the active drug.4
Levodopa (L-Dopa) (2) is an example of a natural precursor of
dopamine (1) (an endogenous ligand at dopaminergic receptor sites) and is
currently a widely used prodrug for dopamine.

Dopamine (1)

Levodopa (2)

Deficiencies of dopamine ' ' in the brain are believed to be associated
with a number of the symptoms of Parkinson's disease (PD). In the last few
decades, a considerable number of investigations have been conducted for
increasing brain dopamine levels in patients suffering from this debilitating
disease.
Dopamine is believed to act as a neurotransmitter at certain corpus
striatal synapses that are concerned with inhibitory effects in the
nigrostriatal pathway in the central nervous system (CNS) 3 .
Compound

(1) itself cannot be administered as it is incapable of

crossing the lipid-like blood-brain barrier (BBB). If exists primarily in its
protonated form under physiological conditions and that gives rise to the
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observed high polarity of the molecule. The p K a values3 for the hydroxyl
and amine functionalities are 8.9 and 10.6 respectively. The other reason
w h y it cannot be used is due to the "first pass" effect5 which results in the
loss of the compound

due to the metabolism of the drug in the

gastrointestinal tract or liver in its initial passage.
It is currently believed that acetylcholine, unlike dopamine, is an
excitatory transmitter for neurones running between the substantia nigra,
the pallidum and corpus striatum in the brain. In Parkinsonism there is an
imbalance between the two transmitters, dopamine and acetylcholine. The
dopaminergic input to the corpus striatum is deficient whereas the
cholinergic input (level of acetylcholine) remains the same. This imbalance
explains3 any apparent increased effect of acetylcholine and rationalises the
former empirical use of anticholinergics in parkinsonism.
It is worthwhile to note here that there are three mechanisms 3 by
which some drugs cause a relative dopamine- acetylcholine imbalance in
the C N S . These are believed to be:
(1) by depletion of dopamine from intraneuronal stores as is the case with
reserpine
(2) by rendering the dopamine receptor less accessible to dopamine, as with
the neuroleptic agents such as the butyrophenones
(3) by increasing acetylcholine levels as occurs with the cholinesterase
inhibitor physostigmine.

1.3.1.1 Pro-drugs for Dopamine
The pro-drug approach has a number of advantages over using the
active compounds directly. A m o n g these are the more aesthetic reasons
such as taste and patient acceptance of the treatment. Other more
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physiologically important reasons include the optimisation of drug delivery
and consequently an improvement in drug efficacy as discussed earlier.
Levodopa, as pointed out in Section 1.2, is an example of prodrug for
dopamine and is used in the treatment of Parkinson's disease. Levodopa
has the ability to cross the B B B by the active transport mechanism for amino
acids. D o p a m i n e is then formed from Levodopa by the cytoplasmic enzyme
aromatic L-amino acid decarboxylase. However, in m a n , dopa decarboxylase
activity is greater in the liver, heart, lungs and kidneys than in brain5. This
fact necessitates the co-administration of peripheral decarboxylase inhibitors
such as carbidopa (3), benserazide hydrochloride (4) and M A O (mono amine
oxidase) inhibitors.

This

consequently increases the proportion of

Levodopa that crosses the BBB.

OH

NH2.HC1

OH

HO.
HO ^ N ^
(4)

L-Dopa treatment can have a n u m b e r of undesirable side-effects
associated with it, both in the long term and short term7. It has been found
that one of the most c o m m o n side effects of L-Dopa therapy is gastric upset
with nausea and vomiting3'8. Also the effectiveness of the treatment in
controlling the s y m p t o m s of Parkinson's disease decreases with time.9
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O n e approach which is widely used 1 0 is the combination of the prodrug, L-dopa with an agonist treatment such as bromocriptine. This allows
for smaller amounts of L-dopa to be administered which can lead to a
reduction of the long term side effects.
Overall, there is still a need for other c o m p o u n d s which can act as
precursors of dopamine after uptake into the C N S .

Another approach

which is being investigated is the development of slow release dopamine
pro-drugs. 1 1

Most of these pro-drugs have large ester or amide groups

which increase lipid solubility, for example in (5) and (6). The c o m p o u n d s
then b e c o m e capable of entering the brain and there are biotransformed
ultimately to dopamine (1). It w a s reported11 that (6) produced prolonged
brain dopamine levels due to lipophilic absorption followed by slow release
of L-dopa. Direct evidence for the brain-specific delivery of dopamine from
the redox chemical delivery system (5) w a s also reported.11

H
jv^

(CH3)3CCOCHQ^/"

/

^

1. Redox

( T V . ) 2. HydrolysisD o P a m m e
N

(CH3)3CCOCT

CH3

(5)

Hydrolysis

Dopamine
(6)

O n e of the problems associated with having large groups on the
prodrugs is that u p o n the enzymatic hydrolysis large fragments are released

1 1

at the site of actions which are undesirable. Reducing the size of amide or
ester group in a way that the lipid solubility of the prodrug molecule would
not be dramatically decreased was thus of interest.
Work carried out from the late 1960's12-17 in relation to the synthesis
of ten membered ring lactams (cyclophane type) from haloacetoamides (7 for
example) led to the idea that these compounds (eg. 8) might have potential
to be used for developing slow release pro-drugs for dopamine. The isomers
(9), (10) and (11) were also obtained from the photolysis of (7) (Scheme 1.1).

(H)

(10)
Scheme 1.1

Demethylation of compound (8) to give the hydroxy cyclophane (12)
has also been reported.17'55

12
O H

^4VN\

HO-^J
(12)

A n alternative route to (12) w a s via demethylation of silyloxv
cyclophane (14) which, in turn, was obtained via the photolysis of N-[2-(4-tbutyldimethylsilyloxy-3-methoxyphenyl)ethyl] chloroacetamide (13) as
shown in Scheme 1.2.17

H
H

3

C O

\^\^\^-

N

^ ^CH2C1

rrr

hi) —

•

t-C4H9(CH3)2SiO

(13)

t-C4H9(CH3)2SiO(14)

Scheme 1.2

It is proposed that the cyclophane-based compound (12) might be able
to cross the blood-brain barrier, since (compared to that of dopamine) the
lipophilicity of the molecule would be significantly increased by blocking
protonation of the nitrogen functionality and ionisation of one hydroxyl
group. The amine and one phenolic hydroxyl groups are tied up as an
amide and ether group respectively by the use of the c o m m o n bridging
chain. The basicity of the amine functionality is greatly reduced by being
part of a lactam and at the same time the phenolic ether derivative formed
would be less polar than the hydroxyl group. At the site of action, the
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compound m a y then be converted to dopamine as a consequence of ring
cleavage by enzymatic processes.
To test this hypothesis, preliminary investigations were carried out

indicating that this cyclic lactam (12) appeared to be stable when subje

basic or enzymatic hydrolysis (amidase). It was thus proposed that if th

bridging chain was modified by introducing certain substituents, a two s

cleavage process might be possible resulting ultimately in dopamine (1).

The first stage was to include ester hydrolysis via an esterase, and rin

opening of the resultant ketal to afford an amide, which now not being p
of the ring, may be more readily hydrolysed enzymatically in the second

stage to give (1). For example, introducing an acyloxy group in the chai

adjacent to the ether oxygen, probably via a photochemical approach, cou

give access to developing a new potential pro-drug for dopamine as shown
in Scheme 1.3.

(H3C)

H20

>—^llc3f-

H
esterase

HO.

RO

/V^

amidase

HO,

NH,

RO'
R = H dopamine (1)
Scheme 1.3
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1.3.2 Design and Development of Non-Natural Ligands
There are a considerable number of exogenously applied substances
which can mimic the action of neurotransmitters and initiate a response in
the neuroeffector tissues. They are referred to as agonists. Tissues generally
have a maximal response which cannot be exceeded; substances which can
initiate the maximal response are known as full agonists. A substance
which can initiate a response in the tissue but which cannot initiate the
maximal response is known as a partial agonist or stimulant. Substances
which prevent an agonist from initiating a response are k n o w n as
antagonists or blockers. Some antagonists have a limited capacity to initiate
a biological response. This property of antagonists is referred to as partial
agonist activity.

1.3.2.1 Dopamine Receptor Agonists
Direct stimulation of dopamine receptors by some agonists has been
used in the treatment of Parkinson's disease.

The drugs used for

stimulating the dopamine receptor directly have a potential advantage over
Levodopa, in that their effect is independent of striatonigral degeneration;
Levodopa depends on the remaining neurones to decarboxylate Levodopa to
dopamine. This realisation led to the development of dopamine agonists.
Dopamine has a neuronal inhibitory effect by binding to the receptor
site of the receiving neurone (postsynaptic neurone).

The molecular

configuration of the receptor site allows only a particular transmitter
molecule to fit the receptor precisely. Therefore receptors embedded in the
cell membrane are selective in their ability to bind to the transmitter for
which they are designed.

1 5

If a drug has a molecular configuration complementary to that of an
endogenous neurotransmitter, it m a y be able to bind to the membrane
receptor and substitute for the neurotransmitter's action. Such drugs, as
discussed earlier are known as receptor agonists. A n example of a drug in
this group is apomorphine (15).3'8

CH3
(15)

In apomorphine, ring A and atoms 1, 2 and 3 produce a substructure
similar to that of dopamine and it is this part of the molecule which is
thought to interact with the dopamine receptor.
Bromocriptine is another example of a drug in this class and it is
widely used in the treatment of Parkinson's disease. There are number of
advantages to the agonist approach, such as high receptor selectivity, small
dosage required and the ability to by-pass the damaged pre-synaptic neurone.
However, rapid introduction causes nausea and vomiting10. Postural
hypotension

is also produced

in m a n y

patients

as a result of

bromomcriptine treatment.
It is notable that stimulation of dopamine release m a y be possible by
using agents such as amantadine (16) that can release dopamine from
peripheral neuronal storage sites.3 Amantadine is a primary amine with a
p K a of 10.8, more basic than the amine group of dopamine (pK a 10.6).

16

Therefore at physiological p H (7.3) it would be in the protonated form, but it
is believed that the cage-like structure of amantadine increases, its
lipophilicity, enabling it to pass through the barrier.

NH2
HC1

X>4
(16)

Furthermore, with regard to treatment of Parkinson's disease, attempts have
been made to increase the central anticholinergic effects by using a number
of naturally occurring and synthetic anticholinergic agents. Examples of
naturally occurring agents are atropine and scopolamine3. Benztropine
mesylate (Cogentive) and biperiden hydrochloride (Akineton) are examples3
of the synthetic agents. Unfortunately there are troublesome side effects
such as dry mouth, blurred vision, constipation and urinary retention.3

1.3.2.2 Serotonin Receptor Agonists
Serotonin (5-Hydroxytryptamine, 5H.T) is a neurotransmitter in the
central nervous system and in the plexus of the gut. It is found in high
concentration in the enterochromafin cells in the lining of the alimentary
canal and in the blood platelets.1 5-HT is a monoamine and m a n y features
of its synthesis, storage, release and inactivation are similar to the processes
occurring in tissues which synthesise the other monoamines such as
dopamine, noradrenaline and adrenaline.1
5 H T (19) is made from the aromatic amino acid 5-hydroxytryptaphan
(5-HTP) (18) which, in turn, is derived from hydroxylation of the L-
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tryptophan (17) by the enzyme tryptophan hydroxylase as shown in Scheme
1.4.

tryptophan
hydrolase

HO

o2
tetrahydropteridine

L-Tryptophan (17)

5-hydroxytryptophan (18)
pyridoxyl
phosphate
L-aromatic
amino acid
decarboxylase

NH,
HO.

5-Hydroxytryptamine (19)
Scheme 1.4

The dysfunction in serotoninergic systems of the brain has been found

to be a most probable cause of illnesses such as anxiety, depression and pani
disorders.18'19 Therefore, compounds with selective actions on different
serotonergic receptors may prove to have clinical utility, besides their use
important pharmacological tools. Apart from serotonin itself, several other
compounds have served as templates for the design of potential new drugs.
It is important here to briefly review 5HT receptors prior to discussing

the use of seretonin agonists. 5-HT receptor classification has been reviewed
several times over the years20'24 since the first attempt by Gaddum and
Picarelli18. The pharmacology, molecular biology and medicinal chemistry
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of 5 H T receptors have also been extensively reviewed.25-31

Until now,

classification of receptor subtypes has been made by differentiation of the
action of more or less selective drugs. The amino acid sequences of most of
the previously known receptor subtypes have been determined and cloned.
The 5-HT receptors can first be divided into the two superfamilies, Gprotein coupled receptors and ligand gated ion channels. The G-protein
coupled 5-HT receptors include the subtypes of the 5HTi, 5HT 2 , 5HT4, 5HT5,
5HTg and 5HT7 receptors. The 5HT3 receptor is a ligand gated ion channel.
8-Hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) (20), whose
synthesis was reported by Arvidsson and co-worker32 in 1981, has been
found to induce the 5 H T behavioural syndrome and decrease the cerebral
5 H T synthesis in the rat, indicative of central 5-HT receptor agonist
properties.

8-OH-DPAT (20)

It has been demonstrated33'34 by in vitro radioligand binding studies,
that 8-OH-DPAT is a potent and selective agonist at the 5HTi subtype
receptor,

5HTLA-

This was supported by in vivo studies.37'38 The cloning

35,36 0 f this receptor indicated that the protein is a single subunit and consists
of 421 amino acids arranged with seven transmembrane helices.35
Hacksell

and

co-workers 39 have prepared

a series of 2-

(dipropylamino)tetralin derivatives (DPAT) in which the C8 substituent is
varied. They pharmacologically evaluated and explored the importance of
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the C 8 substituent in the interaction of 2-aminotetralin-based ligands with
serotonin

(5-HTIA)

receptors. Examples of substituents that they introduce

are triflate, acetyl, phenyl, phenyl carboxy, butyl carboxy, methyl, meth

ester, carboxylic acid, primary amide, and cyano groups. The affinity of
compounds for the

5HTIA

receptor was evaluated by competition

experiments with [3H]-8-OH-DPAT in rat hippocampal and cortical tissue.
addition, the compounds were evaluated for central 5-HT and dopamine

receptor stimulating activity in vivo by use of biochemical and behaviou

assays in rats. They concluded that a number of derivatives have moderat
to high affinities (Kj values range from 0.7 to 130 nM) for

5HTIA,

with n

apparent dopaminergic activity. This group of compounds, being similar i

profile to the 8-OH-DPAT, were described as agonists. They produced a fu
blown 5-HT syndrome in normal as well as in reserpine-treated animals,
inhibit the cage-leaving response, and decreased body temperature and 5
turnover.
In recent years, there has been interest in various non-

benzodiazepine-based treatments of anxiety. Buspirone (21), for example,
has been found to be a potent ligand at

5-HTIA

subtype receptor40, but wit

rather low selectivity verses D2 receptors. However, more selective liga
such as gepirone (22) and ipsapirone (23) have been obtained.41"44
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/=\r-\
\

R=

//—\

N-(CH2)4-R

Buspirone (21)

R=

Gepirone (22)

R=

Ipsapirone (23)

Development of such therapeutic agents that exhibit w e a k or
moderate activity at D2 receptor binding sites and display high affinity for
HTIA

receptor sites has been pursued further which led to synthesis of 3,4-

dihydro-3-amino-2H-l-benzopyran derivatives.45"47 Amongst them, 5-MeODPAC [5-methoxy-3,4-dihydro-3-(di-n-propylamino)-2H-l-benzopyran] (24),
which is closely related to 8-OH-DPAT (20), acts in the nanomolar range at
5HTIA

receptor sites and very poorly recognises D2 receptor sites in rat brai

membranes.

5 - M e O - D P A C (24)
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Studies on the modification of amino substituents and the length of
the alkyl side chains of this c o m p o u n d have been conducted also by Podona
and coworkers.45 They found that the best compounds (25, 26, 27, 28) possess
imido or sulfonamideo functional groups with a preferential length of four
methylenes for the side chain.

n=4 (25)

•(CH2)n.

n=3 (26)

OCHo

O
N — ( C H 2 ) n — S-

6cr

o

\

//

CH,

n=4 (27)
n=2 (28)

These c o m p o u n d s proved to be full agonists, with (25) being the most
potent and selective ligand at the

5HTIA

subtype receptor.

1.4 A i m s of the project
The aims of this project were to investigate the design and synthesis
of n e w ligands which could have potential to mimic the action of
neurotransmitters at receptor sites. In particular, the first aim w a s to
develop n e w c o m p o u n d s which could be ultimately converted to an
endogenous ligand, dopamine. M e d i u m ring cyclophane-based potential
pro-drugs derived from the photolysis of aromatic chloroacetamides, as
discussed in Subsection 1.3.1.1, were the focus of the investigation.

The

specific aim for this part of the project w a s , thus, to investigate the
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preparation of new chloroacetamide derivatives and their photochemical
conversion to m-cyclophanes. It was also planned to study the chemistry
m-cyclophanes in order to develop methods to modify the bridging chain.
The second major aim of the project was to design and develop

selective non-natural ligands for serotonergic sites. As described earli
recent years attention has been focused on using non-benzodiazepine
compounds as agonists at serotonin receptor sites. Structurally related

benzopyran derivatives (24), (25) have attracted much interest in this a

The aim of the work described in the second part of this thesis was to s

the effect of various C5 substituents of (24) and (25) on interactions w
5HT receptors

(5HTIA

and 5HIV subtypes). Furthermore, the intention was

to synthesise a DPAC-based ligand for photo-affinity binding of these
receptors.
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CHAPTER 2
Synthesis of M e d i u m Ring Lactam-Containing ra-Cyclophanes
2.1 Introduction

2.1.1 General Points
In the first part of this introduction a review of the synthesis of
different size bridged m-cyclophanes will be presented. Several examples of
classical methods previously described in the literature are given. Attention
is then focused on the synthesis of ten-membered ring m-cyclophanes via
the photochemical approach. It was expected that the photolysis of new
aromatic chloroacetamides would afford, as indeed had been the case, the
analogous ten-membered lactam-containing m-cyclophanes.
In the second part, structural modifications to induce pharmacological
activity will be discussed. Furthermore, it was hoped that a judicious choice
of substituents for the aromatic chloroacetamide derivatives would facilitate
a high-yield photocyclisation entry to the target medium-ring heterocycles.

2.1.2 Historical Aspects
Notable progress has been made in the last few decades in the
synthesis and properties of compounds containing a benzene ring bridged at
the m-or p-position ([n]metacyclophanes and [njpracyclophanes).
A variety of routes to prepare m-cyclophanes have been described in the
literature. For example, the coupling of Grignard reagents with dihaloaromatic compounds in the presence of a catalytic nickel-phosphane
complex afforded nine to thirteen and fifteen-membered ring m-cyclophanes
as shown in Scheme 2.148
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YMg-(CH2)n-MgY
CI

•

X=N;
n=6-10, 12
X=CH; n=8-10, 12

(CH 2 )/

Scheme 2.1

The short bridged [5]-m-cyclophane (30) was obtained from (29) by the
following elimination rearrangement route (Scheme 2.2)

(CH2)5

48

t-BuOK

DMSO

Scheme 2.2

As shown in Scheme 2.3, [7]-m-cyclophane (32) has also been generated
by treatment of [7]-p-cyclophane (31) with fluorosulfonic acid and ptoluenesulfonic acid in benzene.49

H+

Scheme 2.3

Markl

has reported the rearrangement of [10]-o-cyclophanes that

afforded [10]-m-cyclophanes (Scheme 2.4, R=alkyl groups).50
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(CH

2no

A1CL

cs 0
Scheme 2.4

To date the shortest bridge in a 1,3-position, represented by the
[4]pyrrolophane (34), has been achieved from the thermal rearrangment of
(33) (Scheme 2.5) as reported51 by Patterson and co-workers.

C
N

(CH2)4

(33)
Scheme 2.5

Furthermore, reaction of dithia c o m p o u n d s with dihalogenated arenecontaining compounds (eg. 35) gave ten to sixteen-membered ring mcyclophanes as described52'53'48 by Vogtle and co-workers (Scheme 2.6).

r^^

Br

(35)

OH

*
>

SH

SH

(CH2)n-

•Kt

n=3-9
Scheme 2.6
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The ten-membered ring cyclophane, n=3 above, was originally

obtained, quite unexpectedly, in 18% yield by adding the dibromide (

solution of the bis-dithiane (36) and n-butyllithium in tetrahyrofur

(36)
Ten-membered lactam-containing m-cyclophanes, which are of

particular interest in this work, have been prepared via a photochem
approach. Witkop and co-workers14 reported the isolation of the mcyclophane derivative (8) in low yield (12%) from the photolysis of

dimethoxyphenyl)ethyl]chloroacetamide (7); analogous products were a

obtained in generally low yield from other related photolyses as not

review by Sundberg.12 However, the silylated m-cyclophane (14) derive

from the photolysis of the chloroacetamide (13) was isolated in a be
(31%).17'55

NHCOCH 2 Cl

H 3 CO.

NHCOCHX1

H3CO.

(CH3)3C((CH3)2)SiO

H3CO

(7)

HaCO^ 12

(13)

n

(8)

(CH3)3C((CH3)2)SiO

(14)
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2.1.3 Structural Modifications
Cyclophanes (bridged aromatic compounds) represent an important
class of synthetic receptor (hosts) in molecular recognition. All types

substrates (guests) from inorganic and organic cations to neutral molecu
have been complexed by tailor-made cyclophanes.56 In these association
processes, all known modes of intermolecular binding interactions have
been used. A majority of the crown ethers and cryptands and all of the
spherands and cavitands for cation complexation are cyclophanes. In a

variety of studies on biomimetic research,56 the nature of weak non-cova
interactions in biological systems and mechanistic details of enzymatic
reactions have also been modelled by using cyclophanes without any
receptor properties.
m-Cyclophanes, have been used not only for modelling of biological

interactions and processes but also they are of continuing interest with

regard to structure modifications for inducing pharmacological activity.
notable that some m-cyclophanes are naturally occurring compounds. One

of the simplest natural phanes is (37) which is also available by synthe

37

As the search for biological properties of m-cyclophanes continues,
approaches to design some4 m-cyclophanes which might have potential as
pro-drugs for dopamine were pursued (See Subsection 1.3.1.1).
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O n the basis that the lactam-containing m-cyclophane skeleton m a y be
utilised for developing new potential pro-drugs , it was decided to seek ways
to increase the photochemical yield of this system from chloroacetamide
precursors.
A further aim of the work presented in this chapter was to investigate
the power of the photochemical approach to synthesise n e w lactamcontaining ten-membered ring m-cyclophanes with different substituents in
the bridging chain, including the 7, 6, 4 and 3 positions (compound 8). For
example, introducing an acyloxy group at the 3 position, via a photochemical
approach, could ultimately give access to a n e w potential pro-drug for
dopamine as shown in Scheme 1.3 (Subsection 1.3.1.1). Hence, a wider range
of N-chloroacetamides and derivatives needed to be investigated for
photolysis.

2.2 Synthesis of Precursors for Photolyses
For the purposes discussed above, a number of different N monochloroacetamides, di and trichloroacetamides, azidoacetamides, fluoro
and bromoacetamides were successfully prepared in generally high yields for
later photochemical investigation.

2.2.1 Preparation of N-Chloroacetamide Derivatives

2.2.1.1 Preparation of Methyl 2-chloroacetamido-3-(3,4-dimethylphenyl)
propanoate (40)
Introducing a methyl ester group at the 7 position of the lactamcontaining m-cyclophanes would provide an essential skeleton for these
compounds to be used for designing potential pro-drugs for L-dopa, the
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natural precursor of dopamine. Hence, it was necessary to synthesise (40) for
photochemical investigation. The effect of the methyl ester substituent
the amide chain of the chloroacetamide on the photochemical yield of the
ten-membered cyclophane system was also to be studied.
The chloroacetamide (40) was derived from commercially available L-

dopa. The L-dopa was first esterified using methanol and hydrogen chlori

gas to afford (38) (See Scheme 2.7). The methyl ester was then reacted w

chloroacetyl chloride, using triethylamine as a base, to give the dihydro
chloroacetamide derivative (39). The methylation of (39) with
diazomethane in a mixture of methanol and diethyl ether led to formation
of the dimethoxy chloroacetamide derivative (40) in good yield (75%).

CH3OH/H
COOH
HO

NH,.HC1

HO.

NH,

HO.

4

COOCH,
90%

HO
(38)

L-Dopa (2)

85%

>^ ^^
H3CO.

S^

^NHCOCH2Cl

CH2N2/CH3OH/
CH

Y Y X
(25)2°
H3CO sKJ
H 'C°°CH3 ^ 75%

ClCH2COCl/TEA/
THF

HO.

NHCOCH2Cl
COOCH.

HO
(39)

(40)
Scheme 2.7

The structures of both chloroacetamides (39 and 40) were confirmed
spectroscopically. A distinctive feature in the iH-nmr spectrum of (39)

two-proton singlet at 8 4.06 assigned to the hydrogen atoms of the methy
group adjacent to the chlorine atom. In the ^-nmr spectrum of (40), in

contrast, a geminal coupling ascribable to the protons of the correspond
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methylene group was observed. The two sets of doublets, as a result of the

geminal coupling, were centred at 8 4.02 and 4.06 with a coupling consta
15.2 Hz. The mass spectrum confirmed the presence of one chlorine atom.

The composition of (40) was further supported by elemental microanalysis

2.2.1.2 Preparation of N-[2-(3.4-Diethoxyphenyl)ethyl1 chloroacetamide (
If was also desirable to study the effect of the 3-substituent of
chloroacetamides on photocyclisation process. It was hoped that the
irradiation of a chloroacetamide derivative with an ethoxy instead of a
methoxy group at the 3-position would result in the formation of a more
stable radical (see Subsection 2.3.2). Hence, a higher yield of the mcyclophane with a 3-methyl substituent might be obtained. Therefore,

chloroacetamides (42) and (44) (See Subsection 2.2.1.3) were also synthe
Scheme 2.8 shows the synthetic steps involved to prepare the
diethoxychloroacetamide (42).

H s C O O ^ ^ \ / NHCOCH2Cl
1
H 3

c o ^ ^

BB,

"3
84%

HO v ^j-s^ ^ ^

(7)
H

\

A

/

HOx
V

Q

^NHCOCH,Cl

(41)

NH2.HC1

diethyl sulphate/
methyl ethyl ketone/
reflux; 88%

ClCH2COCl/
NaOH/
THF; 80%

\f

Dopamine hydrochloride

CH 3 CH 2 O v

^ ^ ^

r^i

CH 3 CH 2 0^

m

(4

Scheme 2.8

NHCOCH 2 Cl

3 1

Boron tribromide proved to be an efficient reagent to demethylate N[2-(3,4-dimethoxyphenyl)ethyl]chloroacetamide

(7), resulting in the

dihydroxychloroacetamide (41). This latter compound could also be obtained
from the reaction of dopamine with chloroacetyl chloride in tetrahydrofuran
using sodium hydroxide (2M) as a base. The diethylation of (41) was carried
out in good yield using diethyl sulphate in refluxing methyl ethyl ketone.
The most salient features of the x H-nmr spectrum of (42) were the two
sets of three-proton triplets centred at 8 1.43 and 1.46 indicating the
incorporation of aromatic ethoxy groups. In addition, two-proton quartets,
centred at 8 4.06 and 4.09, were ascribed to the methylene hydrogens adjacent
to the methyl groups. Both the 13 C-nmr and mass spectra were consistent
with the proposed structure. Furthermore, elemental microanalysis for this
compound supported its formula.

2.2.1.3 Preparation of N-[2-(3-Ethoxy-4-methoxyphenyl)ethyl]chloroaceta
(44)
For the same reason described above the synthesis of (44) was also
undertaken. This compound was obtained from the ethylation of N-[2-(3hydroxy-4-methoxyphenyl)ethyl]chloroacetamide (43) with diethyl sulphate
in refluxing methyl ethyl ketone (Scheme 2.9). The amide (43), in turn, was
prepared from a standard reaction of N-2-(3-hydroxy-4-methoxyphenvl)
ethylamine (43a)64'65 with chloroacetyl chloride in a mixture of aqueous
solution of sodium hydroxide and tetrahydrofuran.
In the -^H-nmr spectrum of (44), a three-proton triplet and a twoproton quartet, centred at 8 1.46 and 4.09, respectively were ascribed to the
methyl and the neighbouring methylene groups respectively.
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NH2.HC1

HO.

D ClCH2COCl/
NaOH/THF

1

2)NaOH
3)HC1
88%

H3CO'
(43a)

NHCOCH2Cl

HO
H3CO

diethyl sulphate/
methyl ethyl ketone,
reflux

NHCOCH2Cl

CH3CH20^_^
H3CO
(44)

Scheme 2.9

2.2.1.4 Preparation

of N-Methyl-l"2-(3.4-dimethoxyphenyl)ethyl1

chloroacetamide (46)
To study the effect of an N-methyl group on the photochemical yield

of the m-cyclophane system, the title compound (46) was synthesised. A n

6-substituted lactam-containing m-cyclophane could therefore be obtained

a result of the photocyclisation of (46). Following the general procedur
the preparation of chloroacetamides, the secondary amine, N-methvl

homoveratrylamine (45), was reacted with chloroacetyl chloride to afford
in good yield (Scheme 2.10).

NHCH,

H3CO
(45)

ClCH2COCl/
K2C03/
DCM
•
-%.
94%
H3CO
Scheme 2.10

COCH2Cl

(46)
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In the ^-H-nmr spectrum of (46), the two singlets at 8 2.95 and 3.01,

which integrated overall for three protons, were attributed to the me
group on the nitrogen, the observation of two N-methyl signals being

result of hindered rotation about the amide bond. The mass spectrum o
confirmed the presence of one chlorine atom.

2.2.1.5 Preparation of N-[2-(3-Pivalylcarbonyloxymethoxy-4-methoxyph
ethyl]chloroacetamide (52)

As described in the introduction, preparation of an (acyloxy)alkyl et

group in the chloroacetamide precursor wTas quite desirable. This woul
further expand the study of the effect of the 3-substituent on the

photocyclisation of chloroacetamides. (Acyloxy) alkyl a-ethers of phe
have been reported to be formed in good yield by alkylation with

(acyloxy)alkyl a-chlorides or iodides in acetone in the presence of p

carbonate.57"59 Either partial or complete acylation rather than alkyl
oxygen can take place if the iodo compound is not used.
Complete acylation was indeed the case when (43) was reacted with

commercially available chloromethyl pivalate resulting in (47) (Schem
2.11).

A^'

(H3C)3C^^O
HC

V ^\ .XV^ .NHCOCH2Cl

HoCO
L
3

v

(43)

(CH3)3CCOOCH2Cl/
O ^ ^ \ X \ / NHCOCHK2C03/acetone
•
60%
H3CO
(47)

Scheme 2.11
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M I N D O / 3 S C F M O calculations, reported by Border and coworkers,57

on the carbocation (48a) generated from the ionization of the representa
halide (48) showed that significantly more positive charge was found to
reside on the carbonyl atom than on the alkyl halide carbon atom.

?i ° O

II
H3C
5

C—0-CH 2 Cl — - • H 3 C-C-0-CH 2

II
+
M

^HC_e

OTTTCH.
8+ "

(48) (48a) (48b)

Based on this observation, it was not surprising that the acylated (47)

rather than an alkylated product was isolated from the reaction of the p
(43) with chloromethyl pivalate. According to Border and co-workers, an

excellent yield of the desired alkylated product should be achievable wh
the leaving group is changed to iodide. However, when (43) was treated
with iodomethyl pivalate, partial acylation occurred with the alkylated
acylated products distributed in a ratio of approximately 3:2.
It was thought that the iodide leaving group, after release from the

iodomethyl pivalate, may act as a nucleophile which displaces the chlori

atom of the chloroacetamide (52), setting up an equilibrium (Scheme 2.12)
The release of chloride ions could subsequently result in formation of
chloromethyl pivalate also at equilibrium, as shown in Scheme 2.12. The

presence of a small amount of chloromethyl pivalate in the reaction mixt

could, in turn, lead to formation of some of the acylated chloroacetamide
product (47).
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(H3C)3C

NHCOCH 2 I

H3CO

H 3 CO'
(52)

(51)

O

O

(H 3 C) 3 C—C—O — C H 2 I

(H3C)3C—C—O—CH2C1

+

Chloromethyl pivalate

Iodomethyl pivalate Q\

Scheme 2.12

It is notable that the acylation o n the phenolic group of the
chloroacetamide seemed to proceed at a much faster rate (as observed by thin
layer chromatographic analysis of the reaction mixture during the course of
the reaction) than alkylation. As this causes further release of chloride ions,
the concentration of chloromethyl pivalate is therefore retained by reestablishing the equilibrium.
Efforts to trap the iodide ions by silver nitrate did not improve the
yield of the alkylated product. All the products including the acylated
iodoacetamide (49) were isolated and characterised by their nmr and mass
spectra (see later in this Subsection).

NHCOCH 2 I

H3CO

(49)
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Though there are other factors involved in the product distribution
obtained from the reaction of (acetyloxy)alkyl a-halides with phenols such as
the nucleophilicity of the phenoxide and the ability of the electrophile to
stabilize a carbocation, it w a s decided to carry out the reaction of (43) in a
chloride ion free environment. This indeed prevented the acylation since
no chloromethyl pivalate could be formed and only the alkylated product
was obtained (See Scheme 2.13).

NHCOCH 2 Cl

HO.

NHCOCH^I

HO.
Nal/ acetone
H3CO
H3CO

95%

(43)

(50)

(CH3)3CCOOCH2I/
K2C03/acetone
72%
(H3C)3C

(H3Q.

LiCl/
NHCOCH 2 Cl

^

A g N

°

Q

r^1

3

O O^

NHCOCH 2 I

;>

91%
H3CO

H3CO

(52)

(51)
Scheme 2.13

The above w a s accomplished by converting (43) to the iodoacetamide
(50) in the presence of sodium iodide in acetone followed by a reaction with
iodomethyl pivalate which gave the alkylated product (51) in good yield as
shown in Scheme 2.13. Conversion of (51) to the required chloroacetamide
(52) w a s then achieved using a large excess of lithium chloride and one
equivalent of silver nitrate in acetone.
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The most noticeable feature of the 1 H - n m r spectrum of the alkylated
product (52) was a two-proton singlet at 8 5.77, assigned to the hydrogen
atoms of the OCH20 moiety whereas this did not appear in the iH-nmr

spectrum of the (47) or (49) arising from acylation. The two-proton singlet at
8 3.78 and the nine-proton singlet at 8 1.20 were attributed to the methylene
group adjacent to the iodine atom and the tertiary butyl group respectively.
Evidence for the displacement of iodine with chlorine was a relative
downfield shift in resonance frequency of adjacent protons compared to that
of the starting iodoacetamide. The signal generated by the methylene
protons adjacent to chlorine was downfield by 0.24 ppm. The structural
assignment was further supported by mass spectrometry. This spectrum
confirmed the presence of a chlorine atom. In addition, the molecular
composition, Ci7H24N0535Cl, was established from high resolution mass
spectrometry.

2.2.1.6 Preparation of N-[2-(3-Methoxymethylmethoxy-4-methoxyphenyl)
ethyl]chloroacetamide (53)
The investigation of the effect of the 3-substituent of chloroacetamides
on the photocyclisation process was expanded by preparing (53). The
alkylation of (43) with chloromethyl methyl ether was found to proceed in
good yield (94%) using sodium hydride as a base in tetrahydrofuran (Scheme
2.14).
H 3 CO.
HO

\^X^X\/NHCOCH2C1 CH3OCH2Cl/ I
F
IT
NaH/THF

^O
<«>
Scheme 2.14

O. ^
-•

94%

H3CO

(53)

^

.NHCOCH.C1
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The extra two-proton and three-proton singlets in the

1

H-nmr

spectrum of (53), compared to that of the starting chloroacetamide, at 8

and 3.51 respectively, was indicative of the incorporation of a methylen
ether and an aliphatic methoxy group respectively. The

13

C-nmr spectrum

was consistent with the proposed structure, and the methylene ether carb
resonance appeared at 8 56.1.

2.2.1.7 Preparation of cis and trans isomers of the ester/amide (54)
As introducing various functional groups on the bridging chain of the
lactam-containing m-cyclophanes, particularly at the 3-position, was

desirable, it was decided to also synthesise an enol ether chloroacetami
derivative (54) for photochemical study.
The reaction of (43) with methyl propiolate in the presence of sodium

hydride led to formation of the desired product in moderate yield (Schem
2.15).
H

3CC\^0

O

HO.I

^ s ^

,XJ

H 3 CO

(43)

> ^

NHCOCH 2 Cl

H,CO^^ J
NaH/THF
37%

NHCOCHXl
H3CO

Scheme 2.15

This Michael addition resulted in cis and trans isomers in an

approximately 1:1 ratio as shown by their proton spectra. These two spect

were discriminated based on coupling constants of 7.2 and 12.4 Hz for th
and trans vinyl hydrogens respectively. Both

13

C-nmr and mass spectra

provided further evidence for the proposed structure. In the

13

C-nmr
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spectrum, the aliphatic methoxy group, the amide and ester carbonyl groups
resonated at 8 51.3, 165.8 and 167.7 respectively. The mass spectrum
confirmed the presence of one chlorine atom.

2.2.2 Preparation of Di- and Trichloroacetamide Derivatives
The low yield of the desired m-cyclolactams previously obtained from
the monochloroacetamides was a limitation for further synthetic
transformation. Therefore, the synthesis of di- and trichloroacetamides
precursors for photolysis was investigated. The one or two additional

chlorine atoms would provide built-in functionality at the 4-position i

m-cyclophane photoproducts and this functionality could be used for furt
modifications.
Di- and trichloroacetamide derivatives (55-59) were readily accessible

(Scheme 2.16) using dichloro or trichloroacetyl chloride in the same man

as described in Subsection 2.2.1.1, followed by a reaction with diazomet
in a mixture of methanol and diethyl ether to O-methylate when needed.
The structural assignment of these compounds was made by
comparison with the spectra of the monochloroacetamides. In the 1H-nmr

spectra of the dichloroacetamides, the additional chlorine atom resulted
number of shifts in resonance frequencies of adjacent or nearby nuclei.

signal generated by the methine proton adjacent to the chlorine atoms wa
moved downfield by 2.0-2.7 ppm. Other signals arising from atoms in the
amide chain also exhibited downfield shifts, though not as strongly.

40

NH 0

xrr

R'O

R'O
Cl2CHCOCl
or
Cl3CCOCl

CXY

R'O
R=COOCH 3 , R'=H, R"=H, X=H, Y=C12
(55)
R=COOCH3,R'=H, R"=H, X=C1, Y=Ck
(56)
R=H, R'=CH3, R"=CH3, X=H, Y=C12
(57)

R=COOCH 3 , R'=H, R"=H (38)
R=H, R'=CH3, R"=CH3
(homovertrylamine)

H 3 CO

CH2N2/CH3OH/
diethylether

CXY

H 3 CO
R=COOCH 3 , X=H, Y=C12 (58)
R=COOCH 3 , X=C1, Y=C12 (59)

Scheme 2.16

2.2.3 Preparation of Azidoacetamide Derivatives
It w a s thought that upon the photocyclisation of some aromatic
azidoacetamides, an extra nitrogen atom m a y be incorporated within the
ring moiety of the lactam-containing m-cyclophanes giving scope for further
manipulation. Therefore, it w a s decided to synthesise (60) and (61) (cis and
trans isomers).
H3CON

H 3 CQ

H3CO

Q

NHCOCH.N,

NHCOCH 2 N 3

H 3 CO

4 1

The substitution of the chlorine atom of (7) and (54) by the azido group

took place quite successfully using sodium azide in refluxing methyl et

ketone or acetonitrile. The structures of products (60) and (61) were re
ascertained from the spectroscopic data. An upheld shift of around 0.04
in resonance frequency generated by the methylene hydrogens adjacent to
the azido group was apparent compared to that of the starting
chloroacetamides. In the infrared spectrum of the azidoacetamide

compound (60), an absorption band at 2112 cm-1 was attributed to the azid
group.
2.2.4 Preparation of Miscellaneous N-Substituted Acetamide Derivatives
It was planned that by replacing the chlorine atom with fluorine or
bromine, a study of the leaving group effect upon the formation of the
cyclolactam could be conducted. The procedure used to synthesise the

bromoacetamide (62) involved the addition of a slight excess of bromoac
bromide to commercially available homoveratrylamine in
dichloromethane. The bromoacetamide was then treated with cesium

fluoride in refluxing acetonitrile to afford the fluoroacetamide (63) (
2.17).
H3CO.

^2

BrCH.COBr/
DCM

62%

H3CO-

.NHCOCH.Br

H3CO>

H 3 CO

(62)

homoveratrylamine

97%

NHCOCH2F

H3CO

H3CO

(63)
Scheme 2.17

CsF/
methyl ethyl ketone or
acetonitrile
reflux
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In the 1 H - n m r spectrum of (62), an upheld shift of 0.15 p p m for a

signal generated by the methylene group adjacent to the bromine atom was

observed compared to that of the corresponding chloroacetamide. The mass
spectrum showed bromine-isotope-containing molecular ion peaks,
confirming the presence of one bromine atom. In the ^-nmr spectrum of

the (63) the two-proton doublet centred at 8 4.75, with a large coupling
constant of 47.4 Hz due to the interaction with the fluorine atom, was
attributed to the methylene group adjacent to the fluorine atom. Both

13

C

nmr and mass spectra gave further evidence for the consistency of the
structural assignment. In the

13

C-nmr spectrum, the resonance for the

amidomethylene carbon showed coupling with the fluorine atom and

appeared as a doublet, centred at 8 80.2, with a coupling constant of 18

This interaction with fluorine was also observed for the carbonyl group.

appeared as a doublet which resonated at 8 167.4 with a coupling constan
17 Hz.

2.3 Photolysis of Chloroacetamide Derivatives

2.3.1 Introduction to Mechanistic Aspects
Photolyses of the chloroacetamides were generally conducted in
benzene using a 16 or 250 W mercury lamp and a vycor filter sleeve,
allowing transmission of wavelengths greater than 210 nm. The compound
(8), as shown in Section 2.1, was isolated in 24% yield, which was an
improvement on the yield (12%) obtained14 previously in THF. The reason
is thought to be an increased effectiveness of the solvent cage15 in the
slightly more viscous60 solvent benzene. The low polarity of the solvent

also believed to contribute to the higher yield of (8) obtained, since i
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the formation of the other radical ion derived-products such as 7,8dimethoxy-l,3,4,5-tetrahydro-2H-3-benzazepin-2-one (9),14 which was
isolated in only 6.5% yield. The possible formation of other isomers such as
(10) in benzene was suspected but not isolated.
O

^-NH

H3cosJy

H 3 CO

H 3 CO

H 3 CO'
(9)

(10)

The mechanism leading to the benzazepin-2-one isomers is thought to
involve electron transfer. The first step in this mechanism is believed to be
the photoionization which requires two photons. The first is to excite an
electron to the singlet state and the second to eject the electron from the
aromatic ring to the carbonyl group. This is then followed by chloride
ionization and ultimately aromatization.12 Therefore, a more polar solvent
such as tetrahydrofuran or a mixture of tetrahydrofuran and water should
favour this mechanism and give rise to higher yields of the isomers (9) and
(10). Alternatively, some of the benzazepin-2-one could conceivably also
arise from direct attack on the aromatic ring by the amidomethylene radical
from C-Cl homolysis, particularly in benzene, followed by hydrogen
abstraction and re-aromatization.

CC1 •

A8,14

H
O '

B8,14
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The mechanism leading to products (8) and (14) (Section 2.1) most

probably also involves homolytic cleavage of the C-Cl bond,78'17 affordin

chlorine radical and an amidomethylene radical. The chlorine radical may
then abstract a hydrogen atom from the methoxy group (A8,14) to form a

diradical intermediate. Subsequently, the intra-molecular combination of

the diradical (B8,14) forms the cyclolactams (8) and (14). It is possib

^-butyldimethylsilyloxy group at the 4 position in (13) (See Section 2.

effect upon the conformation of the methoxy group at the 3 position. Thi

sterically demanding group may orient the 3-methoxy group a little clos
the chloroacetyl group resulting in more hydrogen abstraction from the
methoxy group and subsequently formation of (14) in a higher yield; the

bulky silyloxy group may also slow radical diffusion from the solvent ca
Furthermore, with (13) the possible problem of competitive hydrogen

abstraction from a saturated C-H group adjacent to oxygen at the 4-posi
removed.

2.3.2 Results and Discussion
Based on the above observations, it was thought that with the

photocyclisation of the new chloroacetamides described earlier, bridging

chain-substituted m-cyclophanes could be obtained. Indeed, the ultravio

irradiation of (40) afforded the new 7-substituted m-cyclophane derivat

(64) in 30% yield or 60% based on the recovered starting material (Schem
2.18).
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3
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(64)

Scheme 2.18

Distinguishing signals in the 1 H-nmr spectrum of the lactam (64) were
produced by the oxymethylene, aromatic and aliphatic methoxy groups. A
two-proton multiplet at 8 4.28-4.30 was assigned to the oxymethylene group.
The aromatic and aliphatic methoxy groups appeared as singlets at 8 3.88 and
3.81 respectively (Figure 2.2), while ortho coupling was observed for the 10,
11- aromatic hydrogens (J=8.0 Hz) and meta coupling for the 10, 13-aromatic
hydrogens (J=2.0 Hz). Resonances at 8 170.9 and 172.1 in the

13

C-nmr

spectrum were assigned to the lactam carbonyl and carbonyl of the ester
group respectively. The structure of (64) was also confirmed unequivocally
by X-ray crystallography (Assoc. Prof. A. H. White, University of Western
Australia). The structure obtained is shown in Figure 2.1 and non-hydrogen
atom co-ordinates and equivalent isotropic thermal parameters are given in
the appendix 1. It is notable from the figure 2.1 that the lactam moiety is
transoid with the carbonyl group pointing towards the aromatic ring.
A C O S Y experiment indicated the coupling patterns for the methylene
hydrogens as well as their chemical shift values. Figure 2.3 shows the
geminal coupling of the methylene hydrogens. The coupling patterns are
also

observed

for

all

the

neighbouring

methylene

hydrogens.

Characteristically, the methylene hydrogens next to the carbonyl group (4a
and 4b) resonated far apart from each other (centred at 8 2.30 and 2.69),
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Figure 2.1 Molecular projection of the cyclophane (64) normal to the phenyl
ring; 2 0 % thermal ellipsoids are shown for the non-hydrogen atoms,
together with skeletal ring numbering. Hydrogen atoms have arbitrary radii
of 0.1 A.
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Figure 2.2 (top). Proton n m r spectrum of 64 in deuterochloroform.
Figure 2.3 (bottom). COSY spectrum of 64 in deuterochloroform.
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probably because one is influenced more than the other by the shielding

effect of the carbonyl group. Similarly the benzylic methylene hydroge
generated resonances centred at 8 2.54 and 3.22.

It was proposed that if the oxymethylene radical (B8,14), formed via

photolysis, was further stabilized, a better yield of the resulting mmight be obtained. Representation (A42,44) below, shows the diradical

intermediate which would be formed from the photolysis of (42) and (44)

(Subsections 2.2.1.2 and 2.2.1.3). The secondary carbon radical produc

should be more stable allowing greater intramolecular diradical coupli

H
O N.
'
H3C H
RO
A42,44

The ultraviolet irradiation of the these chloroacetamides in benzene

(Scheme 2.19) afforded the new 3-substituted m-cyclophanes (65) and (6
low yields (10-12%). On the other hand, the isomeric benzazepin-2-ones
and 68 derived from photolysis of 42, and 69 and 70 from photolysis of

were isolated in considerably higher combined yields of 28-31% compare
those of the analogous dimethoxy m-cyclophanes.
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H 3 C H 2 C O > s ^ ^ N ^ ^ \ ^ NHCOCH2Cl
p

- ^

^

benzene

RO
R=CH2CH3 (65)
R=CH3 (66)

R=CH2CH3 (42)
R=CH3 (44)
Scheme 2.19

>~NH
H3CH2CO^^vs>^-^

H3CH2CO.

RO
R=CH2CH3 (67)
R=CH3 (69)

R=CH2CH3 (68)
R=CH3 (70)

The reason for the low yield of products (65) and (66) is thought to be
most probably due to a steric hindrance effect of the methyl group on the
secondary carbon radical. Hence, the intramolecular diradical combination
would be retarded and the direct attack on the aromatic ring by the
amidomethylene radical (as represented by A42,44) might become more
favourable, affording higher yields of the seven-membered ring benzazepin2-ones.
The structures of (65) and (66) were based on the spectroscopic data.
The same complex coupling pattern in the ^ - n m r spectra, as described for
(64), w a s observed for (65) and (66). The most salient feature of these spectra
was a three-proton doublet at 8 1.46 ascribable to the methyl substituent at
the 3 position in the bridging chain; this w a s not present in the 1 H - n m r
spectra of the m-cyclophanes with the unsubstituted bridging chain (8 or 14).
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The signal assigned to the carbonyl group appeared at 8 171.8 in the 13 C-nmr
spectrum of (65).
It was decided to investigate the effect of the N-methyl substitutent in
the chloroacetamide derivative (46) on the orientation of the amidecontaining chain. If the amidomethylene group is placed a little closer to the
3-methoxy group, the photolysis of the compound (46) might result in more
hydrogen abstraction from the methoxy group at 3 the position and also
more intramolecular combination of the diradical (as shown by B8,14 page
43) affording a higher yield of m-cyclophane. For this reason, the photolysis
of (46) in benzene was conducted with a view to extending the usefulness of
the photocyclisation approach to lactam-containing m-cyclophanes with a
new substituted bridging chain. Irradiation of (46) in benzene afforded the
corresponding 6-substituted m-cyclophane derivative (71) in 1 8 % yield based
on the recovered starting material (Scheme 2.20). Despite the assumption
that more H-abstraction by the chlorine atom from the 3-methoxy group may
have been favourable due to the orientation of the amide-containing chain,
no improvement in yield was observed, compared to the cyclophane with the
unsubstituted bridging chain. The corresponding benzazepin-2-one isomers
(72) and (73) (Scheme 2.20) were isolated in a combined yield of 22%.
It is notable that the reaction proceeded slowly as 6 2 % of the starting
material was recovered after 19 hours of irradiation. Hindered rotation
about the amide bond, as confirmed by the proton spectrum of this
compound, might be a contributing factor to the slow photochemical process.
The slow inter-conversion of conformers probably retards the photochemical
reaction as one conformer might be less favourable for photocylisation than
the other one. The two conformers m a y be represented by (46a) and (46b),

below.
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CH,
H3CO,

CH,

NL

ci

xrr

H3CO'

(46a)

H 3 CO
(46b)

Hindered rotation about the secondary amide bond in the compound

(7) was not observed, due to less double bond character in the nitroge

carbon (carbon of the carbonyl group) bond resulting in a lower energy
barrier to rotation.

CHn
CH,
NCOCH 2 Cl

hu
19 h

RO
(71)

starting
material

H3CO

N- •CH,

+

H3CO^^^<
62%

O

H3CO

(72) (73)
Scheme 2.20

A distinguishing feature in the ^ - n m r spectrum of the m-cyclophane
product (71) was a three-proton singlet at 8 3.15 which was assigned
methyl group.

The incorporation of an (acyloxy) alkyl a ether substituent at the 3

position of the m-cyclophane bridging chain was also desirable as desc

earlier (Subsections 2.1.3 and 2.2.1.5). However, the irradiation of (5

52

benzene using 16 W or 250 W mercury lamps fitted in a vycor sleeve failed

to give the desired result. The products obtained arose from i) a photo

rearrangement affording (74) and ii) fragmentation/substitution to giv
{77), and (43) (Scheme 2.21).
The assignment of structures to these photolysis products was

supported by analytical and spectroscopic data. The salient feature in

nmr of (74) was two sets of one-proton doublets centred at 8 6.75 and 6

ascribable to aromatic protons, indicating the incorporation of an acy

on the aromatic ring. This was further supported by a nine-proton sing

8 1.20 and the absence of a signal which is generated by the methylene
in the 1H-nmr of the starting chloroacetamide (52). The mass spectrum
confirmed the presence of one chlorine atom.
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(H3C)3.

o

NHCOCH2Cl

hv

benzene

7^

H3co
52

H3CO

hu
benzene

(H

^S f S o

o.

Y'

NHCOCHoCl

NHCOCH2Ph
+

H3CO

+

H3CO

74 (18%)

75 (10%)
NHCOCH2Cl

HO.
H3CO

NHCOCH2Ph

HO,
H3CO

43 (21%)

77 (9%)
Scheme 2.21

The 1 H - n m r of (75) was also quite distinctive. A n extra five-proton
multiplet at 8 7.17-7.32 was attributed to the incorporated phenyl ring.
upfield shift of 0.48 ppm in the resonance frequency generated by the
methylene hydrogens next to the carbonyl group was observed compared to

that of the starting chloroacetamide. Similarly, the 1H-nmr of (77) exhibi

a multiplet resonating at 8 7.17-7.32 which was ascribed to the phenyl gr
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The spectroscopic data obtained for (43) were identical to those
previously described (Subsection 2.2.1.3).
The molecular compositions, Ci6H22N0435Cl, C23H29NO5 and

C17H19NO3 of (74), (75) and (77) respectively, were established from h
resolution mass spectrometry.
The mechanism leading to (74) probably involves homolytic cleavage

of the C-O bond of the ether group to give the intermediate shown by (7

(Scheme 2.22), followed by loss of formaldehyde. The acyl radical could

add to the benzene ring and re-aromatization would give the product (7
The conversion of compound (52) to (43) may conceivably proceed by

acidic ester hydrolysis followed by loss of the formaldehyde group. The

hydrogen chloride required to cleave the ester bond may arise as a res
chlorine atom displacement by the phenyl group which also leads to
formation of (75) and (77).
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hv

(H3C)3C

WO
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NHCOCHoCl
NHCOCH 2 Cl

CH20

or-

H3CO

H3co

(74b)

(74a)
H abstraction
(H 3 Q

HO

NHCOCH 2 Cl

H3CO

(74)
Scheme 2.22

The photolysis of (52) w a s also conducted in tetrahyrofuran. The
change of solvent prevented the formation of products obtained in benzene.
Nevertheless, no m-cyclophane formation was observed. Instead, the
product (78) was isolated in 43% converted yield (Scheme 2.23) most probably
arising from hydrogen abstraction by the amidomethylene radical from the
solvent.
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^^^NHCOCH
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Scheme 2.23

The structure of (78) w a s readily ascertained from spectroscopic data.
A singlet resonating at 8 1.95 in the 1H-nmr spectrum of this compound was
attributed to the methyl group of the acetamide chain, while the 13C-nmr
exhibited a resonance at 8 23.1 ascribable to this methyl group.

Due to the multi-product formation observed upon the photolysis of
(52) in benzene, it was decided to approach the synthesis of 3-alkyloxy
substituted m-cyclophanes from a simpler system. The photolysis of (53) was
therefore investigated. The irradiation of this compound in benzene gave
the products (76) and (77), which were spectroscopically identical to those
isolated from the photolysis of (52), together with a new benzazepin-2-one
derivative (79) (Scheme 2.24); no m-cyclophane formation was observed.
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H
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benzene
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H3CO
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H3CO
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HO,

NCH 2 OH
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+

NHCOCH2Cl
+

H3CO
43 (24%)

79 (18%)
HO.

NHCOCH2Ph

H3CO
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Scheme 2.24

In support of the proposed structure (79), the proton 1 H - n m r of this
compound exhibited a one-proton triplet and two-proton doublet centred at

8 3.19 and 4.90, ascribable to the aliphatic hydroxyl group and the adjace
methylene group respectively. The methylene next to the carbonyl group

appeared as a two-proton singlet at 8 3.78 ppm. The molecular composition,
C12H15NO4, was established from high resolution mass spectrometry.
The course of the reaction appears to be similar to that observed in the

photolysis of (52). However in this case, the photocyclisation forms a se
membered benzazepin-2-one (79). The formaldehyde expelled, most
probably via the same mechanism as described in Scheme 2.22, could add to
the nitrogen of the amide resulting in formation of the acylated amino
alcohol (79).
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Condensation of amides with formaldehyde under neutral, acidic or
basic conditions to give methylolamides has been reported previously.60

RCONH2 + CH20 ^ RCONHCH2OH
N-methylolamide

Amides
formaldehyde.

(and imides) as shown

above, react reversibly with

The reaction is catalysed by either acid or base over a

relatively wide p H range (2-12), and the activation energy of the reverse
reaction remains greater than that of the forward process by about 5
Kcal/mol.61'62 Although the equilibrium favouring the N-methylolamide is
unaffected by pH, elevated temperatures tend to favour the dissociation
reaction which has a higher activation energy. For this reason the isolation
of products often must be carried out at or near room temperature, and
purifications by recrystallisation is conducted with a minimum of heating.60
In the light of the results from the photolyses of (52) and (53), further
work on the photochemical approach to 3 acyl/alkyloxy-substituted mcyclophanes was not pursued further.

Further efforts to introduce a functional group at the 3-position of th
m-cyclophane system involved the photolysis of (54). It was anticipated that
the ultraviolet irradiation of this compound (Subsection 2.2.1.7) might afford
a n e w m-cyclophane via a possible addition of the amidomethylene radical
to either carbon of the double bond. Although not specifically covered by
Baldwin's Rules100, 10-Exo-Tris ring closure would appear to be favourable.
However, in the event, the irradiation of (54) gave a seven-membered ring
benzazepin-2-one analogue (80) together with the phenolic derivative (43)
(Scheme 2.25) as the main products. The yield of the photochemical
formation of (80) was optimized by using acetonitrile as a solvent (34%). The
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hydrolysis of the ester most probably occurs during the work up of the
reaction mixture. The conversion of the trans isomer (54) to the cis isomer
was observed w h e n the photolysis was conducted in benzene.
H co

' V*o

H,C
ht)
benzene or
acetonitrile

NHCOCH 2 Cl
H 3 CO

H 3 CO

54

H-abstraction

or

H 3 COOC
NH

hi)
benzene or
acetonitrile

HO^
-O

H 3 CO

H3CO
O

H

3CO

43 (35%)

80 (34%)

Scheme 2.25

The spectroscopic data for these compounds w a s consistent with the
proposed structures. In the ^-H-nmr of (80), the methylene hydrogens
adjacent to the carbonyl group appeared as a singlet at 8 4.05. The
disappearance of the resonance corresponding to the aliphatic methoxy
group w a s indicative of ester hydrolysis resulting in formation of the
carboxylic group.

The spectroscopic data for (43) w a s identical to that

previously described (Subsection 2.2.1.3).
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Overall, the photochemical approach to the 3 substituted tenmembered lactam-containing m-cyclophanes proved to be quite difficult,

with the exception of the methyl substituted (65) and (66) described e

this Chapter. It appears that a chloroacetamide must possess an alkoxy

as methoxy or ethoxy in order for intramolecular photocyclisation to p

satisfactorily. However, formation of the 7-and 6-substituted m-cyclo

was achievable. The 7-methyl ester substituted m-cyclophane was obtain

in good photochemical yield (60%, based on the recovered starting mate
and no formation of benzazepin-2-ones isomers was observed.
As described earlier, a silyloxy group at the 4 position of a

chloroacetamide also increases the photochemical yield of the ten-memb

m-cyclophane system. In the future, designing a compound as shown below
(81), would seem to be of interest for photochemical investigations in

benzene. It might give access to higher yields of the corresponding ten
membered lactam-containing m-cyclophane.

H3CO

N^\/\/ NHCOCH2Cl

J^ JJ J COOCH3
(CH3)3C((CH3)2)SKT

^

(81)

2.4 Photolysis of Di- and Trichloroacetamides

2.4.1 Results
The photolysis of the dichloroacetamide (57, Subsection 2.2.2) in
benzene resulted in a complicated product mixture as analysed by thin
chromatography. However, benzazepin-2-one isomers (82) and (83) were

obtained as a result of the irradiation of (57) (Subsection 2.2.2). The
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distinguishing feature of the iH-nmr spectra of these compounds w a s a
singlet at 8 4.3 generated by the methine group next to the chlorine atom.
The mass spectra of these compounds exhibited chlorine-isotope-containing
molecular ion peaks confirming the presence of one chlorine atom.

H 3 CO)

>*^^A

H 3 CO

NH

H3co-^y-(

s^^S

H 3 CO

CI
(82)

(83)

To further explore the effect of the acetamide moiety on the
photocyclisation process to m-cyclophanes, the photolysis of
trichloroacetamides was also investigated. Ultraviolet irradiation of (56)

(Subsection 2.2.2) in benzene failed, however, to give any cyclised produc
particular the m-cyclophane system. A carboxylic acid (84) was isolated
instead, as shown in Scheme 2.26.

H

C O

H3CO

N ^ \ / \ / NHCOCCl3

XJ is

COOCH3

(56)

H3CQ
hv

OH

benzene „ _
H C
28%
3 °

Scheme 2.26

2.4.2 Discussion
As shown in Scheme 2.27, the mechanism leading to (84) most
probably involves photo-assisted solvolysis in the presence of adventitious

water to afford an intermediate, (84a), followed by the formation of the aci
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halide (84b) which in turn is converted to the carboxylic acid (84), possibly
during the work up. N o dark reaction was observed w h e n a solution of (56)
in benzene was stirred at 30-35°C.

o

L JL

-HCI

.

O
(84b)

O
(84a)
O
H20

Ml
O

OH

(84)
Scheme 2.27

2.5 Photolysis of Azidoacetamide Derivatives
The irradiation of azidoacetamides (60) and (61) in benzene failed to
give any evidence of m-cyclophane products. A glyoxylamide (85) was
isolated from the photolysis of (60) (Scheme 2.28), and a good yield of 5 1 %
was obtained w h e n a mixture of acetonitrile and water in a ratio of 1:1 was
used as the solvent.
O

H
.N

HgCO.

H
(60)

CH 3 CN/H 2 0
51%

H co6

O
(85)

Scheme 2.28

Mechanistically, as shown in Scheme 2.29, a possible sequence for the
conversion of the azidoacetamide (60) to (85) could involve formation of a
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nitrene intermediate (85a) followed by intramolecular C-H insersion to
afford the imine-amide (85b).

Hydrolysis of the imine to afford the

hyroxylamine intermediate (85c), followed by deamination, could then give
rise to the glyoxylamide (85).

(85)

(85c)
Scheme 2.29

The only change observed upon the irradiation of the azidoacetamide
(61) (Subsection 2.2.3) in benzene was the conversion of the cistothe trans
isomer. N o formation of cyclic products was observed.

2.6 Photolysis of Miscellaneous N-Substituted Acetamide Derivatives
W h e n the fluoroacetamide (63) was irradiated in benzene through
vycor under nitrogen for 4 hours, very little change was observed on
monitoring by thin layer chromatography. N o m-cyclophane was observed
and it appeared that only some polymeric material m a y have been formed.
The photolysis of the bromoacetamide (62) gave rise to a mixture of products
from which the m-cyclophane (8) was isolated in low yield (11%).
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2.7 Photochemical Study on the Benzazepin-2-one Derivative (86)
A photochemical approach to fused heterocycles from benzazepin-2ones was thought to be possible, and this was investigated briefly in
explore the further synthetic usefulness of the photocyclisation of

chloroacetamides. Hence, 7,8-dimethoxy-l,3,4,5-tetrahydro-2H-3-benzaze

2-one (6) was allowed to react with chloroacetyl chloride affording t

aromatic chloroacetamide (86) in good yield (Scheme 2.30). The structu

this compound was readily ascertained from analytical and spectroscopi

data. The salient feature in the ^-nmr spectrum of this compound was a
singlet at 8 4.01 which was attributed to the methylene group next to
chlorine atom. In the

13

C-nmr spectrum, this carbon resonated at 8 41.3

mass spectrum of (86) confirmed the presence of one chlorine atom and
structure was further supported by the elemental microanalysis.

ClCH2COCl/
NH K2CQ3/DCM

H 3 CO.

82%

H 3 CO

hu
CH3CN/H20
3cov

s
3co

T ^ l/

^

<
**^s
N
(87)

\N - ^/°
/

\

O
O H

Sch erne 2.30

W h e n (86) was irradiated for 3 hours in a mixture of acetonitrile and

water, using a 16 W mercury lamp, a new fused heterocycle, the oxazolo[
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fr][3]benzazepinone (87) was formed in good yield (Scheme 2.31). The

assignment of the structure was based on spectroscopic data and chemi

transformation. In the ^-nmr, the benzylic methylene hydrogens next to

the carbon bearing the hydroxyl substituent appeared as a pair of dou

centred at 8 3.15 and 3.26 with a coupling constant of 14.4 Hz as a r

geminal coupling. The methylene hydrogens adjacent to the carbonyl gr

(together with the hydroxy group) generated a multiplet at 8 4.10-4.2
13

C-nmr spectrum of this compound, the most distinguishing feature was

resonance at 8 110.3 generated by the quaternary carbon next to the h

group. In addition, the loss of a chlorine atom as a result of photoc
was confirmed by mass spectrometry. The elemental microanalysis
supported the formula of this compound.

H3CO

TT^^

CH2C1

H3CO>^\^4
(86)

(87)
Scheme 2.31

The mechanism leading to (87), as shown in Scheme 2.31, most

probably involves photo-assisted solvolysis as a major initial step.88

would result in formation of the hydroxy derivative (87a), which could
undergo intramolecular cyclisation to afford (87). To support this
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mechanism, a solution of (86) in a mixture of acetonitrile and water was
refluxed for one hour in the absence of light. The major product isolated
was (9) as a result of hydrolysis of the chloroacetamide (86). Nevertheless, a
small quantity of (87) was also observed on thin layer chromatographic
analysis of the reaction mixture, suggesting the formation of the
intermediate hydroxy compound (87a). N o dark reaction was observed
when

(86) was stirred in a mixture of acetonitrile and water at the

temperature of the photolysis (30-35°C).
W h e n (87) was dissolved in hot ethanol the hydroxyl group was
displaced to afford the ethoxy analogue (88). The structure of this ethoxy
substituted oxazolobenzazepinone derivative was confirmed by spectroscopic
data including high resolution mass
crystallography.

spectrometry

and

by

X-ray

The structure obtained is shown in Figure 2.4; non-

hydrogen atom co-ordinates and equivalent isotropic thermal parameters are
given in appendix 2.

2.8 S o m e

Non-Photochemical

Approaches to Lactam-Containing

m-

Cyclophanes
In view of the difficulties with the photochemical approaches, it was
decided to study lactam-containing m-cyclophane formation via a nonphotochemical route. The possibility of the idoacetamide (50) (Subsection
2.2.1.5) undergoing intramolecular nucleophilic substitution was therefore
investigated.

When

(50) was

treated

with

sodium

hydride

in

tetrahydrofuran in low concentration (6.7 m M ) , the only product isolated
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CO

O

Figure 2.4. Molecular projection of 88, showing the folding of the molecule;
2 0 % thermal ellipsoids are shown for the non-hydrogen atoms, together
with skeletal ring numbering. Hydrogen atoms have arbitrary radii of 0.1 A.

68

was an 18-membered ring bridged derivative (89) in 6 1 % yield (Scheme 2.32).
The assignment of the structure of this symmetrical dimer w a s supported by
analytical and spectroscopic data. The most salient feature of the iH-nmr
spectrum of this compound was a singlet at 8 4.52, which integrated for four
protons, ascribable to the hydrogens of the two methylene groups next to the
carbonyls. The mass spectrum provided further evidence for the dimeric
structure as it exhibited a molecular ion peak at m / z 414. The molecular
composition

of C 2 2 H 2 6 O 6 N 2

w a s consistent with the elemental

microanalysis.
HO.

,NHCOCH2I
NaH/THF

H 3 CO
H3CO

OCH 3

(89)
Scheme 2.32

Attempts at intramolecular cyclisation on the extended amidecontaining chain compound (90), failed to give an alternative route to the
ten-membered ring m-cyclophane (8). The main product isolated was the
elimination product (91). N o intramolecular Michael addition w a s observed

69

when (91) was treated further with the base sodium hydride, presumably due
to steric and entropic constraints.
H

H
HO.

N

XT'

0

H3CO
(90)

(91)

In addition, it was decided to examine an aza-Witting cyclisation
approach to the lactam-containing m-cyclophanes. The intramolecular
version of the aza-Witting reactions has been described by Eguchi and

workers66'67; it has considerable potential for the synthesis of nitroge
containing heterocycles. For example a 2-substituted oxazole (93) has

prepared via this approach, by reacting (92) with triethyl phosphite (
2.33).66
O

O

II

II

.O—C—R

O^ R

P(OEt)3

-N,

N=P(OEt),

(92)

(EtO)3PO

ah

R= Primary alkyl

(93)

Scheme 2.33
Therefore, it seemed worthwhile to assess whether 3-(acetyloxy)

azidoacetamide (95) could be induced to undergo the intramolecular aza-

Witting reaction to afford a ring enlarged diaza m-cyclophane as shown

the Scheme 2.34. Compound (95) was obtained from the acetylation of (94
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which, in turn, w a s derived from (43) via a nucleophilic substitution of the
chlorine atom by the azide ion (Scheme 2.34). Refluxing (95) with triethyl
phosphite in cyclohexane afforded the product (96). According to Eguchi and
co-workers this type of ylide is the intermediate which would be formed
prior to cyclisation. However, compound (96) did not undergo
intramolecular reaction when refluxed in cyclohexane or toluene for 48
hours.
It is thought that because the amidomethylene substituent is oriented
far from the acetyloxy group, the nitrogen cannot attack the carbonyl group
which is required for cyclisation to proceed.
H

HO.

N^^CH 2 C1

HO

On
H 3 CO

NaN 3 /
H3CO
methyl ethyl ketone,
reflux, 73%

(43)

(94)
NaH/CH 3 COCl/
THF, 88%

H
Nv^CH2N=P(OEt)3
O ^

H 3 CO
(96)

cyclohexane/
P(OEt)3, reflux H 3 C O
(95)

toluene, reflux

NH

H3CO-

Scheme 2.34
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CHAPTER 3
Chemistry of Lactam-Containing m-Cylophanes
3.1 Introduction

3.1.2 General points

In the first part of this introduction some examples of m-cyclop
transformations will be given. In the second part the reactivity

bridging chain of lactam-containing m-cyclophanes towards introd

functional groups will be discussed. This proved difficult due t

interactions between the bridge and the aromatic ring. The constr

the aromatic nucleus exerts on the bridge by its being the ancho

attachment, as well as the presence of the 7t-electron system tra

many of the bridge substituents, rendered these interactions more

Efforts were therefore focused on functionalising the bridging ch
to sensitise the lactam moiety for hydrolysis.

3.1.2 Examples of Chemical Transformation
Mefa-cyclophanes have been reported to undergo chemical

transformation via ring openings, introduction of intra-annular f

groups and ring closures. For example, 1,3-bridged naphthalenopha

can undergo a ring opening when treated with hydrogen bromide re
in formation of (98) (Scheme 3.1).68
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Br ( W

(CH2)6Br

(98)
Scheme 3.1

A large number of [n]mefacyclophanes with specific intra-annular

lithiated [n] metacyclophane groups can be prepared from the intra-ann
lithiated [n]metacyclophane as exemplified by Scheme 3.2.69

X= H, D, I, Me,
C0 2 H, CH(OH)Ph,
C(OH)Me2
(CH2)-T

Scheme 3.2

Irradiation

of 2-chloro[6](l,3)naphthalenophane

(99) leads to

transannular cyclisation affording compound (100) and (101) (Scheme 3.3)
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(CH 2 ) 6

hv
+
(100)

(99)

(101)
S c h e m e 3.3

T h e ten-membered lactam-containing m-cyclophane (8), of particular
interest in this work, has been reported to undergo a ring closure and
demethylation upon treatment with hydrobromic acid to give (102) (Scheme
3.4).14

.N.
HBr

XT

HO

H3CO
(8)

(102)
S c h e m e 3.4

3.2 Functionalisation of the Bridging Chain
As the search for approaches associated with the formation of
functionalised bridging chains via photocyclisation of chloroacetamide
derivatives faced some degree of limitation, it was decided to study some
reactions on lactam-containing m-cyclophanes in order to find methods to
functionalise their bridging chain . Appropriate functional groups such as
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an acyloxy group at the 3-position, would theoretically provide the m-

cyclophanes with an essential feature to undergo ring cleavage enzymat
(Subsection 2.1.3).
Treatment of lactam-containing m-cyclophanes with boron tribromide
and N-bromosuccinimide resulted in ring closure involving C-C and C-N

cyclisation respectively, the latter providing access to new fused ind

systems. The C-C cyclisation induced by boron tribromide gave the imin

(102) which, in turn, was used to prepare new chloroacetamide derivativ
for photochemical investigation.
In order to introduce a carbon-carbon double bond adjacent to the

lactam carbonyl group, the reaction of the N-protected m-cyclophane (1
with lithium diisopropylamide and benzeneselenyl bromide was
investigated. In the event, an a,(3-unsaturated amide was obtained
successfully. However, a side process also occurred which resulted in
cleavage.

H 3 CO
(103)

3.2.1 C-N Cyclization
3.2.1.1 Reaction of Methoxy Cyclolactam (8) With N-Bromosuccinimide
It was envisaged that the reaction of N-bromosuccinimide (NBS) with

m-cyclophanes may result in bromination at the a position to the oxygen

the ring moiety, providing a handle for the later introduction of an ac
substituent. In the event, however, this reagent led to intramolecular
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reactions and bromination at the benzylic position forming representatives
of a new tricyclic system.
When the methoxy cyclolactam (8) was treated with N-

bromosuccinimide and azobisisobutyronitrile (AIBN) in refluxing carbon

tetrachloride for 30 minutes the result was C-N cyclisation forming th

seven-membered fused indolic derivative (104) as the major product. Ot

minor products (105)-(108) were also formed (Scheme 3.5). Intramolecul
cyclisation, bromination at the benzylic position and subsequent
dehydrobromination resulted in compound (106). The aromatic

bromination products (107) and (108), which were discriminated on the b
of NOESY experiments, and (105), probably arise from the dihydroindole
derivative (104).

NBS / AIBN
•
CC14/reflux
30min

H 3 CO

H3CO

8

104 (47%)

H3CO

H3CO

H 3 CO

H3CO

107 (7%)

108 (3%)
Scheme 3.5
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The assignment of structures to these compounds

rested on

spectroscopic data. The most significant feature of the iH-nmr spectru

(106) was two sets of one-proton doublet at 8 6.63 and 7.79 ascribed t
hydrogens. In the ^-nmr spectrum of (104), the benzylic methylene

hydrogens together with the methylene group adjacent to the carbonyl g
appeared as a multiplet at 8 3.03-3.10. The molecular compositions,

C12H11NO3 and C12H13NO3 of (106) and (104) respectively, were establis
from high resolution mass spectrometry.

3.2.1.2 Reaction of Methyl Ester Cyclolactam (64) With NBS
The m-cyclophane ester derivative (64) was also treated with N-

bromosuccinimide under the same conditions as for (8) but for double t

time. This resulted in the indole analogues (109-112), with no dihydro

indole derivatives being isolated (Scheme 3.6). The reason for not obt

this latter derivative appears to be the stronger driving force to for
indole ring in this case as a more conjugated system would result. In

addition, the reaction was run for a longer period of time. Hence, the
a greater possibility of bromination at the benzylic position and the
subsequent dehydrobromination.

77
H
/..oCOOCy

i-bc

<

NH

NBS/AIBN

O

CCV reflux
1h

64

coocy

COOChj

coocy

1 1 ^117%)

1 1 (B%)

.ocoocy

11 £11%)
Scheme 3.6

Mechanistically as shown in Scheme 3.7, a plausible sequence could
involve formation of traces of hypobromous acid from N -

bromosuccinimide71 or bromine and adventitious water, followed by

formation of N-bromolactam and water on reaction of the hypobrom

acid with the lactam. The N-bromolactam could then possibly cycl

(with overall loss of hydrogen bromide) or via thermal lactam ra
formation.

Amidyl radical cyclisation on to aromatic rings has been propose

the photolysis or thermolysis of N-iodoacetamides generated in t

amide precursors in the presence of strong base (potassium-f-buto
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Scheme 3.7

In general support of these mechanistic considerations, cyclisation also
resulted on reaction of (8) with excess bromine in refluxing carbon

tetrachloride (30 minutes) to give the 9,10-dibromo derivative of (106

moderate yield. Furthermore, when (8) was refluxed in benzene (1 hour)

the presence of one equivalent of benzoyl peroxide (conditions conduci

amidyl radical formation), the fused dihydroindole (104) was obtained i
35% yield. In contrast, however, when the simpler model compound N-[2(3,4-dimethoxyphenyl)ethyl]acetamide (113) was reacted with N-

bromosuccinimide in refluxing carbon tetrachloride and in the presence

AIBN, aromatic bromination took precedence at the electronically activ
and sterically favoured 2-position to afford the known74 non-cyclised
compound, (114) (Scheme 3.8). This bromo derivative has been cyclised

acetyl-2,3-dihydro-5,6-dimethoxy-lH-indole but only after treatment wi
sodium hydride and copper (I) bromide.74
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C|_,

NBS/AIBN
H3'
CCt, reflux (1 h)
70%

H3<

(11)3
Scheme 3.8

W h e n the secondary lactam functionality in the bridging ring was
protected with a N-f-butoxycarbonyl group (compound 103), cyclisation

prevented and a single brominated product (115) was isolated (Scheme 3

from standard bromination at the benzylic position. Dehydrobromination

does not occur since the driving force to form an indolic system is re
by preventing N-bromination and subsequent formation of the amidyl
radical for cylisation.

NBoc

NBS/AIBN
•
COj , 76%

(10)3

(11)5
Scheme 3.9

O n the basis of this work, a n e w route to fused indole derivatives
based on m-cyclophane lactams has been developed. This work also
provides an alternative strategy towards the synthesis of the indolic

dialkyloxy dihydro indoles and indoles, since hydrolysis of the indoli

moiety should be easily achieved. A previously described approach to t

latter derivatives involves the reductive cyclisation of 2,(3-dinitros
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derivatives with a m m o n i u m formate in the presence of a catalytic amount
of palladium on carbon in refluxing methanol.75
Analogous compounds, the six membered ring fused dihydroindole
derivatives exemplified by (116)79a'b and (117)80, have been reported to show
fungicidal properties. Other fluorinated alkyl derivatives have shown
antihypertensive activity.81a'b Synthesis of (116) has been carried out by
reacting the 7-hydroxy substituted dihydroindole derivative with haloacetyl
halide.79a

X = O t 1)6
X=CH; (1 1)

There have been, however, no reports on the preparation and
properties of the analogous seven membered 1,4-oxazepino ring fused
derivatives as described in this Subsection, while the azepino analogue (118)
has only recently been described82 as the basis for a structually novel tricyclic
dipeptide mimetic.

COO-
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3.2.2 C-C Cyclization and Reactions of the Resulting Imine (102)
Boron tribromide was found to be a mild alternative reagent to
refluxing hydrobromic acid14, for demethylation and cyclisation of (8) . The

reaction was carried out at -78°C to afford (102) in good yield (Scheme 3.10)

O H
BBr3
-78°C
H 3 CO"

""

g2%

(8)
Scheme 3.10

The spectroscopic details of (102) were identical to those previously
reported. The imine (102) was then reacted with chloroacetyl chloride to
afford (119). Since it was decided to investigate the photolysis of the
chloroacetamide (119), it was necessary to protect the hydroxy group of this
compound. This was carried out by silylation with ferf-butyldimethylsilyl
chloride. The ultraviolet irradiation of the resulting silylated compound
(121) afforded a benzopyran chloroacetamide derivative (122) in low yield
(Scheme 3.11).
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CH2C1

Q

O^

/CH2N3

T

ClCH2COCl 1 eq,
DCM

• f ^ f

79%
HO

NaN3/
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3CN^ 0
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(102)

^

78%

^

HO^ ^
(119)
46% \

(120)
HO '

(CH3)3C((CH3)2)Sia
imidazole

DMF

X
O
yv^u

°yCH2C1

H hi) ^%<NN

N^.CH 2 C1

CH3CN/H70

27%
(122)

I ]
O ^>y

(H3C)3C((H3C)2)S,( f
(121)
Scheme 3.11

The assignment of structures was based on spectroscopic data and

elemental microanalysis. In the 1H-nmr spectrum of (119), the most salien

feature was a two-proton doublet centred at 8 5.04 ascribable to the me
group adjacent to the ether oxygen. In the

13

C-spectrum, this methylene

carbon resonated at 8 66.3. In the ^-nmr spectrum of (121) the two sing

at 8 0.18 and 1.00, which were assigned to the methyl groups on the sili
atom and the tertiary butyl group respectively, were indicative of

incorporation of the silyl group. A singlet at 8 4.31 in this spectrum,

ascribed to the methylene protons adjacent to the chlorine atom. In the
nmr of (122) the methylene protons of the chloromethyl group resonated

further upheld (8 4.00) indicating that the nitrogen of the amidomethyl
group was now part of the straight chain ethylacetamide. The methylene
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hydrogens adjacent to the carbonyl group of the benzopyranone ring

appeared as a triplet centred at 8 3.21 which integrated for two proto

methylene hydrogens next to the oxygen in this ring were assigned by a
proton triplet which resonated at 8 4.61. The proposed structure was
supported by mass spectrometry.
The mechanism leading to the formation of the benzopyranone (122)

most probably involves the photohydration of the eneamide (121) to giv

intermediate (122a) which can then rearrange to afford (122) by ring c

and solvolysis (Scheme 3.12). While no dark reaction on (121) was carr

out, it was observed to be stable on chromatography on silica gel pres
with traces of water present.
(121)

hu
H20

O^/,CH2C1

H

wvir
HO
HIM

:/(«i[3C)2)SiO^^'^

(122)
(122a)
Scheme 3.12
An azidoacetamide derivative (120) was also prepared in these studies
by reaction of (119) with sodium azide in refluxing acetonitrile. The
structure of this compound was confirmed by spectroscopic data and

elemental microanalysis. It was thought that (120) might cyclise via t
nitrene formation to possibly form compound (120a). However, in the
event, no change was observed when this compound was refluxed in
toluene for 6 hours.
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The carbon-nitrogen double bond of (102) was also reduced using
lithium aluminium hydride to give a secondary amine (123) (Scheme 3.13)
which was assessed for receptor binding in a broad screen (NovaScreen,
USA). However, no particularly strong binding properties were observed in
a range of receptors including dpominergic Di, D2, and serotonergic 5HT}
and 5HT2 receptors as shown in appendix 3.

°iY

LlAlH
HCT^^

W
69%

(102)

f T C > ^

(123)
Scheme 3.13

A distinguishing feature of the ^-H-nmr spectrum of (123) was an extra
signal which appeared as a multiplet at 8 4.07-4.12 and was ascribed to the
methine hydrogen. In the 13 C-nmr spectrum of (123), the benzylic carbon
next to nitrogen atom was ascribed to the signal at 8 51.6.

3.2.3 Reaction of the N-Protected Cyclophane (103) with Benzenselenyl
Bromide
It is worthwhile to stress here that a pro-drug is a compound which
undergoes biotransformation prior to exhibiting a pharmacological effect4.
This transformation m a y be enzymatically or non-enzymatically induced,
and the latter instance can include acid or base-induced reactions.
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Treatment of the methoxycylolactam (8) with a refluxing solution of
sodium hydroxide did not result in ring cleavage. The lactam

was also

resistant to amidase-induced hydrolysis at pW 7 at room temperature. These
observations justified the efforts directed towards seeking methodologies to
functionalise the bridging chain, particularly at the 3 position, of the lactamcontaining m-cyclophanes.

A suitably functionalised bridge might be

expected to be more susceptible to hydrolytic cleavage.
Hence, introducing a cabon-carbon double bond adjacent to the
carbonyl group was desirable since it could possibly undergo slow hydrolysis
under physiological conditions as shown by Scheme 3.14a.

H
•I
H,0

O H

'^Xf

pH7A

t

H20

o^

(o H

H
amidase

V>
HO.

<
or acylase
R O

R = H dopamine
Scheme 3.14a

Syntheses of a,[3-unsaurated ketones and esters have been described in
the litrature using organoselenium

reagents.76'77

In each case, the

penultimate step involves oxidation of an a-phenylselenocarbonyl
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compound to the corresponding selenoxide which eliminates at room
temperature to the desired olefin (Sheme 3.14).

O

1)LDA
2)PhSeBr

Scheme 3.14
C o m p o u n d (8) was first protected using di-tert-butyl dicarbonate and
triethylamine and 4-(dimethylamino)pyridine as the base. Reaction of the
N-protected

cyclophane

benzeneselenyl

(103) with lithium diisopropylamide and

b r o m i d e 7 6 resulted in ring cleavage.

However, the

benzeneselenyl group was also incorporated leading to (124) (Scheme 3.15).

O

H 3 CO

Boc

XJ

LDA/
PhSeBr/
THF

OcBu

+
H 3 CO

-78°C

124 (38%)

(103)

HO.

OfBu

H 3 CO
125 (29%)

Scheme 3.15
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The incorporation of the benzeneselenyl and diisopropylamino

groups in (124) was confirmed by the iH-nmr and mass spectra. The phen
group in the ^-nmr spectrum gave rise to two-proton and three-proton

multiplets at 8 7.61-7.64 and 7.22-7.29 respectively. In this spectru

sets of doublets, centred at 8 0.92 and 0.94, were ascribed to the met
isopropyl groups and integrated for twelve protons overall.
It appeared that lithium diisopropylamide, in the first step acted as

nucleophile to attack the carbonyl group cleaving the ring to afford t
intermediate (124a) (Scheme 3.16). In the second step, as a base, it
deprotonated the carbon adjacent to the carbonyl group. The carbanion
formed could either attack the benzeneselenyl bromide forming a-

phenylselenocarbonyl (124) or undergo elimination to afford (125) (Sch
3.17).

z'Pr^ ^ z'Pr

(of0

Pr
LDA/
PhSeBr/
THF

Pr- N

Li
N

O
O
H 3 CO

H3CO

XT
(124a)

(103)

LDA/
PhSeBr

Pr

H

SePh

O

Pr —

O

Y**Y^' N V° t B u

H 3 CO
(124)
Scheme 3.16

Y
O

OfBu
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NHCOO'Bu

HO

NHCOO'Bu

-(zPr)2NCOCHCH2
H3CO-

H3CO
125 (29%)
Scheme 3.17

In general support of the fragmentation s h o w n in Scheme 3.17, w h e n
the unprotected methoxy cyclophane (8) w a s reacted with sodium hydride
and methyl iodide in order to methylate the nitrogen, ring cleavage and Omethylation occured giving c o m p o u n d (126) as s h o w n in Scheme 3.17a.

H 3 CQ
NaH
Mel
61%

H 3 CO

H 3 CO
(126)

(8)
Scheme 3.17a

T h e phenylselenyl derivative (124) w a s then oxidised using 7 6
hydrogen peroxide in acetic acid a n d subsequently eliminated to the
corresponding a,(3-unsaturated carbonyl c o m p o u n d (127) (Scheme 3.18). The
side product (125) most probably arises from (127) as a result of acidic
hydrolysis. The structural assignment of (127) rested o n spectroscopic data.
The trans vinylic hydrogens in the i H - n m r appeared as t w o one-proton
doublets (J=12.9 H z ) centred at 8 6.05 and 7.86.

8':)

Pr
H 2 0 2 (30%)/

H

'Pr'

t

N^

(124) ^£22.1

^0 4 Bu

o

+
H3co
(127)
u
N

HO.

^.O'BU

v

T
0

H3CO
(125)

Scheme 3.18

T h e related vinylogous ester analogues of (127) c a n also b e synthesised
alternatively by reacting appropriate phenols, such as (128), with methvl
propiolate. The Michael addition of (128) to methyl propiolate resulted in
the formation of compounds (129) and (130). Intramolecular cyclisation of
(129) and/or (130) gave (131) (Scheme 3.19).

H

H
H3CO

HO.

"\^N^

HO
(128)

.OcBu

ifV^YY^Y°

g NaH/
methyl propiolate/
THF
.

...

Bu

(129)

j^

H3CO
(130)

OB11

^ OCH3
Scheme 3.19
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3.3 Conclusion
While a number of new compounds including those which are

representative of new heterocyclic systems were produced, appropriatel
substituted m-cyclophane lactams for assessment as potential dopamine
drugs could not be synthesised.
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CHAPTER 4
Synthesis of New Benzopyran Derivatives
4.1 Introduction

4.1.1 General points

The work in this chapter, which was carried out under a scientif

exchange program, represents a different class of heterocycles (

which were investigated with respect to activity at serotonin re

Some compounds based on the benzopyran skeleton for future photoaffinity labelling of serotonergic sub-type receptors were also

continuing the theme of photochemistry in drug design and develo

4.1.2. Synthetic Background

Several benzopyran derivatives act as agonists at serotonin rece

Amongst them, Guillaumet and co-workers have reported the synthe

methoxy-3,4-dihydro-3-(di-n-propylamino)-2H-l-benzopyran (137) (
4.1) and the analogous 5-hydroxy compound (138).46

Commercially substituted 2-hydroxybenzaldehyde (132) was treated

with nitroethene in the presence of di-n-butylamine in chlorofor

the nitro derivative (133). The unsaturated compound was then rea

with sodium borohydride in the presence of silica gel in a mixtu

chloroform and isopropyl alcohol to give the saturated nitro com

(134). This product was then converted to the corresponding amino

derivative (135) by means of a procedure that involved using hyd

the presence of Raney nickel. The amine (135) was then reacted w

bromide in toluene in the presence of a saturated aqueous soluti

potassium carbonate to afford (136). Catalytic hydrogenation in e
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in the presence of palladium on carbon and triethylamine then resulted in

formation of (137) which was demethylated with hydrobromic acid to aff
(138).
The alkylation on the nitrogen in (135) was carried out alternatively
using iodopropane and potassium carbonate in N,N-dimethylformamide at
60°C

OCH,

OCH
C H O

02NCH=CH2/
nBu2NH, CHC13

NO-,

OH
(133)

(132)

NaBH4, SiOz,
CHC13, zPrOH
OCH
NH

Raney Ni,
H2N-NH2, EtOH

OCH
NO,

(135)
(134)
BrCH2CH=CH2,
K2C03, PhCH3

OCH

H2, Pd/C, AcOEt,
FtnN

N
\ ^ ^

_ ^

(136)

Scheme 4.1

^r

93

Preparation of the 8-azaspiro[4.5]decane-7,9-dione analogue (140a) has
been described by Pondona and co-workers as s h o w n in Scheme 4.2.46
Reductive animation83 of ketone (139)84, which in turn was obtained from 2hydroxy-6-methoxybenzaldeyde according to a procedure described by Wise
and co-workers 85 with

8-(4-aminobutyl)-8-azaspiro[4.5]decane-7,9-dione

hydrochloride86'87, afforded (140a).
OCH
O

OCH

EtOH, NaOH
H2, Pd/C 10%

(140a)

Scheme 4.2

A n alternative route to compound (140a) has also been reported45 that
involved direct alkylation of 3,4-dihydro-3-amino-2H-l-benzopyran (135)
using appropriate alkylating agents as shown in Scheme 4.3.
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OCH,

(135)

(140a)

O

Scheme 4.3

4.1.3 Structural Modification
C o m p o u n d s (137), (138) and (140a) proved to have the necessary
structural requirements for good affinity to 5 - H T I A receptors and high
selectivity versus other receptors. Modifications in these compounds of the
extracyclic amino substituents involving the length of the alkyl side chains
and their substituents have been explored45 previously. The most potent
c o m p o u n d s possessed imido or sulfonamido functional groups with a
preferential length of four methylenes for the side chain. It is notable that
after resolution, the dextrorotatory enantiomers showed better affinity and
selectivity for the 5 H I A receptor. These compounds have been shown to be
full agonists.45
The aim of the work presented in this chapter, w a s to investigate the
effect of C5-substituents in 3,4-dihydro-3-amino-2H-l-benzopyran
derivatives on interactions with the serotonergic receptor subtypes, 5 H I A
and 5HT7. Therefore, n e w substituents needed to be incorporated at the 5
position. It must be noted that the cloning and characterisation of the novel
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serotonin receptor, designated as 5HT7, have been conducted only
recently88'89. This receptor has unique pharmacological profiles that

redefines the agonist and antagonist classification of ligands previou
thought to be selective.
An appropriate azido group containing ligand also needed to be
prepared for later photo-affinity labelling of the above receptors.

4.2 Results and Discussion

4.2.1 Synthesis of 5-methoxy-3,4-dihydro-3-di-N-propylamino-2H-lbezopyran (5-MeO-DPAC) Derivatives
Various substituents were introduced in generally high yields at the 5
position, via well documented95'96 palladium-mediated cross-coupling
reactions . The compound (137) (5-MeO-DPAC) was demethylated using

hydrogen bromide in acetic acid at 140°C to afford the corresponding h

compound which was then reacted with triflic anydride in dichlorometha

in the presence of pyridine to give the 5-triflate analogue (141) (Sch

OCH 3
1) HBr/CH3COOH
140°C, 90%
2) (Tf)20/pyridine/CH2Cl2
72%

% / ^ Q
(141)

Scheme 4.4

The compound

(141) was coupled with vinyltributyltin using a

palladium (II) complex in N,N-dimethylformamide at 90°C to afford the 5

vinyl analogue (142) in good yield (Scheme 4.5). In order to remove the
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excess of tin reagent and the tributyltin hydride, the compound (142) was
isolated as its hydrochloride salt. The compound (142) was then
hydrogenated using a palladium on carbon catalyst to give the target
compound (143) (Scheme 4.5).

*Sn(Bu)3
Pd(PPh3)2Cl2/
DMF, 90°C

H 2 , Pd/C
EtOH
86%

Scheme 4.5

The assignment of structures was supported by elemental

microanalyses and spectroscopic data. In the ^-H-nmr spectrum of (142) the
vinyl hydrogens appeared as three sets of doublets of doublets centred at
5.32, 5.65 and 6.87. The disappearance of these resonances in the T-H-nmr
spectrum of compound (143) was indicative of the reduction of the carboncarbon double bond.

In order to prepare the 5-acetyl derivative (145), (141) was reacted with

(l-ethoxyvinyl)tributyltin to afford the intermediate (144) which was then
treated with hydrochloric acid (10%) to give the amino ketone (145) after
basification of the reaction mixture (Scheme 4.6).
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*Sn(Bu)3
Pd(PPh3)2Cl2/
DMF, 90°C
(141)
1)HC1 (10%)
2) K 2 C 0 3
% overall

Scheme 4.6

The structure of (145) was readily ascertained from the spectroscopic
data. A characteristic signal in the ^ - n m r spectrum w a s a three-proton
singlet at 8 2.60 which was assigned to the acetyl methyl group. In the
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C-

n m r spectrum this carbonyl group resonated at 8 205.0. Mass spectrometry
and elemental microanalysis further supported the structure.

The 5-phenyl benzopyran derivative (146) was obtained in good yield
via a Suzuki coupling, as shown in Scheme 4.7.

PhB(OH)2, Pd(PPh3)4
NaHC0 3 , toluene /ethanol
»
89%

(146)
Scheme 4.7
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The substitution of the triflate with the phenyl group was confirmed
by elemental microanalysis and the spectroscopic data. In the iH-nmr

spectrum of (146) a multiplet at 8 7.33-7.48 was assigned to the incor
phenyl ring. In addition, the structure was further supported by mass
spectrometry.

It was desirable to prepare the 5-cyano derivative (147) since the study

of the effect of this electron withdrawing substituent on interaction w
seretonergic receptors was also of interest. Furthermore, the cyano

derivative would also serve as a good starting material to further dive
functional groups at the 5 position. The cyano group was therefore
introduced in good yield using tetrakis(tripheylphosphine)palladium(0)

zinc cyanide in N,N-dimethylformamide at 90°C (Scheme 4.8). The infrare
spectrum of (147) showed an absorption band at 2228 cm4 consistent with
the presence of a cyano group.

Pd(PPh3)4 1 eq
Zn(CN)2, DMF, 90°C

89%

75%
LiAlH4
95%
CH 2 NH 2

?

reflux

H2N^>^

(149)
Scheme 4.8

NaOH
H20/EtOH
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The reaction mechanism for palladium-mediated cyanation of the aryl

triflates is dissimilar to that of the so-called cross-coupling reacti

equivalent of the palladium complex is required for the reaction to pr
in good yield. The process cannot construct a catalytic cycle because
deposition of metallic palladium.97
The 5-cyano derivative (147) was reduced with lithium aluminium
hydride in absolute ethanol to afford the amine (149). The structural

assignment of this compound rested on spectroscopic data. In the ^-nmr
spectrum, the methylene hydrogens adjacent to the primary amino group
appeared as a singlet at 8 3.86.

An attempt to hydrolyse the nitrile (147) by refluxing in a solution o

sodium hydroxide in a mixture of ethanol and water resulted in formati
of a primary amide (148). The spectroscopic data of this compound was

consistent with the proposed structure. In the ^-nmr spectrum, a singl

8 7.22 was assigned to the hydrogens of the primary amide group. In th

nmr spectrum the amide carbonyl group resonated at 8 171.7. The infrar
spectrum showed absorption bands at 3202 and 3392 cm'1 which were
attributed to the amide hydrogens.

4.2.2 Synthesis of 8-[4-N-propyl-jV-(5-methoxv-3,4-dihydro-2H-l-benzo
3-yl)amino-propyl]-8-azaspirof4.5]decane-7,9-dione
Previous investigations have shown that an imide-containing side
chain on the nitrogen increases the potency of benzopyran derivatives
5HTIA

receptor. Hence, there was a need to also vary the substituent at

position of these compounds in order study their effects on the intera
with the receptors.
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The same methodology as described in Subsection 4.2.1 was used to

introduce different groups at the 5 position. Since the imide-containi
chain was likely to be unstable in acidic or basic conditions, it was

incorporate this group after the palladium-catalysed cross-coupling re

The starting material for this sequence was the N-protected triflate (
prepared in turn from (135). This methoxy derivative was demethylated
using hydrogen bromide and acetic acid to afford (150) which was then

reacted with di-terr-butyl dicarbonate giving (151) (Scheme 4.9). Trea

(151) with triflic anhydride in the presence of pyridine led to format
(152) in good yield (Scheme 4.9).

OCH
NH2.HC1

HBr/CH3COOH

99%

&y

NH2.HC1

(150)

(135)

OH
NHBoc

(Tf)20, Pyridine,
CH2C12

t

(Boc)20,1M NaOH
98%

NHBoc

93%
(152)
Scheme 4.9

C o m p o u n d (152) was then utilised to perform the coupling reactions

to introduce phenyl, ethyl, and acetyl groups, at the 5 position. Scheme

gives the conditions used, as described earlier, to obtain the respecti
compounds (156), (154) and (157).
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OTf
NHBoc

^Nn(Bu)3

PhB(OH)2
Pd(Ph3)4
NaHC0 3 , toluene/EtOH
80%

(152)

Pd(PPh3)2Cl2

OEt

DMF, 9 0 ° C / 7 5 %
"' Sn(Bu)3
Pd(PPh3)2Cl2
DMF, 90°C
NHBoc

NHBoc
NHBoc

OCT

(153)

O

H 2 , Pd/C
EtOH
87%

(156)

HC1 (10%), H 2 0
79% overall

t
NHBoc

(154)

NHBoc

(157)
Scheme 4.10

These Boc-protected products were deprotected in high yields using
trifluoroacetic acid in dichloromethane (Scheme 4.11). Alkylations on the
nitrogen were carried out using appropriate alkylating agents and potassium
carbonate in N,N-dimethylformamide in moderate to high yields. The
unprotected primary amines were reacted with 8-(4-bromobutyl)-8azaspiro[4.5]decane-7,9-dione45 to afford secondary amines which, in turn,

were reacted with iodopropane to obtain the target tertiary amines (158), (1
and (160) (Scheme 4.11).
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A
NHBoc

ay

CF3COOH

NH,

90-99%

O

A=Ph, CH 2 CH 3 , C O C H 3
K 2 C0 3 , Nal, D M F

ztPrl, K 2 CO s ,

Nal, DMF *

6cr

A = P h (158), C H 2 C H 3 (159),
C O C H 3 (160)
Scheme 4.11

The structural assignment of these compounds w a s based on
spectroscopic data and elemental microanalysis. In the iH-nmr spectrum of
compound (158), the aromatic protons in the phenyl group at the 5 position
appeared as multiplets at 8 7.33-7.48. In the ^-nmr spectrum of (159), a

three-proton triplet at 8 1.25 was assigned to the methyl of the ethyl grou

The iH-nmr spectrum of (160) showed a three-proton singlet at 8 2.58 which
was consistent with the presence of an acetyl group.
Under the above alkylation conditions a carbamate side product,

arising from the carbonylation of nitrogen, was isolated (24-56%) during e
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alkylation step. C o m p o u n d s (161), (162) and (163), which were obtained in
the first alkylation step, were isolated using column chromatography.

A = Ph (161), C H 2 C H 3 (162) and
COCH 3 (163)

During the second alkylation step, compounds (164), (165) and (166)
were formed as side products. The separation of each carbamate from the
corresponding tertiary amine was carried out by oxalate formation. The
assignment of structures was supported by both the nmr and mass spectral
data.

A = Ph (164), C H 2 C H 3 (165)
and COCH 3 (166)

The carbonylation of primary and secondary amines has been
reported90'91 previously under the these conditions. It was proposed that
carbamate esters were derived from the alkylation of an intermediate

carbamate anion generated by the reaction of the amine with carbon dioxid
(Scheme 4.12). In turn, it was hypothesised that the carbon dioxide was

104

generated in situ from neutralisation of potassium carbonate (Scheme 4.13).
The reaction w a s solvent dependent, as no carbamate ester formation was
observed in either acetonitrile or tetrahyrofuran. However, the rate of the
required alkylation reactions were reduced w h e n these alternative solvents
were used.

R—NH2 +

-H+
^

C0 2

O
R—N
H

A>-

O
RH 2 C—I

R—N
H

A

O"

,CH2R

Scheme 4.12

'RH2C—I
R—NH2

+

R—N
H

1/2K2C03

/ CH2R

+ KI + 1/2H20 + 1/2C02
Scheme 4.13

4.3 Synthesis of the 5-Azidophenyl Derivative A s a Potential Photoaffinity
Ligand
A m o n g the m a n y proteins that respond to 5-hydroxytryptamine, the
5HTIA

receptor is distinguished by both ligand-binding and functional

characteristics.92
Photolabile aryl azide groups have previously been appended to some
high-affinity ligands for photoaffinity labelling of the 5 H T I A receptor.
Ransom and co-workers have photolysed [3H]-l-[(/?-azidophenyl)ethyl]-4[(trifluoromethyl)-phenyl]piperazine ([ 3 H]p-N3PAPP) in bovine cortical
membranes

and obtained 93 binding to a 55-KDa protein that shows

characteristics of a 5 H T I A binding protein. Emerit and co-workers have
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used94 8-methoxy-2-[N-n-propyl-N-[3-[(p-azidophenyl)amino]-propyl]amino]

-1,2,3,4-tetrahydronaphthalene to obtain 55-60% irreversible inhibitio

[3H]-8-OH-DPAT binding. However, there is still a need for more select

photo-affinity labels to probe in greater detail the molecular basis o
receptor binding.
The moderate selectivity and nanomolar affinity of the agonist 5-

phenyl benzopyrane (146) for the 5HT7 receptor, as discussed in Sectio

has made this the ligand of choice to label this receptor. Hence, it w
decided to prepare a new photo-affinity ligand based on the 5-phenyl

benzopyran skeleton. It was therefore necessary to seek ways to incorp

an azidophenyl group at the 5 position as the resulting azido compound

would most likely have the structural requirements necessary for photo
affinity labelling via aryl nitrene formation.

Palladium-catalysed cross-coupling reactions on the triflate derivati

(141), using commercially available m-nitrophenyl boronic acid or 111-

aminophenyl boronic acid, seemed to be a judicious choice. Reactions w

carried out according to the procedures described earlier in Subsecti

and 4.2.2 (Scheme 4.14). The nitrophenyl derivative (167) obtained was
reduced using activated zinc power in dichloromethane in the presence

acetic acid to afford the 5-aminophenyl analogue (168). It was also po

perform the coupling reaction on (141) using m-aminophenyl boronic ac
obtain the 5-aminophenyl derivative (168) directly (Scheme 4.14).
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NO-,
NaHC03,
toluene / ethanol

NaHC0 3 ,
X B (° H )2
toluene/ethanol

Zn,
CH3COOH/DCM

'O'
(168)
Scheme 4.14
The amine (168) was then converted to the 5-azidophenyl analogue

via diazonium salt formation (intermediate 168a) as shown in Scheme 4.15.
,NH2

r"V N2+

NaN02, H2S04

o°c

fr~YN
(168a)
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The structural assignment of compound (169) and the starting
materials (167) and (168) was based on spectroscopic data. In the infrared
spectrum of the azidophenyl compound (169), a strong absroption band at
2102 cm-1 was attributed to the azide group.
Time constraints prevented photo-affinity labelling studies to be
undertaken.

4.4 Pharmacological Studies
Drugs interacting with the 5-HTiA-subtype of serotonin (5-HT)
receptors are of potential clinical interest in the treatment of anxiety and
depression,18'19 and 5-methoxy-3,4-dihydro-3-(di-n-propylamino)-2H-lbenzopyran (137) and the analogue 8-[4-N-propyl-N-(5-methoxy-3,4-dihydro2H-l-benzopyran-3-yl)amino-propyl]-8-azaspiro[4.5]decane-7,9-dione (141) are
probably amongst the most thoroughly examined 5 - H T I A receptor agonists.45
As shown in Table 4.1, most of the new derivatives have moderate to
high affinity for the 5 - H T I A receptor; this testing was done by the
pharmaceutical company SERVIER in France. In fact, (145) and (160) are
more potent in this respect than the previously described lead compounds
(141) and (137). The derivative substituted with an ethyl group at the 5
position (159, an analogue of 141) exhibits high affinity for the 5 - H T I A
receptor. Compounds (146), (143) and (178) are less potent, whereas (158) (the
phenyl analogue of 141) displays intermediate affinity.
Compound (160) is also more potent than the previously reported45
compounds (137) and (141) at the 5-HT7 subtype receptor site. It is believed
that (146) and (158) should serve as new lead compounds for conducting
further work to explore the development of medicinal agents which act as
selective agonists at the 5-HT7 receptor sub-type. Such agents would be of
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value in the treatment of illnesses such as depression, anxiety, and panic
disorders.

Table 4.1 IC50 (nM) values in the binding tests

R
1

r"

^N/Ns

rS
1
UJ

Compd

R

5HT1A

5HT7

146

Ph

62

107

143

CH3CH2

30.7

157

145

CH3CO

0.6

31.5

137

CH3O

6i)

50

Compd

R

5H 7

178

CH3O

5HT1A
190

Compd
158
159
160
141

1100
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4.5 Synthesis of Benzopyran Chloroacetamide Derivatives for Photochemical
Investigation
Photolysis of chloroacetamide derivatives, as presented in Chapter 2,

proved to be a useful method for ring constructions. The work here pre

attempts that were made to photocyclise the benzopyran chloroacetamide
(170) and (175) which, in turn, were prepared from the standard
chloroacetylation of primary amines (135) and (149) respectively. The
intention of this aspect of the work was to try and prepare tricyclic
benzopyran derivatives for pharmacological evaluation.
Photolysis of (170) in benzene afforded the reduced product (171)
(Scheme 4.16) as a result of hydrogen abstraction by the intermediate
amidomethylene radical. The solvent, benzene, is not a good hydrogen

donor so it is most likely that the hydrogen is abstracted from the be
position of this benzopyran derivative.

OCH

OCH
NH 2

ClCH2COCl, K2C03
DCM

N\^CH 2 C1

j

98%
hv
CH3CN/H2Q,
20%

hi)

benzene
26%

OCH

OCH,
H
N ^ ^CH,OH

ay Y
o

(172)
Scheme 4.16
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Ultraviolet irradiation of c o m p o u n d (170) in a mixture of acetonitrile
and water, to promote e-transfer, afforded the hydroxy derivative (172)
(Scheme 4.16) which is believed to arise via photo-assisted solvolysis; no
cyclisation to the methoxy group was observed.
It was thought that the photolysis of (175) may result in the strcturally
novel six-and/or seven-membered ring fused heterocycles (173) and (174) as
shown below.

H //o
N—V

H o w e v e r , ultaviolet irradiation of (149) failed to give any ring
construction products, and the only product isolated in low yield was (176)
resulting from amidomethylene radical attack on benzene (Scheme 4.17).

O^

ClCH2COCl, K 2 CO,

^CH 2 CI

,

^ v ^ N ^

DCM
67%
(149)
hv

y

(175)

benzene

O ^ ^CH 2 Ph

% > ^

(176)

Scheme 4.17

4.6 Conclusion
New desired DP AC derivatives were successfully synthesised. The
effect of various substituents in the 5-position of these compounds on
interactions with

5HTIA

and 5HT7 subtype receptors was studied. In general,

the acetyl and ethyl groups gave rise to improvement in the receptor
binding. Furthermore, a new DPAC-based ligand for future photo-affinity
binding of these receptors was prepared.
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Chapter 5
Experimental
General Procedures:
All melting points were determined using a Reichert hot stage or
Gallenkamp Melting Point apparatus and are uncorrected. The infrared
spectra were recorded using a Digilab FTS-7 spectrophotometer and NaCl
disks on mulls in nujol or hexachloro-l,3-butadiene (HCB).

The peak

positions were recorded in wave numbers (cm-1). The X H nuclear magnetic
resonance spectra (nmr) were determined at 300 or 400 M H z with a Varian
Unity-300 or 400 spectrometer.
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C nmr spectra were recorded using the

same instruments at 75 or 100 M H z . Unless otherwise stated, the spectra
were obtained on solutions in CDCI3 and referenced to T M S . Chemical shifts
of the outer peaks are given for specified multiplet patterns in the 1 H - n m r
spectra. Ultra-violet/visible spectra were recorded on a Shimadzu UVvisible 160 spectrophotometer.
Vacuum

General

Mass spectra (EI) were obtained using

12-12, V a c u u m

General

- Quattro, or

MAT-44

spectrometers and the direct insertion technique, with an electron beam
energy of 70 eV and a source temperature of 200°C. The peak intensities, in
parentheses, are expressed as the percentage abundance. In the CI mass
spectra, methane was used as the ionising gas. High resolution mass spectra
were run in the Research School of Chemistry, Australian National
University, by Dr. J.K. MacLeod using a V G 70-70 double focussing mass
spectrometer, in the Central Science Laboratory, University of Tasmania by
Dr. N. Davies using a Kratos Concept ISQ or a V G 7070F mass spectrometer
or in the Department of Chemistry, University of Wollongong, by Mr. Larry
Hick using a Fisons/VG Austospec-OA-TOF Mass Spectrometer. The optical
rotation was determined on a J A S C O digital polarimeter, Model DIP-370.
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Elemental microanalyses of samples were carried out at the Australian
National University and the University of Queensland or in SERVIER
(French pharmaceutical company); analytical values are given as
percentages. Analytical thin layer chromatography (tic) was performed
Merck Kieselgel 6OPF254 silica on aluminium sheets. Rf values were

recorded from the centre of spots. All chromatographic solvent proport
are volume for volume. Column chromatography was performed using

Merck silica gel under medium pressure. Dry DMF was distilled from BaO
and dry THF was distilled from sodium metal and benzophenone. Light
petroleum had a boiling point range of 60-80°C. Solvents were removed

under reduced pressure by rotary evaporation, and organic solvent extr
were dried with anhydrous Na2S04.
The 5-HT receptor binding tests were carried out by SERVIER. Tests

for various other receptors including dopaminergic and also serotonerg
sites were conducted by NOVASCREEN (a division of Oceanix Biosciences
Corporation, USA)

General Information for the Photolyses:
The photolyses were conducted in a large quartz immersion well

reactor (model RQ 400) supplied by Photochemical Reactors Ltd., U.K. T
lamp was housed internally in a vycor glass sleeve (transmission >210

and the solution was saturated with N2 before and during photolysis. T
lamp used was a 16 W mercury lamp unless otherwise stated.
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5.1 Experimental for Chapter 2
Preparation of L-dopa Methyl Ester Hydrochloride (38)
H

°^^Y^^ NH2.HC1

^Ljl
HO

H

"cOOCH3
^^

Hydrogen chloride was bubbled into a refluxing solution of L-dopa (1.0

g, 5.07 mmol) in methanol (40 ml) for 5.5 h. The solvent was then remove
in vacuo and the residue was dried under high vacuum to give L-dopa
methylester hydrochloride17 (38) (l.lg, 90%) as colourless hygroscopic

crystals. iH-Nmr (D20) 8: 2.94 (dd, J=14.0, J=6.8 Hz, 1H, CHAr), 3.10 (dd

J=14.0, J=5.6 Hz, 1H, CHAr), 3.68 (s, 3H, COOCH3), 4.15-4.21 (m, 1H, CHNH2),

6.53 (dd, J=8.0, J=2.0, Hz, 1H, 6-Harom), 6.62 (d, J=2.0 Hz, 1H, 2-Harom), 6.74
1=8.0 Hz, 1H, 5-Harom).

Preparation of Methyl 2-Chloroacetamido-3-(3,4-dihydroxyphenyl)
propanoate (39)
H

°^^V^\/ NHCOCH2Cl

Js^J

H

"'COOCH3

HO

To a solution of (38) (810 g, 3.27 mmol) in dry THF (40 ml) were added

triethylamine (0.91 ml, 6.54 mmol) and chloroacetyl chloride (0.388 g, 0
ml, 3.50 mmol). The solution was then stirred at room temperature for 48

Water (20 ml) was then added and the solution was extracted with DCM (3 x
40 ml). The combined organic extracts were washed with water (3 x 10 ml)

and then dried. The organic solvent was removed to give a yellow oil. The

oil was chromatographed (MeOH : DCM, 4 : 96) to give 2-chloroacetamido-3-

(3,4-dihydroxyphenyl)propanoate (39) as a pale yellow oil (799 mg, 85%);
0.20 (MeOH : DCM, 4 : 96). iH-Nmr (CDCI3) 8: 2.97 (dd, J=14.0, J=6.8 Hz,
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CHAr), 3.06 (dd, J=14.0, J=5.6 Hz, 1H, CHAr), 3.74 (s, 3H, COOCH 3 ), 4.06 (s, 2H,
CH2C1), 4.78-4.83 (m, 1H, C H N H ) , 6.50 (dd, J=8.0, J=2.0, Hz, 1H, 6-Harom). 6.65

(d, J=2.0 Hz, 1H, 2-H arom ), 6.75 (d, J=8.0 Hz, 1H, 5-H arom ), 7.12 (d, J=8.4 Hz, 1H,
NH).
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C-Nmr (CDCI3) 8: 37.2 (CH2Ar), 42.3 (CH2C1), 52.7 (COOCH3), 53.7

(CHNH), 115.4 (ArC-H), 116.0 (ArC-H), 121.4 (ArC-H), 127.4 (ArC-CH2), 143.4
(ArC-OH), 144.1 (ArC-OH), 166.5 (COCH 2 ), 171.6 (COOCH3). M s (EI) m/z (%):
287 (1, M+; accurate mass 287.0571, Ci 2 Hi 4 N0 5 35 Cl requires 287.0561), 228 (2,
M+l), 194 (50), 163 (15), 123 (100).

Preparation of Methyl 2-Chloroacetamido-3-(3,4-dimethoxyphenyl)
propanoate (40)

H CO

3 \<^\s/\w^ NHCOCH2Cl
I. I|
H3CO
^^

' ''COOCH3
n

To a solution of (39) (800 mg, 2.78 mmol) in M e O H (10 ml) was added
diazomethane in ether (30 ml). The solution was kept at 1°C for 10 h and
then at room temperature for 40 h. The organic solvent was then removed
by rotary evaporation and then further M e O H (10 ml) and diazomethane (in
excess) in ether (30 ml) was added. The solution was kept at 1°C overnight.
The organic solvent was evaporated in vacuo to give a colourless solid. The
solid was

recrystallized

from

ethanol/ether to give methyl 2-

chloroacetamido-3-(3,4-dimethoxyphenyl)propanoate (40) (660 mg, 75%
colourless crystals; m p 106-107°C. iPI-Nmr (CDCI3) 8: 3.10 (d, J=6.0 Hz, 2H,
CH 2 Ar), 3.75 (s, 3H, COOCH3), 3.856 (s, 3H, Ar-OCH 3), 3.861 (s, 3H, Ar-OCH3),
4.02 (d, J=15.2 Hz, 1H, CHC1), 4.06 (d, J=15.2 Hz, 1H, CHC1), 4.83-4.87 (m, 1H,
C H N H ) , 6.64 (dd, J=5.6, J=2.0 Hz, 1H, 6-H arom )' 6.68 (d, J=2.4 Hz, 1H, 2-Harom),
6.80 (d, J=8.0 Hz, 1H, 5-H arom ), 7.02 (d, J=8.0 Hz, 1H, NH).
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C-Nmr (CDCI3) 8:
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37.2 (CH2Ar), 42.3 (CH2C1), 52.4 (COOCH 3 ), 53.3 (CHNH), 55.7(Ar-OCH3), 111.1
(ArC-H), 112.1 (ArC-H), 121.2 (ArC-H), 127.6(ArC-CH2), 148.1 (ArC-OCH3),
165.4 (COCH2Cl), 171.2 (COOCH3). M s (EI) m/z (%): 315 (2, M+,35C1), 222 (35),
191 (5), 151 (100), 137 (5). Anal. Calcd for Ci 4 H 18 N0 5 Cl: C, 53.25; H, 5.75; N,
4.44. Found: C, 53.27; H, 5.85; N, 4.34.

Photolysis of Methyl 2-Chloroacetamido-3-(3.4-dimethoxyphenyl)pro
(64)
(i) A solution of (40) (200 mg, 0.634 mmol) in benzene (300 ml) was
irradiated for 5 h. The organic solvent was evaporated in vacuo to give a
pale yellow oil. The oil was then chromatographed (ethyl acetate : hexane,
70 : 30) to give two fractions after solvent evaporation. The first fraction was
the starting material (130 mg, 65%). The second fraction was recrystallized
from ethanol to give (64) (37 mg, 21%; 6 0 % based on recovered starting
material) as colourless needle-like crystals; m p 234-236°C; [a]D°°= +105.0° (c.
lg/100ml, CHCI3). iH-Nmr (CDCI3) 8: 2.28-2.33 (m, 1H, CHCO), 2.54 (dd,
J=13.0, J=11.6 Hz,lH, CHAr), 2.65-2.72 (ddd, J=13.6, J=9.6, J=4.0 Hz, 1H, CHCO),
3.22 (dd, J=13.0, J=3.2 Hz, 1H, CHAr ), 3.81 (s, 3H, COOCH3), 3.88 (s, 3H,
ArOCH 3 ), 4.28-4.30 (m, 2H, CH 2 0), 4.35 (dt, 1=11.2, J=3.6 Hz, 1H, C H N H ) , 5.96
(d, J=10.8,1H, N H ) , 6.88 (d, J=8.0 Hz, 1H, ll-Harom), 6.97(d, J=2.0 Hz, 13-Harom),
7.00 (dd, J=8.0, J=2.0 Hz, 1H, 10-Harom). 13C-Nmr (CDCI3) 8: 39.6 (CH 2 CO), 41.8
(CH2Ar), 52.6 (CHNH), 55.9 (COOCH3), 57.3 (CH3OAr), 71.7 (CH 2 0), 133.6
(ArC-H), 125.3 (ArC-H), 128.3 (ArC-H), 128.6 (ArC-CH2), 146.3 (ArC-OCH3),
151.5 (ArC-OCH2), 170.9 (COCH 2 ), 172.1 (COOCH3). M s (EI) m/z (%): 279 (10,
M+), 262 (5), 220 (5), 223 (46), 192 (45), 164 (100), 149 (46), 137 (50), 121 (20), 108
(70). Anal. Calcd for C14H17NO5: C, 60.21; H, 6.14; N, 5.02. Found: C, 60.45; H,
6.33; N, 4.86.
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O

H
I

0 COOCH 3

r^^N;
H3CO
(64)

(ii) A solution of (40) (150 m g , 0.475 m m o l ) in benzene (300 ml) was
irradiated for 10 h. The organic solvent was evaporated in vacuo to give a
pale yellow oil. The oil was chromatographed as above to give the starting
material (40 m g , 11%) and (64) (40 m g , 30%; 3 9 % based on recovered starting
material) after recrystallization from ethanol.

Preparation of N-[2-(3,4-Dihyroxyphenol)ethyl]chloacetamide (41)

H

HO.

V ^ y ^ , N^^^CHzCl

AJ

HO

v

Y
o

To a stirred solution of N-[2-(3,4-dimethoxyphenyl)ethyl]
chloacetamide (7) (0.2 g, 0.77 mmol) in dry D C M (5 ml), under N 2 / at -78°C
was added boron tribromide (0.2 ml, 2.12 mmol). The solution was allowed
to stir at this temperature for 0.5 h and then at room temperature overnight.
A saturated solution of a m m o n i u m chloride (1 ml) was added and the pH
was adjusted to 7 ( N a O H , 1M). A small amount of sodium chloride was
then added and the solution was extracted with EtOAc (3 x 40 ml). The
combined extracts were dried, evaporated and chromatographed ( D C M :
M e O H , 96 : 4) to give N-[2-(3,4-dihydroxyphenol)ethyl]chloroacetamide (41)
(150 mg, 84%) as a colourless oil. l H ( C D 3 O D , 400 M H z ) 8: 2.65 (t, J=7.2 Hz, 2H,
CH 2 Ar), 3.37 (t, J=7.2 Hz, 2H, C H 2 N H ) , 4.00 (s, 2H, CH 2 C1), 6.52 (dd, J=8.0,1=2.4
Hz, l H a r o m ) , 6.64 (d, J=2.4 Hz, l H a r o m ) , 6.67 (d, J=8.0 Hz, l H a r o m ) - M s (CI) m / z
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(%): 232 (35, M++1,37C1), 230 (100, M++1, 35C1), 194 (10), 137 (100), 136 (100),
123 (100).

Preparation of N-[2-(3.4-Diethoxyphenyl)ethyl]chloroacetamide (42

AJ5
H3CH2CO
^^
A mixture of N-[2-(3,4-dihydroxyphenyl)ethyl]chloroacetamide (41)
(200 mg, 1.0307 mmol), potassium carbonate (300 mg, 2.171 mmol) and
diethyl sulfate (0.42 ml) in methyl ethyl ketone (10 ml) was refluxed
overnight. Water (15 ml) and a saturated solution of ammonium chloride
(2 ml) were then added and the mixture was extracted with D C M (3 x 20 ml).
The

combined

chromatographed

extracts
(DCM

were

washed, dried, evaporated

and

: M e O H , 99 : 1) to give N-[2-(3,4-

diethoxyphenyl)ethyl]chloroacetamide (42) (328 mg, 88%) as colourless
crystals, m p 89-90°C (DCM/MeOH). iH-Nmr (CDC13/ 400 M H z ) 8: 1.43 (t,
J=4.0 Hz, 3H, CH3CH2O), 1.46 (t, J=4.0 Hz, 3H, CH3CH2O), 2.77 (t, J=6.8 Hz, 2H,
CH 2 Ar), 3.53 (q, J=6.8 Hz, C H 2 N H ) , 4.02 (s, 2H, CH2C1), 4.06 (q, J=4.0 Hz, 2H,
C H 3 C H 2 0 ) , 4.09 (q, J=4.0 Hz, 2H, CH3CH2O), 6.64 (s, 1H, N H ) , 6.70-6.84 (m,
3H a r o m ). 13 C-Nmr (CDCI3,100 M H z ) 8: 14.8 (2 x CH3CH2O), 34.9 (CH2Ar), 41.0
(CH 2 NH), 42.6 (CH2C1), 64.4 (CH3CH2O), 64.5 (CH3CH2O), 113.7 (ArC-H), 113.9
(ArC-H), 120.7 (ArC-H), 130.8 (ArC-CH2), 147.4 (ArC-O), 148.8 (ArC-O), 165.7
(CO). M s (EI) m/z (%): 287 (0.2, M+, 37C1), 285 (0.6, M + ,35C1), 236 (0.1), 226
(0.1), 222 (0.4), 192 (100), 179 (20), 164 (38), 151 (34), 136 (50), 123 (71). Anal.
Calcd for Ci 4 H 2 o0 3 N 35 Cl: C, 58.92; H, 7.07; N, 4.91. Found: C, 58.54; H, 7.10;
N, 4.79.
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Photolysis of N-[2-(3,4-Diethoxyphenyl)ethyl]chloroacetamide (42)
A solution of (42) (270 mg, 0.946 mmol) in benzene (350 ml) was

irradiated at room temperature for 4 h. The solvent was then evaporate
and the residue was chromatographed (EtOAc : hexane, 70 : 30 and then

DCM : MeOH, 98.5 : 1.5) to give three fractions. The first fraction was

material (100 mg, 35%). The second fraction was rechromatographed (sam

conditions as above) to give 12-ethoxy-3-methyl-2-oxa-6-azabicyclo[7.3
trideca-l(13),9,ll-trien-5-one (65) (26 mg, 11%) as a pale yellow gum
evaporation. lH-Nmr (CDC13, 400 MHz) 8: 1.43 (t, J=6.8 Hz, 3H,
CH3CH2OAr), 1.46 (d, J=6.8Hz, 3H, CHsCHOAr), 2.35-2.37 (m, 1H, CHCO),

2.38-2.50 (m, 2H, CH2Ar), 2.78-2.84 (m, 1H, CHCO), 3.08-3.12 (m, 1H, CHNH

3.36-3.44 (m, 1H, CHNH), 4.03-4.17 (m, 2H, CH3CH2OAr), 4.42-4.50 (m, 1H,
CH3CHOAr), 4.98 (d, 1H, NH), 6.82 (d, J=2.0 Hz, lHarom), 6.86 (d, 1=8.0 Hz,
lHarom), 6.91 (dd, J=8.0, J=2.0 Hz, lHarom)-
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C-Nmr (CDC13,100 MHz) 8: 15.0

(CH3CH2OAr), 22.1 (CH3CHOAr), 38.4 (CH2Ar), 44.0 (CH2NH), (CH2CO), 46.4
(CH2CO), 53.4 (CH3CH2OAr), 78.7 (CH3CHOAr), 115.2 (ArC-H), 124.4 (ArC-H),
128.4 (ArC-H), 123.0 (ArC-CH2), 146.4 (ArC-O), 150.6 (ArC-O), 171.8 (CO). Ms
(EI) m/z (%) 249 (27, M+; accurate mass 249.1379, Ci4H19N03 requires

249.1365), 220 (3), 206 (9), 192 (11), 177 (5), 164 (100), 151 (17), 149 (37

123 (30). The third fraction was a mixture of 7,8-diethoxy-l/2,4/5-tetr
2H-3-benzazepin-2-one (67) and 8,9-diethoxy-l,2,4,5-tetrahydro-3H-3benzazepin-2-one (68) (72 mg, 31%) as a pale yellow oil. ^-Nmr (CDCI3,

MHz) 8: 1.38-1.45 (m, 12H, 4 x CH3CH2O), 2.99-3.07 (m, 4H, 2 x CH2CH2NH)
3.49-3.58 (m, 4H, 2 x CH2CH2NH), 3.74 (s, 2H, COCH2), 3.94 (s, 2H, COCH2),

3.99-4.08 (m, 8H, 4 x CH3CH2O), 6.27 (s, 1H, NH), 2.45 (s, 1H, NH), 6.61
lHarom), 6.63 (s, lHarom), 6.74 (d, J=8.0 Hz, lHar0m), 6.79 (d, 1=8.0 Hz, lHarom)-

Ms (EI) m/z (%): 249 (65, M+), 234 (4), 221 (14), 220 (18), 206 (8), 193 (1
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(32), 177 (20), 165 (22), 164 (100), 163 (36), 149 (35), 140 (40), 136 (60), 135 (46), 123
(35).

O
y^—-NH
H

3

CH

2

CO

N

l/

NH
H3CH2CO^
(67)

H 3 CH 2 CO

0

(65)

Vv

^
(68)

Preparation of N-[2-(3-Hydroxy-4-methoxyphenyl)ethyl]chloroacetamide (43)

HO

NH

ys r ^s/ N.Y C H 2 a

HgCO^^^^

To a stirred solution of N-2-(3-hydroxy-4-methoxyphenyl)ethylamine
hydrochloride64'65 (200 m g , 0.98 mmol) in T H F (20 ml), under N 2 , was added
an aqueous sodium hydroxide solution (3.5 ml, 5M). The solution was then
allowed to cool in an ice bath. Chloroacetyl chloride was added dropwise
until a white precipitate was observed. The mixture was allowed to stir for 1
h. It was basified to p H 9 (1M N a O H ) and then acidified to p H 6.5 (1M HC1).
This solution w a s then extracted with D C M (3 x 30 ml). The combined
organic extracts were washed with water (15 ml), dried and evaporated to
give a yellow oil. The oil was then chromatographed. Elution with EtOAc :
hexane, 45 : 55 gave N-[2-(3-hydroxy-4-methoxyphenyl)ethyl]chloroacetamide
(43) as a colourless oil (210 m g , 88 % ) . i H - N m r (CDC1 3 , 400 M H z ) 8: 2.75 (t,
J=7.2 Hz, 2H, CH 2 Ar), 3.53 (q, J=7.2 Hz, 2H, C H 2 N H ) , 3.88 (s, 3H, CH3O), 4.02 (s,
2H, CH 2 C1), 6.61 (s, 1H, N H ) , 6.68 (dd, J=8.0, J=2.0 Hz, lH a r om), 6.78 (d, J=2.0,
l H a r o m ) , 6.80 (d, J=8.0 H z , l H a r o m ) . M s (CI) m / z (%): 246 (4, M++1, 37 C1), 244

21

(11, M++1, 35C1), 150 (93), 137 (100), 135 (48); (EI) m/z: accurate mass 243.0658,
CnHi4N0335Cl requires 243.0662.

Preparation of N-[2-(3-Ethoxy-4-methoxyphenyl)ethyl]chloroacetami

H 3 CH 2 CO^ ^^

^^

N^

^CH2C1

YY^Y

H3CO

V

A mixture of N-[2-(3-hydroxy-4-methoxyphenyl)ethyl]chloroacetamid

(43) (210 mg, 0.863 mmol), potassium carbonate (200 mg, 1.447 mmo

diethyl sulfate (0.3 ml) in methyl ethyl ketone (8 ml) was reflux

The mixture was placed in an ultrasonic bath for 10 min to make a

homogeneous suspension and then it wTas allowed to continue reflu

overnight. Water (10 ml) and a saturated ammonium chloride soluti

ml) were added and the mixture was extracted with DCM (3 x 20 ml)

combined extracts were dried, evaporated and chromatographed (EtO
hexane, 40 : 60) to give N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]

chloroacetamide (44) (165 mg, 55%) as colourless crystals, mp 80-

(EtOAc/hexane). lH-Nmr (CDCI3, 300 MHz) 8: 1.46 (t, J=6.0 Hz, 3H,

CH3CH2O), 2.77 (t, J=6.9 Hz, 2H, CH2Ar), 3.53 (q, J=6.9 Hz, 2H, CH2NH

(s, 3H, CH3O), 4.01 (s, 2H, CH2C1), 4.09 (q, J=6.0 Hz, CH3CH2O), 6.69
NH), 6.72-6.84 (m, 3Harom).
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C-Nmr (CDCI3, 75 MHz) 8: 14.7 (CH3CH20),

34.9 (CH2Ar), 40.9 (CH2NH), 42.5 (CH2C1), 55.9 (CH3O), 64.2 (CH3CH20), 1

(ArC-H), 113.4 (ArC-H), 120.6 (ArC-H), 130.7 (ArC-CH2), 148.1 (ArC-O),
(Ar-O), 165.6 (CO). Ms (EI) m/z (%): 273 (3, M+,

37

C1), 271 (9, M+,

35

C1), 17

(17), 178 (100), 165 (46), 150 (46), 150 (37), 137 (40), 135 (25), 12

Calcd for Cli3Hi803N35Cl: C, 57.54; H, 6.69; N, 5.17. Found: C, 57.7
N, 4.94.

12°

Photolysis of N-[2-(3-Ethoxy-4-methoxyphenyl)ethyl]chloroacetamide (44)
A solution of (44) (270 m g , 1.006 mmol) in benzene (350 ml) was
irradiated at room temperature for 4 h. The solvent was then evaporated
and the residue was chromatographed (EtOAc : hexane, 70 : 30 and then
D C M : M e O H , 98.5 : 1.5) to give three fractions. The first fraction was stating
material (98 m g , 36%). The second fraction was rechromatographed to give

12-methoxy-3-methyl-2-oxa-6-azabicyclo[7.3.1.]trideca-l(13)/9,ll-trien(66) (28 m g , 12%) as a pale yellow g u m after evaporation. iH-Nmr (CDCI3,
400 M H z ) 8: 1.45 (d, J=6.8Hz, 3H, C H 3 C H O A r ) , 2.35-2.37 (m, 1H, C H C O ) , 2.382.50 (m, 2H, CH 2 Ar), 2.78-2.84 (m, 1H, C H C O ) , 3.08-3.12 (m, 1H, C H N H ) , 3.363.44 (m, 1H, C H N H ) , 3.88 (s, 3H, CH3O), 4.42-4.51 (m, 1H, C H 3 C H O A r ) , 4.97 (d,
1H, N H ) , 6.81 (d, J=2.0 Hz, l H a r o m ) , 6.85 (d, J=8.0 Hz, lH aror n), 6.90 (dd, J=8.0,
J=2.0 H z , lHarom)- M s (EI) m / z (%) 235 (30, M + ; accurate mass 235.1193,
C13H17NO3 requires 235.1208), 164 (100), 151 (17). The third fraction was a

mixture of 7-ethoxy-8-methoxy-l,2,4,5-tetrahydro-2H-3-benzazepin-2-one (

and 8-methoxy-9-ethoxy-l,2,4,5-tetrahydro-3H-3-benzazepin-2-one (70) (76
mg, 32%). iH-Nmr (CDCI3, 400 M H z ) 8: 1.37-1.44 (m, 6H, 2 x C H 3 C H 2 0 ) , 2.993.08 (m, 4H, 2 x C H 2 C H 2 N H ) , 3.48-3.58 (m, 4H, 2 x C H 2 C H 2 N H ) , 3.74 (s, 2H,
C O C H 2 ) , 3.94 (s, 2H, C O C H 2 ) , 3.88 (s, 3H, CH3O), 3.89 (s, 3H, CH3O), 3.99-4.08
(m, 4H, 2 x C H 3 C H 2 O ) , 6.28 (s, 1H, N H ) , 2.44 (s, 1H, N H ) , 6.61 (s, l H a r o m ) , 6.64
(s, l H a r o m ) , 6.75 (d, J=8.0 Hz, l H a r o m ) , 6.78 (d, J=8.0 Hz, l H a r o m ) .

HoC
H3CH2CO,
NH
H3CO
(69)

°

(70)
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Preparation of N-[2-(3-Hydroxy-4-methoxyphenyl)ethyl]iodoacetamide (50)

HO.

^cv.

TT

S^

H3CO'

H

^
2
•^ ^ N^
^
\ ^ /,CH,I

O

^

A mixture of (43) (200 m g , 0.821 mmol) and sodium iodide (410 m g ,
2.73 m m o l ) in acetone (10 ml) was allowed to stir overnight. The solvent
was then evaporated and the crude residue was chromatographed. Elution
with EtOAc : hexane, 50 : 50 gave N-[2-(3-hydroxy-4-methoxyphenyl)ethyl]
iodoacetamide (50) (262 m g , 95 % ) as a colourless crystalline solid after
evaporation, m p 131-133°C i H - N m r (CDC1 3/ 400 M H z ) 8: 2.73 (t, J=9.6 H z ,
2H, C H 2 A r ) , 3.49 (q, J=9.6 H z , 2H, C H 2 N H ) , 3.65 (s, 2H, CH 2 I), 3.88 (s, 3H,
C H 3 O ) , 5.61 (s, 1H, O H ) , 6.01 (s, 1H, N H ) , 6.68 (dd, J=12.0, J=3.4 Hz, l H a r 0 m ) ,
6.78 (d, J=3.4 Hz, l H a r o m ) , 6.80 (d, J=12.0 Hz, l H a r o m ) . M s (CI) m / z (%): 336 (40,
M + + 1 ) , 208 (10), 191 (12), 151 (80), 150 (100), 137 (100), 135 (61); (EI) m / z :
accurate mass 335.0003, C11H14NO3I requires 335.0018.

Preparation of N-[2-(3-Pivalylcarbonyloxymethoxy-4-methoxyphenyl)ethyl]
iodoacetamide (51)

W ^ C ^ ^,0^

0

O.

..

M

^CH9I

„^\}

H3CO'

A mixture of (50) (700 m g , 2.09 mmol), iodomethyl pivalate57 (0.6 ml)
and potassium carbonate (520 m g , 3.77 mmol) in acetone (15 ml) was allowed
to stir overnight under N 2 . The solvent was then evaporated and the crude
residue was chromatographed. Elution with EtOAc : hexane, 45 : 55, afforded
two fractions. The solvent in the first fraction was evaporated to give N-[2-
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(3-pivalylcarbonyloxymethoxy-4-methoxyphenyl)ethyl]iodoacetamide (

(591 mg, 63 %, 72 % based on recovered starting material) as a pal
iH-Nmr (CDC13, 400 MHz) 8: 1.20 (s, 9H, (CH3)3C), 2.78 (t, J=7.0 Hz,
CH2Ar), 3.52 (q, J=7.0 Hz, 2H, CH2NH), 3.78 (s, 2H, CH2I), 3.85 (s, 3H,

5.77 (s, 2H, OCH20), 6.68 (s, 1H, NH), 6.87-6.91 (m, 3Harom). Ms (EI) m/
449 (20, M+; accurate mass 449.0697, Ci7H24N05I requires 449.0699),
137 (100). The second fraction contained the starting material (86

Preparation of N-[2-(3-Pivalylcarbonyloxymethoxy-4-methoxyphenyl)
chloroacetamide (52)

(H3C)3C^^ o^ O S -

v^n-i^,!

O
H3CO

A mixture of (51) (590 mg, 1.65 mmol), lithium chloride (355 mg, 8.

mmol) and silver nitrate (384 mg, 2.26 mmol) in acetone (10 ml) wa

to stir for 48 h. The solvent was then evaporated and the crude re

extracted with DCM (50 ml). The extract was washed with water (2 x

dried and evaporated to give N-[2-(3-pivalylcarbonyloxyuiethoxy-4methoxyphenyl) ethyl]chloroacetamide (52) (537 mg, 91%) as a pale

oil. iH-Nmr (CDCI3, 400 MHz) 8: 1.20 (s, 9H, (CH3)3C), 2.78 (t, 7.0 H

CH2Ar), 3.52 (q, J=7.0 Hz, 2H, CH2NH), 3.85 (s, 1H, NH), 4.02 (s, 2H, C
5.77 (s, 2H, OCH20), 6.68 (s, 1H, NH), 6.87-6.91 (m, 3Harom)-
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C-Nmr (C

100 MHz) 26.8 ((CH3)3C), 27.2 ((CH3)3C), 34.7 (CH2Ar), 40.9 (CH2NH), 42.5
(CH2C1), 55.8 (CH3O), 86.9 (OCH20), 112.0 (ArC-H), 118.1 (ArC-H), 123.7

H), 130.7 (ArC-CH2), 145.9 (ArC-O), 148.9 (ArC-O), 165.7 (COCH2Cl), 177
((CH3)3CCO). Ms (EI) m/z (%): 357 (0.7, M+,

35

C1; accurate mass 357.1

25
C i 7 H 2 4 N 0 5 3 5 C l requires 357.1343), 327 (1), 256 (2), 235 (41), 234 (7), 233 (2), 226
(2).
Reaction of N-[2-(3-Hydroxy-4-methoxyphenyl)ethyl]chloroacetamide (43)
with Chloromethyl Pivalate
A mixture of (43) (0.206 m g , 0.846 mmol), chloromethyl pivalate (0.25
ml) and potassium carbonate (140 m g , 1.013 mmol) in acetone (5 ml) was
allowed to stir overnight under N 2 . The solvent was then evaporated and
the crude residue was chromatographed. Elution with EtOAc : hexane, 45 :
55, afforded

N-[2-(3-pivalylcarbonyloxy-4-methoxyphenyl)ethyl]

chloroacetamide (47) as a pale yellow oil. iH-Nmr (CDCb, 400 M H z ) 8: 1.19
(s, 9H, (CH 3 ) 3 C), 2.77 (t, 7.0 Hz, 2H, CH 2 Ar), 3.54 (q, J=7.0 Hz, 2H, C H 2 N H ) , 3.84
(s, 1H, N H ) , 4.02 (s, 2H, CH 2 C1), 5.77 6.68 (s, 1H, N H ) , 6.86-6.91 (m, 3 H a r o m ) .
M s (EI) m / z (%): 327 (2, M + , 35 C1; accurate mass 327.1235, C i 6 H 2 2 N 0 4 3 5 C l
requires 327.1237), 256 (3), 235 (40).

(H 3 C) 3 C^O
NHCOCH2Cl

H3CO

(47)

Reaction of N-[2-(3-Hydroxv-4-methoxyphenyl)ethyllchloroacetamide (43)
with Iodomethyl Pivalate
A mixture of (43) (0.201 m g , 0.825 mmol), chloromethyl pivalate (0.25
ml) and potassium carbonate (140 m g , 1.013 mmol) in acetone (5 ml) was
allowed to stir overnight under N 2 . The solvent was then evaporated and
the crude residue was chromatographed. Elution with EtOAc : hexane, 45 :
55, afforded two fractions. The first fraction contained (47) and (52) (121 mg),

126

in a ratio of 2:3 respectively, as a pale yellow oil. The second fraction was
evaporated to give (49) and (51) (149 m g ) , in a ratio of approximately 2:3, as a
pale yellow oil.

The oil w a s rechromatographed to give N-[2-(3-

pivalylcarbonyloxy-4-methoxyphenyl)ethyl] chloroacetamide (49) (50 m g ,
15%) as a pale yellow oil. ^ - N m r (CDC1 3/ 400 M H z ) 8: 1.21 (s, 9H, (CH 3 ) 3 C),
2.78 (t, 7.0 H z , 2H, C H 2 A r ) , 3.53 (q, J=7.0 H z , 2H, C H 2 N H ) , 3.84 (s, 1H, N H ) ,
3.78 (s, 2H, CH 2 I), 5.77 6.68 (s, 1H, N H ) , 6.85-6.91 (m, 3 H a r o m ) . M s (EI) m / z
(%): 419 (3, M + ; accurate mass 419.2594, C i 6 H 2 2 N 0 4 I requires 419.2595), 235
(45).

NHCOCHnl
H3CO
(49)

Photolysis of N-[2-(3-Pivalylcarbonyloxymethoxy-4-methoxyphenyl)ethyl]
chloroacetamide (52) in Benzene
A solution of (52) (140 m g , 0.392 m m o l ) in benzene (350 ml) was
irradiated for 4 h at room temperature. The organic solvent was evaporated
in vacuo and the residual oil was dissolved in EtOAc (80 ml). The extract
was washed with brine (3 x 15 ml), dried, evaporated and chromatographed
(DCM

: M e O H , 98 : 2) to leave a yellow oil.

The oil w a s then

rechromatographed. Elution with EtOAc : hexane, 45 : 55 gave five fractions.
The first fraction contained the starting material (52) (25 m g , 18 %,). The
solvent in the second fraction was evaporated to give (74) (20 m g , 16 % ) as a
pale yellow oil. i H - N m r (CDCI3, 400 M H z ) 8: 1.25 (s, 9H, (CH 3 ) 3 C), 2.58 (t,
J=6.4 H z , 2H, C H 2 A r ) , 3.47 (q, J=6.4 H z , 2H, C H 2 N H ) , 3.90 (s, 3H, C H 3 O ) , 4.00 (s,
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2H, CH 2 C1), 5.76 (s, 1H, O H ) , 6.75 (d, 1=8.4 Hz, l H a r o m ) , 6.82 (d, J=8.4 Hz,
lHarom)-

13

C-Nmr (CDC13, 100 MHz) 8: 26.9 ((CH3)3C), 27.4 ((CH3)3C), 31.9

(CH 2 Ar), 41.5 ( C H 2 N H ) , 42.6 (CH2C1), 59.1 (CH3O), 110.9 (ArC-H), 121.0 (ArCH), 127.3 (ArC-CH2), 129.1 (ArC-CO), 129.4 (ArC-O), 141.0 (ArC-O), 166.3
(COCH2Cl), 182.9 (COC(CH3)3). Ms (EI) m/z (%): 327 (2, M+,

35

C1; accurate

mass 327.1248, Ci6H22N0435Cl requires 327.1237), 270 (10), 252 (2), 234 (1
(13), 165 (8), 150 (13), 137 (17). The third fraction was evaporated to give (75)
(15 mg, 10%) as a pale yellow oil. iH-Nmr (CDCI3, 400 MHz) 8: 1.18 (s,
(CH 3 ) 3 C), 2.65 (t, J=7.2 Hz, 2H, CH 2 Ar), 3.42 (q, J=7.2 Hz, 2H, C H 2 N H ) , 3.54 (s,
2H, CH2Ph), 3.84 (s, 3H, CH3O), 5.73 (s, 2H, OCH20), 6.67-6.81 (m, 3Harom),

7.17-7.32 (m, 5Harom). Ms (EI) m/z (%): 399 (0.5, M+), 369 (0.5), 298 (1.2), 29

(1), 285 (0.5), 264 (2), 234 (6). The fourth fraction was (43) (20 mg, 21

solvent in the fifth fraction was evaporated to give (77) (10 mg, 9%) a

yellow oil. iH-Nmr (CDCI3, 400 MHz) 8: 2.63 (t, J=6.8 Hz, 2H, CH2Ar), 3.4
J=6.8 H z , 2H, C H 2 N H ) , 3.54 (s, 2H, CH 2 Ph), 3.87 (s, 3H, CH3O), 5.34 (s, 1H,

NH), 5.60 (s, 1H, OH), 6.50 (dd, J=8.0, J=2.0 Hz, lHarom), 6.63 (d, 1=2.0 Hz,

lHarom), 6.70 (d, J=8.4 Hz, lHarom), 7.17-7.33 (m, 5Harom). Ms (EI) m/z (%) 285
(1, M + ; accurate mass 285.1359, C17H19NO3 requires 285.1365), 271 (0.8), 255
(0.2), 219 (0.8), 194 (1), 150 (100), 137 (34), 135 (30), 91 (81).

C(CH3)3

c=o
^

V

V

^

H3CO
(74)

N^.CH 2 C1

(H3C)3CCO< >i 1,« 1)
H 3 CO

H

°\^/-^N

CH2Ph

(77)

Photolysis of N-![2-(3-Pivalylcarbonyloxymethoxy-4-methoxyphenyl)ethyl]
chloroacetamide (52) in T H F
A solution of (52) (390 m g , 1.09 mmol) in T H F was photolysed for 4 h
at room temperature. The solvent was evaporated in vacuo and the crude
residue was chromatographed. The first elution with EtOAc : hexane, 50 : 50
gave the starting material (160 m g , 41%). The second elution with D C M :
M e O H , 98 : 2, gave

N-[2-(3-pivalylcarbonyloxymethoxy-4-

methoxyphenyl)ethyl]acetamide (78) (90 m g , 25%, 4 3 % based on recovered
starting material) as a pale yellow oil. ^ - N m r (CDCI3, 300 M H z ) 8: 1.19 (s,
9H, (CH 3 ) 3 C), 1.95 (s, 3H, C O C H 3 ) , 2.09 (s, 1H, N H ) , 2.74 (t, J=9.4 H z , 2H,
CH 2 Ar), 3.46 (q, J=9.4 Hz, 2H, C H 2 N H ) , 3.85 (s, 3H, CH3O), 5.77 (s, 2H, O C H 2 0 ) ,
6.86-6.90 (m, 3 H a r 0 m ) -
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C - N m r (CDCI3, 75 M H z ) 8: 23.1 (COCH3), 26.9

((CH3)3C), 34.8 (CH 2 Ar), 40.6 ( C H 2 N H ) , 55.9 (CH3O), 87.0 (OCH 2 0), 112.3 (ArCH ) , 118.5 (ArC-H), 123.9 (ArC-H), 131.4 (ArC-CH 2 ), 145.8 (ArC-O), 170.0
( C O C H 3 ) , 177.3 ((CH 3 ) 3 CCO). M s (EI) m / z (%): 323 (3, M + , accurate mass
323.1738, C17H25NO5 requires 323.1733), 293 (2), 264 (4), 234 (40), 222 (2), 192
(10), 180 (5), 163 (5), 150 (100), 137 (13), 135 (12).

H 3 CO

^^
(78)
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Preparation of N-f2-(3-Methoxymethylmethoxy-4-methoxyphenyl)ethyn
chloroacetamide (53)

H3CO

\^°\^\^v^N

.CH2C1

XT-T

H3CO

A stirred solution of N-[2-(3-hydroxy-4-methoxyphenyl)ethyl]
chloroacetamide (43) (91 m g , 0.374 mmol) in T H F (5 ml), under N 2 , was
cooled in an ice bath. To this solution was added sodium hydride (35 mg,
60%, 0.87 mmol).

After 5 min, chloromethyl methyl ether (0.05 ml, 4.27

mmol) was then added. The solution was allowed to stir for 3 h and then
filtered through a filter aid (Celite).

Solvent was evaporated and the

remaining residue was chromatographed. Elution with EtOAc : hexane, 50 :
50 gave N-12- (3 -methoxyme

thy Imethoxy-4-methoxyphenyl)

ethyl]

chloroacetamide (53) (100 m g , 94%) as a colourless oil after evaporation.

a

H-

N m r (CDCI3, 400 M H z ) 8: 2.77 (t, J=6.8 Hz, CH 2 Ar), 3.51 (s, 3H, C H 2 O C H 3 ) ,
3.53 (q, J=6.8, C H 2 N H ) , 3.86 (s, 3H, CH 3 0-Ar), 4.02 (s, 2H, CH 2 C1), 5.22 (s, 2H,
O C H 2 0 ) , 6.72 (s, 1H, N H ) , 6.80-6.86 (m, 3 H a r o m ) .
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C-Nmr (CDCI3, 100 M H z )

8: 34.6 (CH 2 Ar), 40.9 ( C H 2 N H ) , 42.5 (CH2C1), 55.8 (CH 3 0-Ar), 56.1 (CH2OCH3),
95.3 (OCH2O), 111.8 (ArC-H), 122.2 (ArC-H), 130.8 (ArC-CH2), 146.3 (ArC-O),
148.3 (ArC-O), 165.7 (CO). M s (EI) m / z (%): 287 (2, M + , 35C1; accurate mass
287.0922, Ci 3 Hi 8 N0 4 3 5 Cl requires 287.0924), 255 (2), 220 (1), 194 (14), 181 (14),
181 (3), 164 (12), 150 (7), 137 (5).

Photolysis of N-[2-(3-Methoxymethylmethoxv-4-methoxyphenyl)ethvl]
chloroacetamide (53)
A solution of (53) (100 m g , 0.348 mmol) in benzene (350 ml) was
irradiated for 3.5 h at room temperature. Solvent was evaporated in vacuo
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and the remaining crude residue was chromatographed. Elution with D C M :

MeOH : 98 : 2, gave four fractions. The first fraction was (43) (20 mg

obtained as a pale yellow oil after evaporation. The solvent in the se

fraction was evaporated to give (77) (15 mg, 15%) as a pale yellow cry
solid. The third fraction was unidentified. The fourth fraction was
rechromatographed. Elution with DCM : MeOH, 98 : 2, gave N -

methylenehydroxy-7-hydroxy-8-methoxy-l,2,4,5-tetrahydro-2H-3-benzazepi

2-one (79) as a pale yellow crystalline solid (15 mg, 18%) after evapo

mp 144-147°C (DCM/MeOH). iH-Nmr (CDC13, 400 MHz) 8: 3.09 (t, J=6.0, 2H,

CH2CH2N), 3.19 (t, J=8.0 Hz, 1H, CH2OH), 3.78 (s, 2H, COCH2), 3.82 (t, J=6.0

2H, CH2CH2N), 3.86 (s, 3H, CH3O), 4.90 (d, J=8.0 Hz, 2H, CH2OH), 5.51 (s, 1H
ArOH), 6.59 (s, lHarom), 6.67 (s, lHar0m)- Ms (EI) m/z (%): 237 (7.5, M+), 219

(3), 207 (16), 193 (5), 178 (2.5), 163 (7), 151 (57), 150 (67), 137 (20), 136 (1

(32); (CI) m/z: accurate mass 238.1065 (MH+), 238.1065, Ci2Hi6N04 require
238.1079.

HO>
||

NCH
N 2 OH

(79)

°

Preparation of N-(2-[3-((E)-2'-Methoxycarbonvlethpnyloxv)-4-methoxyphenyl
ethyllchloroacetamide (54. cis and trans isomers)

H

3 C O \ ^ ^ v ^O

^^

..

M

CH2C1

s^XT^
H300-

To a stirred solution of N-[2-(3-hydroxy-4-methoxyphenyl)ethvl]
chloroacetamide (43) (390 m g , 1.602 mmol) in dry T H F (20 ml), under N 2 /
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added sodium hydride (120 m g , 60%, 3.00 mmol). Methyl propiolate (0.2 ml,
2.38 m m o l ) was then added. The solution was allowed to stir overnight.
The solvent was then evaporated and the crude residue was extracted with
D C M (30 ml). The extract was washed with water (2 x 10 ml), dried,
evaporated and chromatographed on aluminium oxide, neutral activity I.
Elution with

EtOAc

: hexane, 35

: 65, gave

N-{2-[3-((E)-2'-

methoxycarbonylethenyloxy)-4-methoxyphenyl]ethyl)chloroacetamide (54)
(105 m g , 20%) as a colourless crystalline solid after evaporation, m p 77-79°C
(EtOAc/hexane). i H - N m r (CDC1 3 , 400 M H z ) 8: 2.79 (t, J=7.2 H z , 2H, C H 2 A r ) ,
3.53 (q, J=7.2 H z , 2H, C H 2 N H ) , 3.71 (s, 3H, C O O C H 3 ) , 3.85 (s, 3H, CHsOAr), 4.04
(s, 2H, CH 2 C1), 5.43 (d, J=12.4 Hz, 1H, C O C H C H ) , 6.60 (s, 1H, N H ) , 6.90 (d, J=2.0
Hz, lH a r 0 m), 6.92 (d, J=8.4 H z , lH a r 0 m), 7.01 (dd, J=8.4, J=2.0 Hz, lH a r 0 m), 7.71
(d, J=12.4 H z , C O C H C H ) .

13

C - N m r (CDCI3, 75 M H z ) 8: 34.6 (CH 2 Ar), 40.9

( C H 2 N H ) , 42.6 (CH 2 C1), 51.3 ( C O O C H 3 ) , 56.1 (CH 3 OAr), 100.8 (ArC-H), 113.2
(ArC-H), 120.7 (ArC-H), 126.3 ( C O C H C H ) , 131.4 (ArC-CH 2 ), 144.4 (ArC-O),
149.2 (ArC-O), 160.7 ( C O C H C H ) , 165.8 (COCH 2 Cl), 167.7 (COOCH3). M s (EI)
m / z (%): 329 (1.3, M + , 3 7 C1), 327 (4, M + , 3 5 C1; accurate mass 327.0870,
Ci5Hi 8 N05 3 5 Cl requires 327.0874), 234 (100), 221 (8), 203 (11), 175 (8), 147 (7),
135 (35), 134 (18). Further elution with D C M : M e O H , 98 : 2, gave N-{2-[3-((Z)~
2'-methoxycarbonylethenyloxy)-4-methoxyphenyl]ethyl}chloroacetamide (54)
(90 mg, 17%) as a colourless oil. lU-Nmr

(CDCI3, 400 M H z ) , 2.79 (t, J=7.2 H z ,

2H, CH 2 Ar), 3.53 (q, J=7.2 H z , 2H, C H 2 N H ) , 3.75 (s, 3H, C O O C H 3 ) , 3.84 (s, 3H,
C H 3 O A r ) , 4.03 (s, 2H, CH 2 C1), 5.11 (d, J=7.2 H z , 1H, C O C H C H ) , 6.65 (s, 1H,
N H ) , 6.75 (d, J=7.2 H z , 1H, C O C H C H ) , 6.91 (d, J=8.0 Hz, lH a r o r n ), 6.97 (d, J=2.0
Hz, l H a r o m ) , 6.98 (dd, J=8.0, J=2.0 H z , l H a r o m ) . M s (EI) m / z (%): 329 (1.6, M + ,
37

C1), 327 (5, M + ,35 C1), 234 (100), 221 (12), 203 (17), 175 (13), 135 (69), 134 (41).

Photolysis of N-{2-[3-((E)-2'-Methoxycarbonylethenyloxy)-4-methoxyphenyn
ethylkhloroacetamide (54) in Acetonitrile
A solution of (54) (trans isomer) (70 m g , 0.214 m m o l ) in acetonitrile
(350 ml) was irradiated for 3 h at room temperature using. Potassium
carbonate (150 m g , 1.09 m m o l ) was then added and the solvent was
evaporated in vacuo. The crude residue was extracted with D C M (40 ml).
The extract was washed with water (2 x 10 ml), dried and evaporated to give a
yellow oil. The oil was chromatographed (EtOAc : hexane, 65 : 35 and then
D C M : M e O H , 98.5 : 1.5) to give two fractions. The first fraction was (43) (18
mg, 35%).

The second fraction was evapoated to give 7-((E)-2-

hydroxycarbonylethenyloxy)-8-methoxy-l,2,4,5-tetrahydro-2H-3-benzazepin2-one (80) (20 m g , 34%) as a pale yellow solid, m p 145-148°C ( D C M / M e O H ) .
iH-Nmr (CDC13, 300 M H z ) 8: 3.03 (t, J=7.2 Hz, 2H, C H 2 C H 2 N H ) , 3.49 (q, J=7.2
Hz, 2H, C H 2 C H 2 N H ) , 3.94 (s, 3H, CH3O), 4.05 (s, 2H, C O C H 2 ) , 6.48 (d, J=9.9 Hz,
1H, C O C H C H ) , 6.76 (s, 1H, N H ) , (s, l H a r o m ) , 7.03 (s, l H a r o m ) , 8.05 (d, J=9.9 Hz,
1H, C O C H C H ) . M s (EI) m / z (%): 277 (5, M + ; accurate mass 277.0948,
C14H15NO5 requires 277.0950), 135 (30).

O

H 3 CO' > ^ N -<
(80)

°

Photolysis of N-f2-r3-((E)-2'-Methoxycarbonylethenyloxy)-4-methoxvphenyl]
ethyPchloroacetamide (54) in Benzene
A solution of (54) (trans isomer) (70 m g , 0.214 mmol) in benzene (350
ml) was irradiated for 3 h at room temperature using 1 6 W mercury lamp.
The solvent was evaporated and the remaining crude was chromatographed
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(EtOAc : hexane, 65 : 35, and then D C M : M e O H , 98.5 : 1.5 to give two factions.
The first fraction was (54) (cis isomer) (15 mg, 21%). The second fraction
consisted (80) (16 mg, 27%).

Preparation of N-MethyH2-(3,4-dimethoxyphenyl)ethylkhloroacetamide (46)

CH3
H3C

°\^Y-V^N CH2C1

H3CO^^^
A mixture of N-methylhomoveratrylamine (510 mg, 2.61 mmol) and
sodium carbonate (310 mg, 292 mmol) in dry DCM (8 ml) was added
chloroacetyl chloride (0.3 ml, 3.762 mmol). The mixture was allowed to stir
overnight. Water (10 ml) was added and the two layers were separated. The
aqueous layer was extracted with further DCM (2 x 15 ml) and the combined
extracts were washed with water (2 x 10 ml), evaporated and
chromatographed. Elution with DCM : MeOH, 99 : 1, gave N-methyl-[2-(3,4dimethoxyphenyl)ethyl]chloroacetamide (46) (666 mg, 94%) as a colourless
crystalline solid after evaporation, mp 53-55°C (DCM/MeOH). iH-Nmr

(CDC13,400 MHz) 8: 2.80-2.86 (m, 2H, CH2Ar), 2.95 (s, 3/2H, 1/2 x CH3N), 3.01
(s, 3/2H, 1/2 x CH3N), 3.54-3.60 (m, 2H, CH2N), 3.69 (s, 1H, 1/2 x CH2C1), 3.86
(s, 3/2H, 1/2 x CH3O), 3.87 (s, 3/2H, 1/2 x CH3O), 3.87 (s, 3/2H, 1/2 x CH3O),

3.88 (s, 3/2H, 1/2 x CH3O), 4.06 (s, 1H, 1/2 x CH2C1), 6.65-6.83 (m, 3Harom)
Ms (CI) m/z (%): 273 (18, M++l,
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C1), 271 (5, M++1,

35

C1; accurate mass

271.0980 Ci3Hi8N0335Cl requires 271.0975), 235 (10), 165 (75), 164 (100), 152
(30), 151 (100), 149 (63).

Photolysis of N-methyl-|"2-(3,4-dimethoxyphenyl)ethyllchloroacetamidp (46)
A solution N-methyl-[2-(3,4-dimethoxyphenyl)ethyl]chloroacetamide
(46) (1.94 g, 7.145 mmol) in benzene (350 ml) was irradiated at room
temperature for 19 h using a 180W mercury lamp.

The solvent was

evaporated and the residue was chromatographed (EtOAc : hexane, 70 : 30, 80
: 20, and then 90 : 10) to give four fractions. The first fraction was the starting
material (1.2 g, 62%). The solvent in the second fraction was evaporated to
give (72) ( 50 mg, 3%, 8 % based on recovered starting material) as a pale
yellow oil. !H-Nmr (CDC13, 300 M H z ) 8: 2.99 (s, 3H, CH3N), 3.08 (t, J=6.4 Hz,
2H, CH2CH2N), 3.64 (t, J=6.4 Hz, 2H, CH2CII2N), 3.81 (s, 3H, CH3O), 3.84 (s,
3H, CH3O), 3.97 (s, 2H, CH 2 CO), 6.76 (d, J=9.4 Hz, lH a r o m ), 6.83 (d, J=9.4 Hz,
lH a r o m )-

The third fraction consisted of (73) ( 90 mg, 5%, 14% based on

recovered starting material) as pale yellow oil after evaporation. ^ - N m r
(CDCI3, 300 M H z ) 8: 3.03 (s, 3H, CH3N), 3.06 (t, J=6.8 Hz, 2H, ClfcC^N), 3.71
(t, J=6.8 Hz, 2H, CH2CIT2N), 3.840 (s, 3H, CH3O), 3.843 (s, 3H, CH3O), 3.88 (s,
C H 2 C O ) , 6.58 (s, lH a rom)/ 6.62 (s, l H a r 0 m ) -

The fourth fraction

rechromatographed (DCM : M e O H , 98.5 : 1.5) to give N-methyl-12-methoxy-

2-oxa-6-azabicyclo[7.3.1.]trideca-l(13),9,U-trien-5-one (71) (112 mg, 7
based on recovered starting material) as a pale yellow oil. ^ - N m r (CDCI3,
300 M H z ) 8: 2.57-2.59 (m, 1H, C H C O ) , 2.61-2.63 (m, 1H, CHAr), 2.71-2.75 (m,
1H, CHAr), 2.77-2.81 (m, 1H, CHCO), 2.86-2.88 (m, 1H, CHNCH3), 2.90-2.93 (m,
1H, CHNCH3), 3.15 (s, 3H, CH3N), 3.89 (s, 3H, CH3O), 4.13-4.16 (m, 2H, CH 2 0),
6.91-6.92 (m, 3 H a r o m ) .

M s (EI): 235 (22, M + ; accurate mass 235.1191,

C13H17NO3 requires 235.1208), 22 (2), 192 (6), 164 (40), 151 (10), 150 (10).

CH3

O I

NCH3
H3CQ

»3cXj

H 3 C O Xi

H3C 0 XJC^

C

(71) (72) (73)

Preparation of Methyl

2,2-Dichloroacetamido-3-(3,4-dihydroxyphenyl)

propanoate (55)
H

°WV NHCOCHCl2

J^J H "'COOCH3
HCT

^^

To a solution of L-dopa methyl ester hydrochloride (38) (0.5 g, 2.02

mmol) in dry THF (25 ml) under N2 were added triethylamine (0.56 ml,

mmol) and dichloroacethyl chloride (0.195 ml, 2.02 mmol). The solutio
was allowed to stir for 48 h at room temperature. Water (20 ml) was

added and the mixture was extracted with DCM (3 x 30 ml). The combin

extracts were washed with water (7 x 10 ml ). The combined wash solu

were extracted with DCM (20 ml) and then the combined organic extrac

were dried, evaporated and chromatographed. Elution with DCM : MeOH,
97 : 3, gave methyl 2,2-dichloroacetamido-3-(3,4-dihydroxyphenyl)

propanoate (55) (480 mg, 74%) as a pale yellow crystalline solid aft
evaporation, mp 134-136°C (DCM/MeOH). iH-Nmr (CDCI3,400 MHz) 8: 3.01

(dd, J=14.8, J=6.4 Hz, 1H, CHAr), 3.06 (dd, J=14.8, J=14.8, J=6.4,1H, C

(s, 3H, COOCH3), 4.73-4.76 (m, 1H, CHNH), 6.00 (s, 1H, CHC12), 6.49 (dd,
J=2.0 Hz, lHarom), 6.61 (d, J=2.0 Hz, lHarom), 6.75 (d, J=8.0 Hz, lHarom)-
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Nmr (CDCI3, 100 MHz) 8: 36.7 (CH2Ar), 52.5 (COOCH3), 53.9 (CHNH), 65.9

(CHC12), 115.1 (ArC-H), 115.8 (ArC-H), 120.9 (ArC-H), 126.7 (ArC-CH2), 143

(ArC-O), 144.4 (ArC-O), 164.0 (COCHCl2), 171.2 (COOCH3). M s (EI) m/z (%):
323 (0.45, M + , 3 7 C 1 ) , 321 (0.52, M + , 3 5 C1, accurate mass 321.0174,
Ci2Hi 3 N0 5 35 Cl 2 requires 321.0171), 262 (0.46), 238 (0.47), 222 (0.35), 194 (17),
123 (100).

Preparation of Methyl 2,2-Dichloroacetamido-3-(3,4-dimethoxyphenyl)
propanoate (58)

H3CO^^sv/vs^ NHCOCHCl2

H3COXJ

c

T' °°™^

To a solution (55) (500 m g , 1.553 m m o l ) in M e O H (10 ml) was added
excess of diazomethane in ether (30 ml). The solution was kept at 1°C for 20
h. The solvent was then evaporated in vacuo to give a yellow solid. The
solid w a s recrystallised from ethanol/diethylether to give methyl 2,2dichloroacetamido-3-(3,4-dimethoxyphenyl)propanoate (58) (460 m g , 85%) as
colourless crystals, m p 93-94°C (EtOH/Et 2 0). !H-Nmr (CDCI3, 400 M H z ) 8:
3.14-3.15 (m, 2H, C H 2 A r ) , 3.78 (s, 3H, C O O C H 3 ) , 3.85 (s, 3H, C H 3 O A r ) , 3.86 (s,
3H, C H 3 O A r ) , 5.94 (s, 1H, CHCI2), 4.81-4.85 (m, 1H, C H N H ) , 6.65 (dd, J=8.0,
J=2.0 H z , l H a r o m ) , 6.66 (d, J=2.0 Hz, lH a r o r n ), 6.80 (d, J=8.0 Hz, l H a r o m ) , 7.01 (d,
J=8.0 H z , 1H, N H ) .
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C-Nmr

(CDCI3, 100 M H z ) 8: 37.0 (CH 2 Ar), 52.6

(COOCH3), 53.8 ( C H N H ) , 55.8 (2 x C H 3 O A r ) , 66.0 (CHC1 2 ), 111.2 (ArC-H), 112.2
(ArC-H), 121.4 (ArC-H), 127.3 (ArC-CH 2 ), 148.3 (ArC-O), 148.8 (ArC-O), 163.4
(COCHCl 2 ), 170.9 ( C O O C H 3 ) . M s (EI) m / z (%): 351 (0.52, M + , 37 C1), 349 (0.96,
M+,35Q,

accurate mass 349.0494, C i 4 H i 7 N 0 5 3 5 C l 2 requires 349.0484), 318

(0.12), 292 (0.2), 290 (0.32), 266 (0.44), 236 (2), 222 (13), 151 (100).
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Photolysis of Methyl

2,2-Dichloroacetamido-3-(3.4-dimethoxyphenyl)

propanoate (58)
A solution of (58) (200 mg, 0.685 mmol) in benzene (350 ml) was

irradiated at room temperature for 2 h. The solvent was evaporated to gi
a yellow oil. The structures of the products remains undetermined.

Preparation of N-[2-(3,4-Dimethoxyphenyl)ethyl]dichloroacetamide (57)

A solution of homoveratrylamine (2.0 g, 11.0 mmol) and a finelv
divided anhydrous sodium carbonate (2.33 g, 22.0 mmol) in DCM (40 ml)

was stirred vigorously at 3°C while dichloroacetyl chloride (1.23 ml, 12
mmol) was added dropwise during 10 min. The mixture was allowed to stir
for further 1 h. Sodium carbonate was then removed by filtration and
washed with dichrorpmethane (25 ml). The combined organic phases were
washed with water (3 x 20 ml), dried and evaporated to give N-f2-(3,4-

dimethoxyphenyl)ethyl]dichloroacetamide (57) (2.221g, 69%) as pale yello
oil. iH-Nmr (CDCI3, 400 MHz) 8: 2.82 (t, J=7.6, 2H, CH2Ar), 3.57 (q, 1=7.6

2H, CH2NH), 3.88 (s, 3H, CH3O), 3.89 (s, 3H, CH3O), 5.91 (s, 1H, CHC12), 6.72 (d
J=2.0, lHarom), 6.76 (dd, J=8.0, J=2.0 Hz, lHarom), 6.83 (d, J=8.0 Hz, lHarom).

Photolysis of N-[2-(3.4-Dimethoxyphenyl)ethyl]dichloroacetamide (57)
A solution of (57) (200 mg, 0.685 mmol) in benzene (350 ml) was

irradiated at room temperature for 2 h. The solvent was evaporated and t

residue was chromatographed (DCM : MeOH, 97 : 3 ) to give a fraction whi

consisted of a mixture of the benzazepin-2-one isomers (82) and (83). Ms (EI)
m/z (%): 357 (20, M + , 37C1), 355 (61, M + , 35C1).

Preparation of Methyl 2.2.2-Trichloroacetamido-3-(3,4-dihydroxvphenvl
propanoate (56)

H0

N*100^

WV
J^J

HO

/'''COOCH3

^^
To a solution of L-dopa methylester (38) (300 mg, 1.211 mmol) in dry

THF (20 ml) under N 2 were added triethylamine (0.34 ml, 2.42 mmol) and
trichloroacethyl chloride (0.135 ml, 1.21 mmol). The solution was allowed to
stir at room temperature for 48 h. Water (15 ml) was then added and the
mixture was extracted with D C M ( 3 x 25 ml). The combined extracts were
washed with water (3 x 10 ml). The combined wash solutions were extracted
with EtOAc (2 x 20 ml) and then the combined organic extracts were dried
and evaporated to give methyl

2,2,2-trichloroacetamido-3-(3,4-

dihydroxyphenyl) propanoate (56) (415 mg, 96%) as a yellow oil.

^-Nmr

(CDC13,400 MHz) 8: 3.06 (dd, J=14.0, J=5.6 Hz, 1H, CHAr), 3.14 (dd, J=14.0, J=5.6
Hz, 1H, CHAr), 3.79 (s, 3H, COOCH3), 4.75-4.79 (m, 1H, C H N H ) , 6.51 (dd, J=8.0,
J=2.0 Hz, lH ar0 m), 6.65 (d, J=2.0 Hz, lH ar0 m)' 6.77 (d, J=8.0 Hz, lH a r o m ), 7.25 (d,
J=7.2 Hz, 1H, NH).

Preparation of Methyl 2.2.2-Trichloroacetamido-3-(3.4-dimethoxvphenvl
propanoate (59)

H a C O ^ ^ ^ / s ^ NHCOCCI3

SKJ
CH3O

H

"*COOCH3
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To a solution (56) (500 mg, 1.403 mmol) in M e O H (10 ml) was added

excess of diazomethane in ether (30 ml). The solution was kept at 1°
h. The solvent was then evaporated in vacuo to give a yellow solid.
3

solid was recrystallised from ethanol/diethylether to give methyl 2,

trichloroacetamido-3-(3,4-dimethoxyphenyl)propanoate (59) (465 mg, 8
pale yellow oil. iH-Nmr (CDC13, 400 MHz) 8: 3.12-3.22 (m, 2H, CH2Ar),

(s, 3H, COOCH3), 3.83 (s, 3H, CHsOAr), 3.84 (s, 3H, CH3OAr), 4.78-4.82 (

CHNH), 6.61 (dd, J=8.0, J=2.0 Hz, lHar0m), 6.64 (d, J=2.0 Hz, lHar0m), 6.78
J=8.0 Hz, lHarom), 7.20 (d, J=8.0 Hz, 1H, NH).

13

C-Nmr (CDCI3, 100 MHz)

36.4 (CH2Ar), 52.4 (COOCH3), 54.5 (CHNH), 55.4 (2 x CH3OAr), 110.8 (ArC-H),

111.8 (ArC-H), 121.0 (ArC-H), 126.7 (ArC-CH2), 134.0 (CCI3), 148.0 (ArC-O)
148.5 (ArC-O), 160.6 (COCHCl2), 170.2 (COOCH3).

Photolysis of Methyl 2.2,2-Trichloroacetamido-3-(3.4-dimethoxyphenyl
propanoate (59)
A solution of (59) (200 mg, 0.522 mmol) in benzene (350 ml) was

irradiated at room temperature for 2 h. The solvent was evaporated a
residue was chromatographed (DCM : MeOH, 97 : 3 ) to give N-l3-(3,4-

dimethoxyphenyl)-l-methoxycarbonyl]propyloxamic acid (84) (45 mg, 28

as a pale yellow oil. ^-Nmr (CDCI3, 300 MHz) 8: 4.14 (d, J=5.4 Hz, 2H

CH2Ar), 3.76 (s, 3H, COOCH3), 3.84 (s, 3H, CH3OAr), 3.85 (s, 3H, CH3OAr), 4
(dt, J=7.5, J=5.4 Hz, 1H, CHNH), 6.66-6.77 (m, 3Harom), 7.40 (d, J=7.5
NH).
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C-Nmr (CDCI3, 75 MHz) 8: 36.9 (CH2Ar), 52.5 (COOCH3), 54.9

(CHNH), 55.86 (CH3OAr), 55.89 (CH3OAr), 111.3 (ArC-H), 112.6 (ArC-H), 121
(ArC-H), 127.5 (ArC-CH2), 148.4 (ArC-O), 149.0 (ArC-O), 161.4 (COCOOH),

170.8 (COOCH3), 189.8 (COC.OOH). Ms (EI) m/z (%): 311 (2, M+,accurate m

311.1108, C i 4 H i 7 N 0 7 requires 311.1005, 266 (2), 236 (2), 22 (42), 150 (100), 107
(8).

H3C

VY\\xV^

H 3 OT ^ ^ H
(84)

COOCH 3

Preparation of N-{2-f3-((E)-2'-Methoxycarbonylethenyloxy)-4-methoxyphenyl]
ethyllazidoacetamide (61, cis and trans isomers)

:i;Ca

^%^^°Vv<>^V^^^^Nv^^CH2N3

"

O

xrr

H3CO

A mixture of 54 (cis isomer) (115 m g ) and sodium azide (115 mg, 1.771
mmol) in acetonitrile (25 ml) was refluxed for llh. The solvent was then
evaporated and the residue was chromatographed ( EtOAc : hexane, 55 : 45
and then D C M : M e O H , 98 : 2) to give two fractions. The solvent in first
fraction was evaporated to give N-{2-[3-((E)-2'-methoxycarbonylethenyloxy)4-methoxyphenyl]elhyl] azido acetamide (61 trans) (53 mg, 45%) as a pale
yellow gum. lH-Nmr (CDCI3, 300 M H z ) 8: 2.78 (t, J=8.0 Hz, 2H, CH 2 Ar), 3.52
(q, J=8.0 Hz, 2H, C H 2 N H ) , 3.72 (s, 3H, C O O C H 3 ) , 3.85 (s, 3H, CH 3 OAr), 3.97 (s,
1H, C H 2 N 3 ) , 5.43 (d, J=12.2 Hz, C O C H C H ) , 6.89 (d, J=1.8, lH a r 0 m), 6.93 (d, J=8.1
Hz, lHarom), 7.01 (dd, J=8.1, J=1.8 Hz, lH a r 0 m), 7.72 (d, J=12.2 Hz, C O C H C H ) .
The second w a s

N-{2-[3-((Z)-2'-methoxycarbonylethenyloxy)-4-

methoxyphenylkthyljazidoacetamide (61, cis) (48 mg, 41%) as pale yellow oil
after evaporation. iH-Nmr (CDCI3, 300 M H z ) 8: 2.77 (t, J=8.0 Hz, 2H, CH 2 Ar),
3.51 (q, J=8.0 Hz, 2H, CFfcNH), 3.75 (s, 3H, C O O C H 3 ) , 3.85 (s, 3H, CH 3 OAr), 3.94
(s, 2H, C H 2 N 3 ) , 5.10 (d, J=7.2 H z , 1H, C O C H C H ) , 6.74 (d, J=7.2 Hz, 1H,
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C O C H C H ) , 6.89-6.99 (m, 3 H a r o m ) . M s (EI) (%): 334 (5, M + , accurate mass

357.1280, Ci5Hi8N405 requires 334.1277), 250 (9), 234 (76), 221 (9), 203 (10),
(5), 150 (100), 137 (56), 135 (45).

Preparation of N-[2-(3,4-Dimethoxyphenyl)ethyl]azidoacetamide (60)
H3CON' V y ^ Y ^ s ^ N

CH2N3

J***J o

H 3 CO

A mixture of N-[2-(3,4-dimethoxyphenyl)ethyl]chloroacetamide14'17
and sodium azide (402 mg, 6.188 mmol) in methyl ethyl ketone (20 ml) was

refluxed for 24h. To the resulting mixture was added water (25 ml) and the
solution was then extracted with EtOAc (3 x 25 ml). The combined extracts

were washed with water (15 ml), dried and evaporated in vacuo to give pale
brown residue. The residue was then chromatographed. Elution with DCM

: MeOH, 99.5 : 0.5, gave N-[2-(3,4-dimethoxyphenyl)ethyl]azidoacetamuie (6
(179 mg, 74%) as colourless crystals, mp 72-74°C XH-Nmr (CDC13, 400 MHz)
8: 2.81 (t, J=8.5 Hz, 2H, CH2Ar), 3.47 (q, 1=8.5 Hz, CH2NH), 3.90 (s, 3H, CH30),
3.91 (s, 3H, CH3O), 3.99 (s, 2H, CH2N3), 6.34 (s, 1H, NH), 6.72-6.87 (m, 3Harom)Ms (EI) m/z (%): 264 (5, M+, accurate mass 264.1224, Ci2Hi6N403 requires
264.1222), 164 (100), 151 (55), 135 (4), 121 (5), 107 (12). Ir (Nujol) vmax:
(NH), 2900 (Ar-H), 2112 (N3), 1653 (CO) cm"1.

Photolysis of N-[2-(3.4-Dimethoxyphenyl)ethy1]azidoacetamide (60)

A solution of (60) (200 mg, 758 mmol) in acetonitrile and water (50 :
50) was irradiated for 3.5 h at room temperature.

The solvent was

evaporated in vacuo and the yellow residual oil was chromatographed.
Elution with D C M : M e O H , 98 : 2, gave N-[2-(3,4-dimethoxyphenyl)
ethyllglyoxylamide (85) (91 mg, 51%) as a yellow oil after evaporation. *HN m r (CDC13, 400 M H z ) 8: 2.82 (t, J=7.0 Hz, CH 2 Ar), 3.59 (q, J=7.0 Hz, 2H,
CH2NH), 3.870 (s, 3H, CH3O), 3.874 (s 3H, CH3O), 6.70-6.83 (m, 3H a r o m ), 9.22 (s,
1H, CHO).
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C-Nmr (CDCI3,100 M H z ) 8: 34.6 (CH2Ar), 40.9 (CH 2 NH), 56.0 (2

x CH3O), 111.8 ArC-H), 112.0 (ArC-H), 121.0 (ArC-H), 130.8 (ArC-CH2), 148.0
(Ar£-OCH3), 149.5 (ArC-OCH 3 ), 160.1 (CO-CHO), 188.8 (CO-CHO). M s (CI)
m/z (%): 238 (10, M++1), 220 (12), 208 (15), 192 (12), 165 (65), 164 (93), 151 (100);
(EI) m/z: accurate mass 219.0891, C12H13NO3 requires 219.0895. Ir (Nujol)
Vmax: 1732 (CO), 1656 (CO).

Preparation of N-[2-(3,4-Dimethoxyphenyl)ethyl]bromoacetamide (62)

H3CO'^^^
To a stirred mixture of homoveratrylamine (5.0 g, 27.6 mmol) and
sodium carbonate (2.29 g, 27.6 mmol) in dry D C M (30 ml) was added
bromoacetyl bromide (2.61 ml, 30.0 mmol). The mixture was then allowed to
stir overnight. Water (30 ml) was added and the two layers were separated.
The aqueous layer was extracted with further D C M (30 ml). The combined
organic extracts were dried and evaporated to give a solid crude residue. The
solid was recrystallised from EtOH/diethyl ether to give N-[2-(3,4dimethoxyphenyl)ethyl]bromoacetamide (62) (5.18, 62%) as colourless
crystals, m p 115-117QC (EtOH/Et20). lH-Nmr (CDCI3, 300 M H z ) 8: 2.77 (t,

J=7.0 Hz, 2H, CH 2 Ar), 3.54 (q, J=7.0 Hz, 2H, CH^NH), 3.84 (s, 3H, CH3O), 3.85 (s,
3H, CH3O), 3.87 (s, 2H, CH2Br), 6.50 (s, 1H, N H ) , 6.76-6.80 (m, 3Har0m)- M s (CI)
m/z (%): 304 (20, M++1, 8lBr), 302 (20, M++1, 79Br), 258 (100), 222 (16), 221 (16),
205 (30), 165 (100), 164 (100), 152 (100), 151 (100), 149 (80).

Photolysis of N-r2-(3.4-Dimethoxyphenyl)ethyllbromoacetamide (62)
A solution of (57) (200 mg, 0.664 mmol) in benzene (350 ml) was
irradiated at room temperature for 3 h. The solvent was evaporated and the
residue was chromatographed (DCM : M e O H , 97 : 3 ) to give a fraction which
consisted of (8) (22 mg, 15 % ) .

Preparation of N-[2-(3,4~Dimethoxyphenyl)ethyl]fluoroacetamide (63)

A mixture of N-[2-(3,4-dimethoxyphenyl)ethyl]bromoacetamide (62)
(44 mg, 1.457 mmol) and cesium fluoride (1.07 g, 7.086 mmol) in acetonitrile
(25 ml) was refluxed overnight. The solvent was then evaporated and the
crude was extracted with D C M (40 ml). The extract was washed with water (3
x 10 ml), dried and evaporated to give N-[2-(3,4-dimethoxyphenyl)ethyl]
fluoroacetamide (63) (340 mg, 97%) as a colourless crystalline solid, m p 8990°C !H-Nmr (CDCI3,300 M H z ) 8: 2.78 (t, J=7.2 Hz, 2H, CH 2 Ar), 3.55 (q, J=7.2
Hz, 2H, QI2NH), 3.84 (s, 3H, CH3O), 3.85 (s, 3H, CH3O), 4.75 (d, J=47.4 Hz, 2H,
CH 2 F), 6.38 (s, 1H, N H ) , 6.70-6,81 (m, 3H a r o m ).
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C-Nmr (CDCI3, 75 M H z ) 8:

35.1 (CH2Ar), 40.0 (CH 2 NH), 55.78 (CH3O), 55.80 (CH3O), 80.2 (d, J=184 Hz,
CH 2 F), 115.5 (ArC-H), 111.8 (ArC-H), 120.5 (ArC-H), 130.8 (Ar£_-CH2), 147.8
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(ArC-O), 149.1 (ArC-O), 167.4 (d, J=17 H z , CO). M s (EI) (%): 241 (12, M + ) , 164
(100), 151 (61), 149 (18), 135 (4).

Photolysis of N-f2-(3,4-Dimethoxyphenyl)ethyl]fluoroacetamide (63)
A solution of (57) (200 m g , 0.830 m m o l ) in benzene (350 ml) was
irradiated at room temperature for 6 h. The solvent was evaporated and the
residue was chromatographed ( D C M : M e O H , 97 : 3 ) to give a fraction which
consisted the starting material (190 m g , 95 % ) .

Preparation of 3-Chloroacetyl-7,8-dimethoxy-l,3,4,5-tetrahydro-lH-3benzazepin-2-one (86)

o
To a stirred mixture of 7,8-dimethoxy-l,3,4,5-tetrahydro-2H-3benzazepin-2-one (9)14'17 (100 m g , 0.452 mmol) and potassium carbonate (85
mg, 0.615 mmol) in dry D C M (5 ml) was added chloroacetyl chloride (0.075
ml, 0.940 mmol). The mixture was allowed to stir overnight. Water (10 ml)
was then added and the two layers were separated. The aqueous layer was
extracted with D C M (3 x 10 ml). The combined extracts were dried and
evaporated to give solid residue. Recrystallisation from EtOAc/hexane gave
3-chloroacetyl-7,8-dimethoxy-4,5-dihydro-lH-3-benzazepin-2(3H)-one (86)
(110 m g , 82%) as colourless crystals, m p 155-157°C (EtOAc/hexane). !H-Nmr
(CDC13,300 M H z ) 8: 3.15 (t, J=6.0 Hz, 2H, C H 2 C H 2 N ) , 3.84 (s, 3H, C H 3 O ) , 3.86
(s, 3H, C H 3 O ) , 4.01 (s, 2H, CH 2 C1), 4.38 (t, J=6.0 Hz, C H 2 C H 2 N ) , 4.73 (s, 2H,
A r C H 2 C O ) , 6.57 (s, l H a r o m ) , 6.58 (s, l H a r o m ) -

13

C-Nmr (CDCI3, 75 M H z ) 8: 31.9

( C H 2 C H 2 N ) , 41.3 (CH 2 C1), 44.3 ( C H 2 C H 2 N ) , 47.3 (ArCH 2 CO), 55.57 (CH3O),
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55.64 (CH 3 0), 112.9 (ArC-H), 113.7 (ArC-H), 120.2 (ArC-CH 2 ), 126.5 (ArC-CH2),
147.2 (ArC-O), 148.4 (ArC-O), 168.5 (COCH2Cl), 173.1 (ArCH:>CO). Ms (EI) m/z
(%): 299 (13, M+, 37C1), 297 (40, M+, 35C1), 261 (21), 246 (15), 204 (60), 191 (30),

177 (100), 164 (59), 149 (21), 146 (22). Anal. Calcd for Ci4Hi6N0435Cl: C, 56.
H, 5.43, N, 4.71. Found: C, 56.48; H, 5.46; N, 4.45.

Photolysis of 3-Chloroacetyl-7.8-dimethoxy-4,5-dihydro-lH-3-benzazepin2(3H)-one (86)
A solution of 3-chloroacetyl-7,8-dimethoxy-4,5-dihydro-lH-3benzazepin-2(3H)-one (86) (100 mg, 0.336) in water and acetonitrile (350
50 : 50, v/v) was irradiated for 5 h using 16 W mercury lamp and a vycor
filter. The solvent was then evaporated and the residue was
chromatographed (EtOAc : hexane : MeOH, 75 : 22.5 : 2.5) to give 11ahydroxy-8,9-dimethoxy-5,6,ll,lla-tetrahydrooxazolo[2,3-b][3]benzazepin-

3(2H)-one (87) (76 mg, 81%) as a colourless crystalline solid after evapor
mp 136.5-138.5 °C. 1H (acetone-d6, 300 MHz) 8: 2.83-2.89 (m, 4H, CH2CH2N),

3.15 (d, J=14.4 Hz, 1H, ArCHC-OH), 3.26 (d, J=14.4 Hz, 1H, ArCHC-OH), 3.78 (
6H, 2 x CH3O), 4.10-4.25 (m, 3H, CH20 and OH), 6.79 (s, lHarom), 6.82 (s,
lHarom)-
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C-Nmr (acetone-d6, 75 MHz) 8: 34.9 (CH2CH2N), 38.8 (CH2CH2N),

46.7 (ArCH2C-OH), 56.3 (CH3O), 56.4 (CH3O), 66.8 (CH2CO), 110.3 (ArCH^OH), 114.9 (ArC-H), 116.9 (ArC-H), 128.3 (ArC-CH2), 134.3 (Ar£-CH2), 148.8
(ArC-O), 149.8 (ArC-O), 169.0 (CO). Ms (Es -ve) m/z (%): 278.3 (100, M+-1). Ms
(EI) m/z (%): 279 (18), 261 (8), 246 (6), 221 (3), 204 (5), 178 (13), 165 (100),

Anal. Calcd for Ci4Hi7N05: C, 60.19; H, 6.14; N, 5.02. Found: C, 60.07; H, 6.
N, 5.03.

H 3 CQ

H 3 CO
(87)

OH

Recrystallisation from E t O H gave lla-ethoxy-8,9-dimethoxy-5,6,11,11atetrahydrooxazolo[2,3-b][3]benzazepin-3(2H)-one (88) as colourless crystals,
m p 125-127 OC. *H (CDCI3, 300 M H z ) 8: 1.11 (t, J=6.9 Hz, 3H, C H 3 C H 2 0 ) , 2.842.90 (m, 4H, CFL2CH2N), 3.22-3.31 (m, 2H, ArCffcC-OH), 3.86 (s, 3H, C H 3 O ) ,
3.87 (s, 3H, CH3O), 4.21-4.38 (m, 2H, C H 2 C O ) , 6.65 (s, lH a r 0 m), 6.70 (s, lHarom)M s (EI) (%): 307 (M+, 37), 278 (72), 262 (43), 246 (17), 179 (58), 178 (57), 162 (34);
(CI) m/z: M + + 1 accurate mass 308.1498, Ci6H 2 2 N05 requires 308.1498.

Reaction of N-[2-(3-Hydroxy-4-methoxyphenyl)ethyl]iodoacetamide (50) with
Sodium Hydride
To a solution on

N-[2-(3-hydroxy-4-methoxyphenyl)ethyl]

iodoacetamide (50) (45 m g , 0.134 m m o l ) in dry T H F (20 ml) under N 2 was
added sodium hydride (58 m g , 60 % , 1.45 mmol). The solution was allowed
to stir overnight. Water (15 ml) was then added and the mixture was
extracted with D C M

(3 x 20 ml). The combined extracts were dried,

evaporated and chromatographed ( D C M : M e O H , 96 : 4) to give a solid
residue. The residue was then crystallised from E t O H to give (89) (17 m g ,
61%) as colourless crystals; m p 263-265 °C. iH-Nmr (CDCI3, 400 M H z ) 8: 2.73
(t, J=6.0 H z , 4H, 2 x C H 2 A r ) , 3.53 (q, J=6.0, 4H, 2 x C H 2 N H ) , 3.85 (s, 6H, 2 x

C H 3 0 ) , 4.52 (s, 4 H , 2 x C O C H 2 ) , 6.48 (s, 2H, 2 x N H ) , 6.50 (d, J=2.0 Hz, 2 x
lHarom), 6.73 (d, J=8.4 Hz, 2 x lH a r o m), 6.77 (dd, J=8.4, J=2.0 Hz, 2 x lH a r 0 m). M s
(EI) m / z (%): 414 (5, M + ) , 382 (2), 207 (47), 176 (11), 136 (6), 150 (20), 137 (8), 135
(10). Anal. Calcd for C 2 2 H 2 6 0 6 N 2 : C, 63.76; H , 6.32; N , 6.72. Found: C, 63.26;
H, 6.36; N , 6.47.

H,G

OCHn

Reaction of N-2-(3-Hydroxy-4-methoxyphenyl)ethylamine Hydrochloride
with 3-Chloropropionyl Chloride
To a solution of N-2-(3-hydroxy-4-methoxyphenyl)ethylamine
hydrochloride64'65 (120 m g , 0.59 m m o l ) in T H F (5 ml), under N 2 , was added
N a O H (0.5 ml, 5 M ) . The solution was then cooled in an ice bath. 3Chloropropionyl chloride was added dropwise until a white precipitate was
observed. Stirring was allowed to continue for 1 h. Water (5 ml) was then
added and the mixture was extracted with D C M (3 x 15 ml). The combined
extracts were dried and evaporated. The crude was dissolved in M e O H (5
ml), potassium carbonate was then added and the mixture was allowed to
stir for 0.5 h. Water (5 ml) was added, the p H was adjusted to 7 (HC1, 1M)
and the solution was extracted with D C M (3 x 15 ml). The combined extracts
were dried and evaporated to give a yellow oil.

The oil was then

chromatographed. Elution with EtOAc : hexane, 45 : 55, gave two fractions.
The solvent in the first fraction was evaporated to give (90) (50 m g , 33%) as

pale yellow oil. iH-Nmr (CDCI3, 400 M H z ) 8: 2.57 (t, J=6.4 Hz, 2H, C O C H 2 ) ,
2.74 (t, J=6.8 H z , 2H, C H 2 A r ) , 3.51 (q, J= 6.8 Hz, 2H, C H ^ N H ) , 3.79 (t, 6.4 Hz, 2H,
CH 2 C1), 3.88 (s, 3H, C H 3 O ) , 5.57 (s, 1H, N H ) , 5.64 (s, 1H, O H ) , 6.68 (dd, J=8.4,2.0
Hz, lHarom), 6.78 (d, J=2.0 H z , lH a r 0 m), 6.80 (d, J=8.4 Hz, lH a r 0 m). M s (EI) m / z
i.

(%): 259 (0.6, M + , 37 C1), 257 (1.8, M + , 35 C1), 247 (0.6), 232 (2), 221 (0.6), 204 (2),
181 (1.9), 178 (3), 167 (2), 150 (100), 137 (30), 135 (35). The second fraction
consisted of (91) (50 m g , 38%) as a pale yellow oil after evaporation. iH-Nmr
(CDC13, 400 M H z ) 8: 2.76 (t, J=6.8 H z , 2H, C H 2 A r ) , 3.57 (q, J=6.8 H z , 2H,
C H 2 N H ) , 3.88 (s, 3H, C H 3 O ) , 5.53 (s, 1H, N H ) , 5.618 (dd, J=10.4, J=1.4 Hz, 1H,
C O C H C H 2 ) , 5.619 (s, 1H, O H ) , 6.02 (dd, J=17.2, J=10.4 Hz, 1H, C O C H C H ) , 6.26
(dd, J=17.2, J=1.4 Hz, 1H, C O C H C H ) , 6.68 (dd, J=8.4, J=2.0 Hz, lH a r 0 m), 6.78 (d,
J=2.0 Hz, lHarom), 6.80 (d, J=8.4 Hz, lHarom)- M s (EI) m / z (%): 221 (37, M+), 167
(12), 151 (100), 149 (84), 138 (47), 137 (100), 135 (100), 122 (100).

ri3UJ H3CO^ ^^

W

(91)

Preparation of N-[2-(3-Hydroxy-4-methoxyphenyl)ethyl]azidoacetamide (94)

XJ o
H3or

^^
A mixture of N-[2-(3-hydroxy-4-methoxyphenyl)]chloroacetamide (43)

(200 m g , 0.821 m m o l ) and sodium azide (267 m g , 4.105 mmol) in methyl
ethyl ketone (15 ml) was refluxed for 28 h. Water (20 ml) was added and the
mixture was then extracted with D C M (3 x 20 ml). The combined extracts
were dried, evaporated and chromatographed. Elution with EtOAc : hexane,
50 : 50 gave a fraction which was evaporated to give N-[2-(3-Hydroxy-4-

methoxy phenyl) ethyl] azidoacetamide (94) (150 mg, 73%) as a colourless
crystalline solid, m p 67-69°C. iH-Nmr (CDC13, 300 M H z ) 8: 2.74 (t, J=6.6 Hz,
2H, CH 2 Ar), 3.51 (q, J=6.6 Hz, 2H, CBL2NH), 3.89 (s, 3H, CH3O), 3.95 (s, 2H,
CH2N3), 5.78 (s, 1H, OH), 6.35 (s, 1H, N H ) , 6.67 (dd, J= 8.4, J=2.1 Hz, lHarom),
6.77 (d, J=2.1 Hz, lHarom), 6.80 (d, J=8.4 Hz, lH ar0 m).
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C-Nmr (CDCI3, 75

MHz) 8: 34.8 (CH2Ar), 40.5 (CH 2 NH), 52.7 (CH 2 N 3 ), 56.0 (CH3O), 110.9 (ArCH), 114.8 (ArC-H), 120.1 (ArC-H), 131.6 (ArC-CH2), 145.4 (ArC-O), 145.8 (ArCO), 166.5 (CO).

Preparation of N-[2-(3-Acetyloxy-4-methoxyphenyl)ethyl]azidoacetamid

Yrr-Y
o

CH3
To a stirred solution of N-[2-(3-hydroxy-4-methoxyphenyl)]

azidoacetamide (94) (170 mg, 0.68 mmol) in THF (7 ml) under N 2 , cooled in
an ice bath, was added sodium hydride (41 mg, 60%, 1.03 mg). After 5 min
acetyl chloride (0.06 ml, 0.84 mmol) was added and the mixture was allowed
to stir for 3 h. The solvent was then evaporated and the crude was extracted
with D C M (30 ml). The extract was washed with water (2 x 10 ml), dried,
evaporated and chromatographed. Elution with EtOAc : hexane, 60 : 40 gave
a fraction which was evaporated to give N-[2-(3-acetyloxy-4-methoxyphenyl)
ethyl]azidoacetamide (95) (175 mg, 88%) as a colourless crystalline solid, 52540C. !H-Nmr (CDCI3, 300 M H z ) 8: 2.32 (s, 3H, COCH3), 2.77 (t, J=6.9 Hz, 2H,
CH 2 Ar), 3.51 (q, J=6.9 Hz, 2H, CH^NH), 3.82 (s, 3H, CH3O), 3.94 (s, 2H, CH 2 N 3 ),
6.37 (s, 1H, N H ) , 6.88 (d, J=1.8 Hz, lH ar0 m), 6.92 (d, J=8.1 Hz, lHarom), 7.03 (dd,
J=8.1, 1.8 Hz, lH arorn ).
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C-Nmr (CDCI3, 75 M H z ) 8: 20.6 (COCH3), 34.5

(CH 2 Ar), 40.0 ( C H 2 N H ) , 52.7 (CH 2 N 3 ), 55.9 (CH3O), 112.6 (ArC-H), 123.1 (ArCH ) , 126.8 (ArC-H), 130.9 (ArC_-CH2), 139.7 (ArC-O), 149.8 (ArC-O), 166.5
(COCH 2 Cl), 169.0 (COCH3).

Reaction of N-r2-(3-Acetyloxy-4-methoxyphenyl)ethyl]azidoacetamide (95)
with Triethylphosphite
A mixture of N-[2-(3-acetyloxy-4-methoxyphenyl)ethyl]azidoacetamide
(95) (150 m g , 0.514 m m o l ) and triethylphophite (0.88 ml, 5.14 mmol) was
refluxed in cyclohexane (25 ml) 5 h. The solvent was evaporated and the
residue was refluxed in toluene (25 ml) for 48 h. The organic solvent was
then evaporated and the crude residue was extracted with D C M (20 ml). The
extract was washed with water ( 2 x 5 ml), dried and evaporated to give (96)
(208 m g , 94%) as a pale yellow oil. ^ - N m r (CDCI3, 300 M H z ) 8: 1.30 (t, J=6.6
Hz, 9H, 3 x O C H 2 C H 3 ) , 2.32 (s, 3H, C O C H 3 ) , 2.77 (t, J=6.9 Hz, 2H, CH 2 Ar), 3.53
(q, J=6.9 H z , 2H, C H 2 N H ) , 3.81 (s, 3H, C H 3 O ) , 4.0-4.07 (m, 8H, C H 2 N , 3 x
O C H 2 C H 3 ) , 6.75 (s, 1H, N H ) , 6.86-7.04 (m, 3 H a r o m ) - M s (EI) m / z (%): 430 (15,
M + ) , 356 (20), 293 (15), 239 (100), 180 (85).
H3C

0

s^

°yy
H

3

H
N ^ . CH 2 N = P(OEt)3

C O ^ ^
(96)

5.2 Experimental for Chapter 3
Reaction of 12-Methoxy-2-oxa-6-azabiryHor7.3.1.1trideca-l(13)f9fH-trien-5-one
(8) with N-Bromosuccinimide
To a stirred solution of 12-methoxy-2-oxa-6-azabicyclo[7.3.1.]tridecal(13),9,ll-trien-5-one (8) (68 m g , 0.308) in CC1 4 (5 ml) was added N -
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bromosuccinimide (55 mg, 0.308 mmol) and AIBN (3 mg, 18.3 mmol). The
mixture was allowed to reflux under N2 for 30 min. The solvent was then
evaporated and the crude residue was chromatographed (EtOAc : hexane, 30 :
70 and then 75 : 25) to give five fractions. The solvent in the first fraction

was evaporated to give 9-bromo-10-methoxy-2,3-dihydro-4H-pyrrolo[l,2,3

e,f][l,4] benzoxazepin-4-one (107) (6 mg, 7%) as a colourless crystalline soli
m p 116-118°C (EtOAc/hexane). iH-Nmr (CDCI3,300 M H z ) 8: 3.33 (t, J=4.8 Hz,
2H, CH 2 CO), 3.89 (s, 3H, CH3O), 4.52 (t, J=4.8 Hz, 2H, CH 2 0), 6.60 (d, J=3.9 Hz,
C H C H N ) , 7.40 (s, lH ar0 m), 7.85 (d, J=3.9 Hz, C H C H N ) . M s (EI) m/z (%): 297
(28, M + , 81Br), 295 (28, M + ,79Br), 281 (10), 280 (11), 243 (5), 241 (6), 228 (7), 226
(7), 55 (100). The second fraction was 8-bromo-10-methoxy-2,3-dihydro-4H-

pyrrolo[l,2,3-e,f][l,4]benzoxazepin-4-one (108) (3 mg, 3%) as a colourles
crystalline solid, m p 142-144°C (EtOAc/hexane). iH-Nmr (CDCI3, 300 M H z )
8:3.30 (t, J=4.5 Hz, 2H, CH 2 CO), 3.93 (s, 3H, CH3O), 4.50 (t, J=4.5 Hz, 2H, CH 2 0),
6.69 (d, J=3.9 Hz, 1H, C H C H N ) , 7.09 (s, lH a r o m ), 7.83 (d, J=3.9 Hz, 1H, CHCHN).
The third fraction consisted of 10-methoxy-2,3-dihydro-4H-pyrrolo[l,2,3-

e,f][l,4]benzoxazepin-4-one (106) (11 mg, 16%) as a colourless crystalline soli
m p 97-98°C (EtOAc/hexane). iH-Nmr (CDCI3, 300 M H z ) 3.31 (t, J=4.8 Hz, 2H,
CH 2 CO), 3.95 (s, 3H, CH3O), 4.52 (t, 1=4.8 Hz, 2H, CH 2 0), 6.63 (d, J=3.9 Hz, 1H,
C H C H N ) , 6.94 (d, J=8.1 Hz, l H a r o m ) , 7.14 (d, J=8.1 Hz, lHarom)/ 7-79 (d, J=3.9
Hz, 1H, C H C H N ) .

13

C-Nmr (CDCI3,300 M H z ) 8: 40.7 (CH 2 CON), 57.1 (CH3O),

63.6 (CH 2 0), 109.4 (CHCHN), 110.0 (ArC-H), 113.7 (ArC-H), 123.3 (ArC-CH),
124.5 (CHCHN), 127.7 (ArC-N), 136.5 (ArC-O), 146.7 (ArC-O), 169.0 (CO). M s
(EI) m / z (%): 217 (53, M + , accurate mass 217.0738, C12H11NO3 requires
217.0739), 202 (9), 163 (22), 148 (20), 134 (4), 55 (100). The fourth fraction gave

9-bromo-10-methoxy-2,3,6,7-tetrahydro-4H-pyrrolo[l,2,3-e,f][l,4]benz
-4-one (105) (10 mg, 11%) as a colourless solid, m p 84-86°C (EtOAc/hexane).
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1H-Nmr (CDCI3, 300 M H z ) 8: 3.01-3.11 (m, 4 H , C H 2 A r and C H 2 C O ) , 3.83 (s,
3H, C H 3 O ) , 4.14 (t, J=8.7 H z , C H 2 N ) , 4.32-4.36 (m, 2H, C H 2 0 ) , 7.19 (s, lH ar om).
M s (EI) m / z (%): 299 (95, M + , 8lBr), 297 (100, M + , 79Br), 244 (80), 243 (83), 163
(20), 148 (24). The fifth fraction afforded 10-methoxy-2,3,6,7-tetrahydro-4Hpyrrolo[l,2,3-e,f][l,4]benzoxazepin-4-one (104) (32 m g , 47%) as a colourless
crystalline solid after evaporation, m p 121-123°C (EtOAc/hexane). ! H - N m r
(CDCI3, 300 M H z ) 8: 3.03-3.10 (m, 4H, C H 2 A r and C H 2 C O ) , 4.14 (t, J=8.7 H z ,
C H 2 N ) , 4.37 (t, J=4.8 H z , 2H, C H 2 0 ) , 6.58 (d, 8.1 H z , l H a r 0 m ) , 6.78 (d, J=8.1,
lHarom)-

13

C - N m r (CDCI3, 300 M H z ) 8: 26.1 (CH 2 Ar), 39.9 ( C H 2 C O ) , 48.2

(CH 2 N), 26.5 (CH3O), 64.2 (CH 2 0), 107.1 (ArC-H), 117.4 (ArC-H), 127.0 (ArCN), 128.5 (ArC-CH 2 ), 136.6 (ArC-O), 149.4 (ArC-O), 170.2 (CO). M s (EI) m / z
(%): 219 (13, M + , accurate mass 219.0901, C12H13NO3 requires 219.0895, 165
(19), 149 (2), 132 (4), 99 (100), 56 (100).

(107)

M
(104) (105)

(108)

H3coW

(106)
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Reaction of 12-Methoxy-2-oxa-6-azabicyclo[7.3.1.]trideca-l(13),9,ll-trien-5-one
(ft) with Bromine
To a solution of 12-methoxy-2-oxa-6-azabicyclo[7.3.1.]trideca-l(13),9,lltrien-5-one (8) (20 m g , 0.9 mmol) in CC1 4 (5 ml) was added excess of bromine.
The solution was refluxed for 1 h. The solvent was evaporated and the
crude residue was chromatographed (EtOAc/hexane, 35:65) to give the 9,10dibromo derivative of (106) (13 m g , 39%) as a pale yellow gum.

^-Nmr

(CDC13,300 M H z ) 8: 3.30 (t, J=4.8 Hz, 2H, C H 2 C O ) , 3.98 (s, 3H, C H 3 O ) , 4.51 (t,
J=4.8 H z , 2H, C H 2 0 ) , 6.62 (d, J=3.9 Hz, 1H, C H C H N ) , 7.80 (d, J=3.9 H z , 1H,

CHCHN).

Reaction of 12-Methoxy-2-oxa-6-azabicyclor7.3.1.1trideca-l(13).9.11-trien(8) with Benzoyl Peroxide
A mixture of 12-methoxy-2-oxa-6-azabicyclo[7.3.1.]trideca-l(13),9,lltrien-5-one (8) (20 m g , 0.09 mol) and benzoyl peroxide (22 m g , 0.09) in
benzene (5 ml) was refluxed for 1 h. The solvent was evaporated and the
residue was chromatographed (EtOAc/hexane, 50:50 and then 80:20) to give
(104) (7 mg, 35%).

Reaction of WT2-f3.4-Dimethoxyphenyl)ethvl]chloroacetarriide (113) with NBromosuccinimide
A mixture of N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide (500, 2.24
mmol) and N-bromosuccinimde (399 m g , 224 mmol) and A I B N (10 m g , 0.05
mmol) in CC1 4 (35 ml) was refluxed for 30 min. The solvent was then
evaporated. The crude residue was extracted with D C M (30 ml). The organic
extract was washed with water (2 x 10 ml), dried and evaporated to give N-[2-

(2-bromo-4,5-dimethoxyphenyl)ethyl)]acetamide (114) (474 m g , 70%) as a
colourless solid, m p 101-103°C (lit.74 102-103°C).

H

3 co >v ^ ^

.

. ^N^

^CHo

yxrr

H3CO^

^

Br
(114)

Reaction of 12-Methoxy-2-oxa-6-azabicyclo[7.3.1.]trideca-l(13).9,ll-trien-5-one
(8) with Sodium Hydride and Iodomethane
To a solution of 12-methoxy-2-oxa-6-azabicyclo[7.3.1.]trideca-l(13),9,lltrien-5-one (8) (50 m g , 0.226 mmol) in T H F (5 ml) was added sodium hydride
(10 m g , 0.249 m m o l ) and iodomethane (0.02 ml, 0.226 mmol). The solution
was allowed to stir overnight. The solvent was evaporated and the crude
residue was extracted with D C M (20 ml). The extract was washed with water
(2x5 ml), dried, evaporated and chromatographed (EtOAchexane, 50:50) to
give (126) (32 m g , 61%) as a pale yellow oil. ^ - N m r (CDCI3) 8: ^ - N m r
(CDC1 3/ 400 M H z ) 8: 2.80 (t, J=7.2 H z , 2H, C H 2 A r ) , 3.57 (q, J=7.2 H z , 2H,
C H 2 N H ) , 3.86 (s, 6H, 2 x CH3O), 5.62 (dd, J=10.4, J=1.6 Hz, 1H, C O C H C H 2 ) , 5.89
(s, 1H, N H ) , 6.06 (dd, 1=17.2, J=10.4 Hz, 1H, C O C H C H ) , 6.26 (dd, J=17.2, J=1.6
Hz, 1H, C O C H C H ) , 6.78 (3H a r o m )- 1 3 C-Nmr (CDCI3) 8: 35.01 (CH 2 Ar), 40.7
(CH 2 N), 55.7 (CH3O), 55.8 (CH3O), 111.2 ( C O C H C H 2 ) , 111.8 ( C O C H C H 2 ) , 120.5
(ArC-H), 126.3 (ArC-H), 130.8 (ArC-H), 131.2 (ArC_-CH2), 147.5 (Ar£-OCH3),
148.9 (Ar£-OCH3), 165.5 (CO).

H,C<

H 3 CO
(126)

Reaction of 12-Methoxy-2-oxa-6-azabicyclol7.3.1.1trideca-l(13).9,ll-trien-5-one
(8) with a Solution of Sodium Hydroxide
A solution of 12-methoxy-2-oxa-6-azabicyclo[7.3.1.]trideca-l(13),9,lltrien-5-one (8) (50 m g , 0.226 m m o l ) in sodim hydroxide (5 ml) w a s refluxed
for a week. N o change w a s observed as reaction w a s monitered by t.l.c. and
iH-Nmr spectrometry.

Reaction of 12-Methoxy-2-oxa-6-azabicyclo[7.3.1.]trideca-l(13),9,ll-trien-5-one
(8) with an Acylase
A solution of 12-methoxy-2-oxa-6-azabicyclo[7.3.1.]trideca-l(13),9,lltrien-5-one (8) (25 m g , 0.113 m m o l ) and acylase I (1 m g ) (Grade I, from
Porcine kidney) in phosphate buffer solution (pH near 7) was stirred for 72 h.
N o change w a s observed as the reaction w a s monitored by t.l.c. and ^ - N m r
spectrometry.

Preparation of N-Protected 12-Methoxy-2-oxa-6-azabicyclor7.3.1.1trideca1(13),9.1 l-trien-5-one (103)
Boc
O I

H3or^
To a solution of 12-methoxy-2-oxa-6-azabicyclo[7.3.1.]trideca-l(13),9,lltrien-5-one (8) ( 50 m g , 0.226 m m o l ) in D C M (2 ml) w a s added triethylamine
(0.04 ml, 0.289 m m o l ) , 4-(dimethylamino) pyridine (27.6 m g , 0.226 m m o l )
and di-tert-butyldimethyldicarbomate (78.6 m g , 0.452 mmol). The mixture
was allowed to stir overnight and then chromatographed (EtOAc : hexane, 55
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: 45 and then D C M : M e O H , 98 : 2) to give two fractions. The solvent in first
fraction was evaporated to give (103) (20 mg, 28%, 69% based on recovered
starting material) as pale yellow oil. 1H-Nmr (CDCI3, 300 MHz) 8: 1.59 (s,

(CH3)3C), 2.55 (dd, J=16.8, J=5.4 Hz, 1H, CHCO), 2.63 (dt, J=13.2, J=2.4 Hz, 1

CHAr), 2.87 (dt, J=13.2, J=4.5 Hz, 1H, CHAr), 3.53 (ddd, J=16.8, J=10.5, J=1.8

1H, CHCO), 3.60 (dd, J=7.8, J=2.4 Hz, 1H, CHN), 3.66 (dt, J=7.8, J=4.5 Hz, 1H
CHN), 3.88 (s, 3H, CH30), 4.27 (t, J=10.5 Hz, 1H, CHO), 4.41 (ddd, 1=10.5,
Hz, 1H, CHO), 6.81-6.90 (m, 3Har0m). Ms (Es +ve) m/z (%): 344.3 (85, M++23),
322.3 (2, M++1), 266.3 (3), 248.2 (11), 244.2 (12).

Reaction of (103) with N-Bromosuccinimide
To a solution of (103) (10 mg, 0.031 mmol) in CCI4 (2 ml) was added Nbromosuccinimide (10 mg, 0.056 mmol) and AIBN (0.4 mg, 0.0024 mmol).
The mixture was allowed to reflux for 10 h. The solvent was then

evaporated and the crude residue was chromatographed (EtOAc : hexane, 20 :
80) to give (115) (9.5 mg, 76%) as colourless crystals, mp 108-109°C
(EtOAc/hexane). iH-Nmr (CDCI3, 300 MHz) 8: 2.48 (dd, J=16.5, J=5.4 Hz, 1H,

CHCO), 3.37 (ddd, J=16.5,10.5, 1.8 Hz, 1H, CHCO), 3.67 (dd, J=19.2, J=10.8 Hz,
1H, CHN), 3.79 (dd, J=19.2, J=3.6 Hz, 1H, CHN), 3.88 (s, 3H, CH3O), 4.18 (t,

Hz, 1H, CHO), 4.31 (ddd, J=10.5, 5.4,1.8 Hz, 1H, CHO), 4.91 (dd, 1=10.8,3.

1H, BrCHAr), 6.67 (d, J=2.1 Hz, lHar0m), 6.92 (d, 8.4 Hz, lHar0m), 7.31 (dd, J=8.4,
J=2.1 Hz, lHarom).
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C-Nmr (CDCI3,300 MHz) 8:15.3 ((CH3)3Q, 28.1 (CH3)3C),

41.7 (CH2CO), 49.3 (CH2N), 56.1 (CH3O), 72.7 (CH20), 84.1 (BrCHAr), 114.6
(ArC-H), 123.2 (ArC-H), 129.5 (ArC-H), 146.7 (ArC-CHBr), 152.1 (ArC-O), 153.1
(ArC-O), 173.7 (CO). Ms (EI): 401 (2, M+,

81

Br), 399 (1.7, M+, accurate mass

399.0677, Ci7H2279BrN05 requires 399.0681), 300 (3), 298 (3), 272 (2), 270 (2)
(15), 191 (7), 164 (12).

H 3 CO
(115)

Reaction of (64) with N-Bromosuccinimide
To a stirred solution of (64) (50 mg, 0.179 mmol) in C D C 1 3 (5 ml) was
added N-bromosuccinimide (32 m g , 0.179 mmol) and A I B N (1.5 m g , 0.0091
mmol). The mixture was allowed to reflux for 1 h. The solvent was then
evaporated and the crude residue was chromatographed (EtOAc, hexane, 30 :
70, and 40 : 60, and then 100 : 0) to give five fractions. The solvent in the first
fraction was evaporated to give methyl 8-brorno-10-methoxy-4-oxo-2,3-

dihydro-4H-pyrrolo[l,2,3-e,f][l,4]benzoxazepine-6-carboxylate (110) (3 m g , 5%
9% based on recovered starting material) as a yellow gum. ^ - N m r (CDCI3,
300 M H z ) 8: 3.34 (t, J=5.1 H z , 2H, C H 2 C O ) , 3.90 (s, 3H, C O O C H 3 ) , 3.91 (s, 3H,
CH 3 OAr), 4.63 (t, J=5.1 Hz, 2H, C H 2 0 ) , 7.06 (s, 1H, C H C - N ) , 7.43 (s, l H a r o m ) . M s
(EI) m / z (%): 355 (2.5, M + , 8iBr), 353 (2.5, M + , 7?Br), 301 (2.5), 299 (2.5), 172 (1),
172 (2). The second fraction consisted of methyl 9-bromo-10-methoxy-4-oxo-

2,3-dihydro-4H-pyrrolo[l,2,3-e,f][l,4] benzoxazepine-6-carboxylate (111) (6 m
9%, 1 7 % based on recovered starting material) as a pale yellow gum.

1

H-

N m r (CDCI3, 300 M H z ) 8: 3.25 (t, J=4.8 Hz, 2H, C H 2 C O ) , 3.85 (s, 3H, C O O H 3 ) ,
3.88 (s, 3H, C H 3 O A r ) , 4.56 (t, J=4.8 Hz, 2H, C H 2 0 ) , 7.04 (s, 1H, C H C - N ) , 7.12 (s,
lH a r om). M s (EI) m / z (%): 355 (3, M + , ^Br), 353 (3, M + , 79 Br). The third
fraction w a s methyl

10-methoxy-4-oxo-2,3-dihydro-4H-pyrrolo[l,2,3-

e,f][l,4]benzoxazepine-6-carboxylate (109) (11 m g , 2 2 % , 4 0 % based on
recovered starting material) as a pale yellow g u m after evaporation. iH-Nmr

(CDC13,300 M H z ) 8: 3.25 (t, J=5.1 Hz, 2H, CH2CO),3.84 (s, 3H, COOH 3 ), 3.89 (s,
3H, CH 3 OAr), 4.58 (t, J=5.1 Hz, 2H, CH 2 0), 6.90 (d, 8.4 Hz, lH a r o m ), 7.07 (s, 1H,
CHC-N), 7.11 (d, J=8.4 Hz, lH ar om).
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C-Nmr (CDCI3, 75 M H z ) 8: 40.1

(CH 2 CO), 52.5 (COOCH3), 57.1 (CH 3 OAr), 64.0 (CH 2 0), 110.1 (CHC-N), 115.2
(ArC-H), 118.0 (ArC-H), 124.6 (ArC-CH), 125.6 (CHC-N), 131.1 (ArC-N), 136.1
(ArC-O), 148.4 (ArC-O), 162.2 (COOCH3), 170.1 ( C H ^ O ) . M s (Es +ve) m/z (%):
276.3 (100, M++1), 244.4 (27); (EI) m/z: accurate mass 275.0808, C14H13NO5
requires 275.0794. The fourth fraction was (112) (4 mg, 6%, 11% based on
recovered starting material) as a colourless crystalline solid, m p 294-296°C
(EtOAc/hexane). M s (EI) m/z (%): 357 (4, M+, 8lBr), 355 (4, M+, 79Br), 272 (14),
270 (14), 216 (20),163 (100). The sixth fraction was the starting material (22
mg, 44%).
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Preparation of 23£,6-Tetrahydropyranor23.4-ij1isoquirtolin-9-o1 (102)

To a solution of 12-methoxy-2-oxa-6-azabicyclo[7.3.1.]trideca-l(13),9,lltrien-5-one (8) (100 m g , 0.453 m m o l ) in dry D C M (3 ml) under N 2 was added
boron tribromide (3.0 ml, 1 M , 3.0 m m o l ) at -78°C The solution was allowed
to stir for 6 h. It was then cooled in an ice bath and saturated solution of
sodium bicarbonate was added (pH 7.5). The resulting mixture was extracted
with D C M (40 ml) and EtOAc (2 x 30 ml). The combined extracts were dried,
evaporated and chromatographed ( D C M : M e O H , 95 : 5) to give 2,3,5,6tetrahydropyrano[2,3,4-ij]isoquinolin-9-ol (102) (70 m g , 82%) as a yellow
crystalline solid, m p 202-204°C (lit.14 204). iH-Nmr (acetone-d6, 300 M H z ) 8:
2.58 (t, J=7.2 H z , 2H, C H 2 A r ) , 2.70 (t, J=6.0 Hz, 2H, O C H 2 C H 2 ) , 3.65 (t, J=7.2 H z ,
2H, C H 2 N ) , 4.41 (t, J=6.0 Hz, 2H, O C H 2 C H 2 ) , 6.59 (d, J=7.8 H z , lH a r 0 m), 6.83 (d,
J=7.8 H z , lHarom)- M s (EI) m / z (%): 189 (100, M + ) , 173 (5), 172 (5), 161 (16).

Preparation of 2,3,3a,4,5,6-Hexahydropyranor2,3.4-ij]isoquinolin-9-ol (123)

H
I

To a solution of 2,3,5,6-tetrahydropyrano[2,3,4-ij]isoquinolin-9-ol (102)
(65 m g , 0.344 m m o l ) in E t O H (5 ml) was added sodium borohydride (40 m g ,
0.86 mmol). The mixture was allowed to stir for 30 min. Saturated solution
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of a m m o n i u m chloride (2 ml) was then added. The mixture was evaporated
and the remaining crude residue was chromatographed ( D C M : M e O H , 85 :

15) to give 2,3,3a/4,5/6-hexahydropyrano[2/3/4-ij]isoquinolin-9-ol (123) (45 mg
69%) as a colourless crystalline solid, m p 166-168°C ( D C M / M e O H ) .

:

H-Nmr

(CD 3 OD, 300 M H z ) 8: 1.88-2.02 (m, 1H, O C H 2 C H ) , 2.20-2.28 (m, 1H, O C H 2 C H ) ,
2.78-2.86 (m, 1H, A r C H C H 2 N H ) , 2.88-3.00 (m, 1H, A r C H C H 2 N H ) , 3.13-3.23
( A r C H 2 C H N H ) , 3.56-3.42 (m, 1H, A r C H 2 C H N H ) , 4.07-4.12 (m, 1H, N H C H A r ) ,
4.19-4.28 (m, 1H, O C H C H 2 ) , 4.47-4.53 (m, 1H, O C H C H 2 ) , 6.52 (d, J=8.4 Hz,
lH a r om), 6.68 (d, J=8.4 Hz, l H a r o m ) .

13

C - N m r (CD3OD, 75 M H z ) 8: 26.7

( O C H 2 C H 2 ) , 28.4 (CH 2 Ar), 43.9 ( C H 2 N H ) , 51.6 ( N H C H A r ) , 116.3 (ArC-H),
119.9 (ArC-CH2), 120.9 (ArC-H), 124.4 (ArC-CH), 142.4 (ArC-O), 144.5 (ArC-O).
M s (EI) m / z (%): 191 (40, M+), 163 (100), 162 (61), 149 (23), 134 (18).

Preparation o^ 4-Chloroacetyl-5,6-dihydropyrano[2,3,4-ij]isoquinoliii-9-o
(119)

°<v /CH2C1

5?
(119)
To a stirred mixture of (102) (70 m g , 0.370), potassium carbonate (56
mg, 0.405 mmol) in D C M (8 ml), under N2, was added chloroacetyl chloride
(0.032 ml, 0.401 mmol). The mixture was placed in ultrasonic bath for 15
min and then was allowed to stir overnight. The solvent was evaporated
and the residue was chromatographed (EtOAc : hexane, 38 : 62) to give two
fractions. The solvent in the first fraction was evaporated to give 9-

chloroacetyloxy-4-chloroacetyl-5,6-dihydropyrano[2,3,4-ij]isoquinoline (11

161
(20 mg, 16%) as a yellow crystalline solid. iH-Nmr (CDC13, 300 M H z ) 8: 2.88

(t, J=5.7,2H, CH 2 Ar), 3.97 (t, J=5.7 Hz, 2H, CH 2 N), 4.30 (s, 2H, NCOCH 2 Cl), 4.3
(s, 2H, OCOCH 2 Cl), 5.01 (d, J=3.6 Hz, OCH 2 ), 5.80 (broad s, 1H, O C H 2 C H ) 6.70
(d, J=8.4 Hz, lH a r o m ), 6.91 (d, J=8.4 Hz, lH a r o m ). The second fraction consisted

of 4-chloroacetyl-5,6-dihydropyrano[2,3,4-ij]isoquinoline-9-ol (1
79%) as a colourless crystalline solid after evaporation, m p 55-57°C
(EtOAc/hexane). iH-Nmr (CDCI3, 300 M H z ) 8: 2.82 (t, 5.7 Hz, 2H, CH 2 Ar),

3.94 (t, J=5.7 Hz, 2H, CH 2 N), 4.31 (s, 2H, CH2C1), 5.04 (d, J=3.9 Hz, 2H, OCH 2 ),
5.80 (broad s, 1H, O C H 2 C H ) , 6.60 (d, J=8.1 Hz, l H a r o m ) , 6.81 (d, 1=8.1 Hz,
lHarom).

13

C-Nmr (acetone-d6, 75 M H z ) 8: 28.5 (CH2Ar), 43.1 (CH2C1), 44.0

(CH 2 N), 66.3 (OCH 2 ), 111.9 (OCH 2 CH), 117.6 (ArC-H), 118.0 (ArC-CH2), 121.3
(ArC-H), 124.7 (ArC-C), 132.5 (OCH 2 CHC), 142.0 (ArC-O), 144.3 (ArC-O), 166.1

(CO). M s (EI) m/z (%): 267 (12, M+, 37C1), 265 (37, M+, 35C1), 230 (100), 202 (8),
180 (100), 160 (17).

Preparation of 4-Azidoacetyl-5,6-dihydropyrano[2,3,4-ij]isoquinol

oyCH2N3

HO^^^^^
A mixture of (119) (110 mg, 0.414 mmol), sodium azide (135 mg, 2.077
mmol) in acetonitrile, under N 2 , (55 ml) was refluxed for 2.5 h. The solvent
was then evaporated and the residue was chromatographed (EtOAc : hexane,

37 : 63) to give 4-azidoacetyl-5,6-dihydropyrano[2,3,4-ij]isocjuinol
(79 mg, 78%) as a colourless crystalline solid, m p 159-161°C (EtOAc/hexane).
iH-Nmr (CDCI3, 300 M H z ) 8: 2.81 (t, J=6.0 Hz, 2H, CH 2 Ar), 3.92 (t, J=6.0 Hz,
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2H, CH 2 N), 4.11 (s, 2H, CH2C1), 5.02 (d, J=3.6 Hz, 2H, OCH 2 ), 5.55 (broad s, 1H,
O C H 2 C H ) , 6.59 (d, J=8.4 Hz, l H a r o m ) , 6.80 (d, J=8.4 Hz, lH a r o m ).

13

C-Nmr

(CDC13/ 75 M H z ) 8: 42.4 (CH2Ar), 51.0 (CH 2 N), 60.4 (CH 2 N 3 ), 66.0 (OCH 2 ),
110.1 (OCH2CH), 116.3 (ArC-CH2), 116.5 (ArC-H), 121.0 (ArC-H), 124.0 (ArC-C),
131.8 (OCH 2 CHC), 140.2 (ArC-O), 142.4 (ArC-O), 166.5 (CO). M s (ES +ve) m/z
(%): 295.4 (100, M++23), 265.5 (50), 218.7 (50). M s (EI) m/z (%): 244 (41), 222
(23), 215 (52), 188 (76), 173 (20), 164 (36), 151 (82). Anal. Cald for C13H12O3N4:
C, 57.33; H, 4.44; N, 20.59. Found: C, 57.55; H, 4.48; N, 20.46.

Preparation of 9-(f-Butyldimethylsilyloxy)-4-chloroacetyl-5,6-dihyd
[2,3,4-ij]isoquinoline (121)
CH2C1
Q

Y

9?

(H3C)3C(H3C)2SiO

^ ^

A mixture of (119) (67 mg, 0.252 mmol), imidazole (26 mg, 0.382
mmol), tert-butyldimethylsilyl chloride (114 mg, 0.756 mmol) in D M F (1 ml)
was allowed to stir overnight. The solvent was evaporated under high
vacuum and the crude residue was chromatographed (EtOAc : hexane, 20 :

80) to give 9-(t-butyldimethylsilyloxy)-4-chloroacetyl-5,6-dihydropy
ij]isoquinoline (121) (44 mg, 46%) as a colourless crystalline solid, m p 101103°C (EtOAc/hexane). iH-Nmr (CDCI3, 300 M H z ) 8: 0.18 (s, 6H, Si(CH3h),
1.00 (s, 9H, (CH3)3CSi), 2.82 (t, J=6.0 Hz, 2H, CH 2 Ar), 3.95 (t, 1=6.0 Hz, CH 2 N),
4.31 (s, 2H, CH2C1), 4.96 (d, J=3.9 Hz, 2H, OCH 2 ), 5.75 (broad s, 1H, O C H 2 C H ) ,
6.55 (d, J=8.4 Hz, lH ar om), 6.72 (d, J=8.4 Hz, lHarom)-

13

C-Nmr (CDCI3, 75

MHz) 8: -4.6 (2 x Si(CH3)2), 18.4 ((CH3)3CSi), 25.7 (3 x (CH3)3CSi), 27.8 (CH2Ar),
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41.3 (CH 2 N), 42.6 (CH 2 C1), 65.3 ( O C H 2 C H ) , 110.7 (OCH2CH), 117.5 (ArC-CH 2 ),
120.6 (ArC-H), 122.5 (ArC-H), 125.3 (ArC-C), 132.3 ( O C H 2 C H C ) , 141.8 (ArC-O),
144.6 (ArC-O), 165.4 (CO). M s (EI) m / z (%): 381 (1, M + , 37 C1), 379 (3, M + , 35C1),
344 (2), 322 (53), 288 (3), 246 (100), 231 (3), 216 (6), 186 (4).

Photolysis of 9-(f-Butyldimethylsilyloxy)-4-chloroacetyl-5,6-dihydropyrano
[2,3,4-ij1isoquinoline (121)
A solution of (121) (40 m g , 0.105) in acetonitrile and water (50 : 50) was
irradiated for 4.5 h at room temperature. The solvent was then evaporated
and the residue was chromatographed (EtOAc : hexane : M e O H , 65 : 33 : 2) to
give (122) (8 m g , 27%) as a pale yellow oil. iH-Nmr (CDC1 3/ 300 M H z ) 8: 2.88
(t, J=6.6 Hz, 2H, CH 2 Ar), 3.21 (t, J=6.6 Hz, 2H, C H 2 C O A r ) , 3.53 (q, 1=6.6 Hz, 2H,
C H 2 N H ) , 4.00 (s, 2H, CH 2 C1), 4.61 (t, J=6.6 H z , O C H 2 ) , 5.53 (s, 1H, O H ) , 6.74 (d,
J=8.1 Hz, l H a r o m ) , 6.87 (s, 1H, N H ) , 7.05 (d, J=8.1 H z , l H a r o m ) . M s (Es -ve) m / z
(%): 282.3 (100, M+-1, 35C1). M s (Es +ve) m / z (%): 308.0 (35, M++23, 37 C1), 306.0
(100, M++23, 35 C1), 284.6 (70, M++1, 35C1). M s (EI) m / z (%): 285 (1, M +
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C1),

283 (3, M + , 35 C1), 221 (10), 190 (50), 189 (32), 178 (18), 164 (14), 150 (42).
H

Of '
HO'^'^^
(122)

Reaction of (103) with Lithium Diisopropylamide and Benzeneselenyl
Bromide
A solution of lithium diisopropylamide (0.286 m m o l ) (prepared from
0.04 ml of diisopropylamine and 0.16 ml of 1.8 M of butyllithium in hexane)
in T H F (3 ml) was prepared under N 2 at -78°C and (103) (45.7 m g , 0.143
mmol) in T H F (2 ml) was added dropwise. The solution was stirred for 15

min and benzeneselenyl bromide (0.143 mmol) (prepared by addition of 0.004
ml of bromine to 22.3 mg of diphenyl diselenide in 0.3 ml of THF) was added
dropwise. The solution was allowed to stir overnight. Water (5ml) was then
added and the mixture was extracted with DCM (3 x 10 ml). The combined
organic extracts were dried, evaporated and chromatographed (EtOAc :
hexane, 20 : 80 and then 30 : 70) to give two fractions. The solvent in the
fraction was evaporated to give (124) (32mg, 38%) as a pale yellow oil. 1HNmr (CDC13, 300 MHz) 8: 0.92 (d, J=4.2 Hz, 6H, CH(CH3)2), 0.94 (d, J=3.9 Hz,
6H, CH(CH3)2), 1.46 (s, 9H, OC(CH3)3), 2.66 (t, J=7.8 Hz, 2H, CH2Ar), 2.87-2.99
(m, 2H, CH2NH), 3.15 (dd, J=10.2, J=9.9 Hz, 1H, CHSePh), 3.72-3.79 (m, 2H,
CH20), 3.86 (s, 3H, CH30), 6.67-6.78 (m, 3Har0m), 7.22-7.29 (m, 3Har0m), 7.61-

7.64 (m, 2Harom). The second fraction was (125) as pale yellow crystals, mp 89
91°C (EtOAc/hexane). iH-Nmr (CDCI3, 300 MHz) 8: 1.44 (s, 9H, OQCHsb),

2.70 (t, J=7.2 Hz, 2H, CH2Ar), 3.34 (q, J=7.2 Hz, 2H, CH2NH), 3.87 (s, 3H, CH3O),
4.54 (s, 1H, NH), 5.64 (s, 1H, OH), 6.67 (dd, J=8.1, J=2.1 Hz, lHar0m), 6.77 (d,
J=2.1 Hz, lHar0m), 6.79 (d, J=8.1 Hz, lHarom). Ms (EI) m/z (%): 267 (3, M+), 211
(32), 194 (10), 150 (100), 137 (78).
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Oxidation of (124) with Hydrogen Peroxide in the Presence of Acetic Acid
To a stirred solution of (124) (15 m g , 0.026 mmol) in T H F (2ml) was
added water (0.1 ml), acetic acid (0.01 ml) and hydrogen peroxide (70 m g ,
30%). The solution was allowed to stir for 30 min. More water (5 ml) was
then added and the mixture was extracted with D C M (3 x 15 ml). The
combined extracts were dried, evaporated and chromatographed (EtOAc :
hexane, 25 : 75) to give two fractions. The first fraction was (125). The
solvent in the second fraction was evaporated to give (127) as pale yellow oil.
iH-Nmr (CDC1 3 , 300 M H z ) 8: 0.82-0.91 (m, 12H, 2 x CH(CH 3 ) 2 ), 1.56 (s, 9H,
OC(CH 3 ) 3 ), 2.04 (m, 2H, CH 2 Ar), 2.78 (m, 2H, C H 2 N H ) , 3.86 (s, 3H, CH3O), 6.05
(d, J=12.9 Hz, O C H C H ) , 6.75-6.83 (m, 3 H a r o m ) , 7.86 (d, J=12.9 Hz, O C H C H ) . M s
(EI) m / z (%): 420 (1, M + ) , 320 (1), 305 (1), 263 (2), 215 (6), 196 (6), 183 (13), 171
(6), 154 (100).
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Reaction of N-Protected Dopamine (128) with Methyl Propiolate
To a stirred solution of N-protected dopamine (128)57 (340 m g , 1.344
mmol) in dry T H F (25 ml), under N 2 , were added N a H (135 m g , 60%, 3.375
mmol) and then methyl propiolate (0.24 ml, 2.698 mmol). The mixture was
allowed to stir for 3 h. Water (15 ml) was then added and the mixture was
extracted with D C M (2 x 30 ml) and (2 x 30 ml). The combined extracts were
dried, evaporated and chromatographed ( D C M : M e O H , 98.5 : 1.5) to give two
fractions. The solvent in the first fraction was evaporated to give (129) (30
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mg, 7%) as a pale yellow oil. iH-Nmr (CDCI3, 400 M H z ) 8: 1.44 (OC(CH3)3),
2.70 (t, J=7.2 Hz, 2H, CH 2 Ar), 2.98 (d, J=5.2,2H, OCHCH^), 3.32 (q, J=7.2 Hz, 2H,
C H 2 N H ) , 3.77 (s, 3H, CH3O), 4.56 (s, 1H, N H ) , 6.51 (t, J=5.2 Hz, 1H, O C H C H 2 ) ,
6.62-6.73 (m, 3H a r 0 m).

13

C-Nmr (CDCI3, 400 M H z ) 8: 28.3 (OC(CH3)3), 40.0

(CH2Ar), 52.1 (CH 2 NH). M s (EI) m/z (%): 337 (8, M+), 281 (18), 264 (11), 220
(90), 207 (30), 190 (15), 175 (50). The second fraction was rechromatographed
(DCM : hexane : M e O H , 90.9 : 9 : 0.1) to give two fractions. The first fraction
was (130) (120 mg, 27%) as a pale yellew oil. iH-Nmr (CDCI3,400 M H z ) 8:1.44
(s, 9H, OC(CH3)3), 2.71 (t, J=7.5 Hz, 2H, CH 2 Ar), 3.33 (q, J=7.5 Hz, 2H, CH2NH),
3.73 (s, 3H, CH3O), 4.62 (s, 1H, N H ) , 5.56 (d, J=12.0 Hz, 1H, O C H C H ) , 6.19 (s,
1H, OH), 6.84-6.93 (m, 3Harom), 7.74 (d, 1=12.0 Hz, O C H C H ) .

13

C-Nmr (CDC13,

400 M H z ) 8: 28.3 (OC(CH3)3), 35.3 (OC(CH3)3), 51.4 (COOCH3), 67.9 (CH 2 NH),
102.1 (OCHCH), 117.0 (ArC-H), 118.6 (ArC-H), 126.3 (ArC-H), 131.6 (ArC-CH2),
142.7 (ArC-O), 145.0 (ArC-O), 156.0 (NHCO), 159.3 (OCHCH), 167.4 (COOCH3).
Ms (EI) m/z (%): 337 (4, M+), 281 (17), 264 (8), 232 (3), 220 (50), 208 (18), 188 (31),
175 (32). The second fraction was (131) (170 mg, 38%) as a pale yellow oil. iHNmr (CDCI3,400 M H z ) 8: 1.44 (s, 9H, OC(CH 3 ) 3 , 2.73 (t, 1=6.8 Hz, 2H, CH 2 Ar),
3.35 (q, J=6.8 Hz, 2H, C H 2 N H ) , 3.72 (s, 3H, CH3O), 4.63 (s, 1H, N H ) , 5.54 (d,
J=12.0 Hz, 1H, O C H C H ) , 6.35 (s, 1H, OH), 6.68-6.95 (m, 3Harom), 7.74 (d, J=12.0
Hz, O C H C H ) .

13

C-Nmr (CDCI3, 400 M H z ) 28.3 (OC(CH3)3), 35.6 (OC(CH3)3),

41.6 (CH2Ar), 51.4 (COOCH3), 60.4 (CH 2 NH), 101.7 (OCHCH), 117.2 (ArC-CH2),
141.4 (ArC-0),146.6 (ArC-O), 159.7 (OCHCH), 156.1 (NHCO), 167.5 (COOCH3).
Ms (EI) m/z (%): 337 (2, M+), 281 (12), 264 (5), 249 (6), 232 (5), 220 (40), 208 (16),
188 (33), 175 (26).
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5.3 Experimental for Chapter 4
Preparation of 5-Triflate-3,4-dihydro-3-(di-n-propylamino)-2H-l-benzopyran
(141)*

'O
(* In the experimental for chapter 4, the 'hydro' substituent ordering is per
Chemical Abstract)
To a stirred solution of 5-hydroxy-3,4-dihydro-3-(di-n-propylamino)2H-l-benzopyran45 (2.225 g, 8.94 mmol) in D C M (50 ml) under argon at -30°C
were

added

pyridine

(1.37

ml,

16.99

mmol)

trifluoromethanesulfonic anhydride (1.83 ml, 11.17 mmol).

and

then

The solution

was stirred at -20° C for 2 h and then allowed to reach the ambient
temperature. It was then washed with a saturated solution of N a H C 0 3 (30
ml) and water (20 ml), dried and evaporated to give a yellow residue. The
crude residue was then chromatographed ( Lp:EtOAc, 94:6) to give 5-triflate3,4-dihydro-3-(di-n-propylamino)-2H-l-benzopyran (141) (2.447 g, 72%) as a
pale yellow oil. iH-Nmr (CDC1 3 ) 8: 0.91 (t, 1=7.4 Hz, 6H, 2 x C H 2 C H 3 ) , 1.411.56 (m, 4H, 2 x C H 2 C H 3 ) , 2.54 (t, J=6.9 H z , 2H, N C H 2 ) , 2.55 (t, J=7.0 H z , 2H,

N C H 2 ) , 2.75 (dd, J=16.4, J=10.6 Hz, 1H, C H A r ) , 2.98 (ddd, J=16.4, J=5.2, J=1.8 Hz,
1H, C H A r ) , 3.12-3.24 (m, 1H, C H N ) , 3.88 (t, J=10.3 H z , 1H, C H O ) , 4.30-4.36 (m,
1H, C H O ) , 6.86 (2d, J=8.3 H z , 2 H a r o m ) , 7.17 (t, J=8.3 H z , l H a r o m ) . " C - N m r
(CDCI3) 8:11.7 (2 x C H ^ H s ) , 21.9 (2 x CTT2CH3), 23.1 (CH 2 Ar), 52.4 (CHN), 54.7
(2 x C H 2 N ) , 68.1 (CH 2 0), 112.9 (ArC-H), 116.2 (ArC), 116.6 (ArC-H), 121.3 (CF3),
127.7 ( ArC-H), 148.6 (ArC), 156.2 (ArC). M s (CI) m / z (%): 382 (20, M+l), 250
(10), 149 (5), 102 (35).

Preparation of 5-Vinyl-3,4-dihydro-3-(di-n-propylamino)-2H-l-benzopyran

To a mixture of (141) (2.50 g, 6.56 mmol), LiCl (836 m g , 16.676 mmol),
Bis (triphenylphosphine)-palladium (II) chloride, containing 1 5 % pd, (230
mg, 0.328 m m o l ) in D M F (30 ml) under argon was added vinyltributyltin
(2.30 ml, 7.87 mmol). The stirred solution was heated at 90°C for 5 h. The
solvent was then removed in vacuo and the remaining residue was
chromatographed (Lp:EtOAc, 90:10, v/v) to give a pale yellow oil. The oil
was then treated with etheral hydrochloric acid to afford 5-vinyl-3,4-dihydro3-(di-n-propylamino)-2H-l-benzopyran hydrochloride (142.HC1) (1.483 g,
76%) as colourless crystals. ^ - N m r (CDCI3) 8: 0.75 (t, J=7.5 H z , 6H, 2 x
C H 2 C H 3 ) , 1.40-1.54 (m, 4H, 2 x CH2CH3), 2.51 (t, 7.0 Hz, 2H, C H 2 N ) , 2.53 (t, 7.0
Hz, 2H, C H 2 N ) , 2.70 (dd, J=16.0, J=10.0 Hz, 1H, CHAr), 2.88 (ddd, J=16.0, J=6.0,
J=2.0 H z , 1H, CHAr), 3.10-3.24 (m, 1H, C H N ) , 3.65 (t, J=10.2 Hz, 1H, C H O ) , 4.254.32 (m, 1H, C H O ) , 5.32 (dd, J=11.2, J=1.4 Hz, 1H, A r - C H C H 2 ) , 5.65 (dd, J=17.7,

J=1.4 Hz, 1H, Ar-CHCH), 6.76 (t, J=6.0 Hz, lH ar0 m), 6.87 (dd, J=17.7,11.2 Hz, 1H,
Ar-CHCH), 7.08 (2d, J=6.0 Hz, 2H ar0 m). 13C-Nmr (CDC13) 8:11.8 (2 x C H ^ H s ) ,
22.0 (2 x C H 2 C H 3 ) , 26.0 (CH2Ar), 52.8 (2 x C H 2 N ) , 53.5 (CHN), 67.4 (CH 2 0),
116.0 (Ar-C_HCH2), 116.1 (ArC-H), 117.9 (ArC-H), 119.7 (ArC), 126.9 (ArC-H),
134.0 (Ar-CHCH 2 ), 138.3 (ArC), 154.6 (ArC). Ms (CI) m/z (%): 260 (67, M+l),
230 (4), 159 (3).

Preparation of 5-Ethyl-3,4-dihydro-3-(di-r?-propylamino)-2H-l-benzop

A solution of (142) (532 mg, 2.05 mmol) in ethanol (10 ml) was
hydrogenated at 50 p.s.i. at room temperature for 6 h in the presence of
palladium on carbon (10% pd). The resulting solution was filtered through
celite, evaporated and the remaining crude residue was chromatographed

(LP:EtOAc, 90:10) to give 5-ethyl-3,4-dihydro-3-(di-n-propylamino)-2H-l
benzopyran (143) (461 mg, 86%) as a colourless oil. iH-Nmr (CDCI3) 8: 1.06 (t,
1=7.4 Hz, 6H, 2 x N C H 2 C H 2 C H 3 ) , 1.39 (t, ]=7.5 Hz, 3H, Ar-CH 2 CH3), 1.57-1.71
(m, 4H, 2 x NCH 2 CH2CH 3 ), 2.61-2.88 (m, 7H, N(CH 2 ) 2 , Ar-CHCH, ArCH2CH 3 ),
2.99 (ddd, J=16.4, J=5.2, J=1.8 Hz, 1H, CHAr), 3.28-3.40 (m, 1H, C H N ) , 3.93 (t,
J=10.3 Hz, 1H, CHO), 4.42-4.49 (m, 1H, CHO), 6.85 (d, J=8.1 Hz, lH ar0 m), 6.94 (d,
J=8.1 Hz, lHarom), 7.22 (t, J=8.1 Hz, lH a r o m ).
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C-Nmr (CDCI3) 8: 18.9 (2 x

N C H 2 C H 2 C H 3 ) , 21.2 (Ar-CH^Hs), 29.1 (2 x C H 2 C H 2 C H 3 ) , 32.5 (CH2Ar), 32.7
(CH2Ar), 59.8 (2 x C H 2 N ) , 60.5 (CHN), 74.3 (CH 2 0), 121.3 (ArC-H), 127.0 (ArCH), 127.1 (ArC), 133.9 (ArC-H), 150.8 (ArC), 161.6 (ArC). M s (CI) m/z (%) 262

(65, M+l), 232 (3), 161 (2). Anal. Calcd for Ci 7 H 27 NO.HCl: C, 68.55; H, 9.47; N,
4.70. Found: C, 68.57; H, 9.59; N, 4.67.

Preparation of 5-Phenyl-3,4-dihydro-3-(di-n-propylamino)-2H-l-benzo
{146}

O
To a stirred solution of (141) (800 mg, 2.10 mmol) in toluene (40 ml)
under argon was added tetrakis (triphenylphosphine) palladium (0) (122 mg,
0.105 mmol).

The mixture was allowed to stir for 30 min at ambient

temperature. Phenylboronic acid (384 mg, 3.15 mmol) was then added,
followed immediately by saturated solution of N a H C 0 3 (15 ml). This
biphasic solution was thereafter refluxed for 5 h. Brine solution was then
added, the two layers formed were separated and the aqueous phase was
extracted with D C M (3 x 30 ml). The combined organic extracts were dried,
evaporated and chromatographed (LP:EtOAc, 95:5, v/v) to give 5-phenyl-3,4dihydro-3-(di-n-propylamino)-2H-l-benzopyran (146) (580 mg, 89%) as
colourless crystals, m p 69-71°C (EtOAc/Lp). iH-Nmr (CDC13) 8: 0.85 (t, J=7.4
Hz, 6H, 2 x CH 2 CH3), 1.34-1.49 (m, 4H, 2 x CH^-CHs), 2.46 (t, J=7.6 Hz, 4H, 2 x
C H 2 N ) , 2.59-2.81 (m, 2H, CH 2 Ar), 3.04-3.16 (m, 1H, C H N ) , 3.90 (t, J=10.2 Hz,
1H, C H O ) , 4.30-4.36 (m, 1H, C H O ) , 6.85 (d, J=7.4 Hz, lH ar0 m), 6.87 (d, J=7.4 Hz,
lHarom), 7.18 (t, J=7.4 Hz, lH ar0 m), 7.33-7.48 (m, 5H ar0 m).
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C-Nmr (CDCI3) 8:

12.1 (2 x C H 2 C H 3 ) , 22.3 (2 x C H 2 C H 3 ) , 27.9 (CH2Ar), 53.1 (2 x CH 2 N), 54.1 (2 x
C H N ) , 68.2 (CH 2 0), 116.0 (ArC-H), 120.1 (ArC), 122.5 (ArC-H), 127.3 (ArC-H),

127.4 (ArC-H), 128.6 (2 x ArC-H), 129.4 (2 x ArC-H), 141.4 (ArC), 143.8 (ArC),
155.0 (ArC). M s (CI) m/z (%): 310 (95, M+l), 280 (5), 209 (4), 128 (4). Anal.
Calcd for C 2 iH 2 7 NO: C, 81.51; H, 8.79; N, 4.53. Found: C, 80.88; H, 8.74; N, 4.40.

Preparation of 5-Acetvl-3.4-dihydro-3-(di-n-propylamino)-2H-l-benz
045}

ay
To a mixture of (141) (1.30 g, 3.41 mmol), LiCl (435 mg, 10.24 mmol),
Bis(tiphenylphosphine)-palladium (II) chloride containing 15% pd (120 mg,
0.171

mmol)

in

DMF

(20 ml) under

ethoxyvinyl)tributyltin (1.38 ml, 4.094 mmol).

argon

was

added (1-

The stirred solution was

heated at 90 °C for 3.5 h. The solvent was then removed in vacuo and the
crude residue was chromatographed (Lp:EtOAc, 90:10) to give a pale yellow
oil.

The oil was then treated with hydrochloric acid (10%) at room

temperature for 1 h. Potassium carbonate was added to adjust the p H to 9.
The solution was then extracted with D C M (3 x 20 ml). The combined
organic extracts were dried, evaporated and treated with etheral hydrochloric

acid to afford 5-acetyl-3,4-dihydro-3-(di-n-propylamino)-2H-l-benzopy
hydrochloride (145.HC1) (940 mg, 88%). iH-Nmr (D20) 8: 0.89-0.96 (m, 6H, 2 x
CH 2 CH3), 1.59-1.84 (m, 4H, 2 x CH2CH3), 2.60 (s, 3H, COCH3), 3.10-3.25 (m, 4H,
2 x C H 2 N ) , 3.31-3.55 (m, 2H, CH 2 Ar), 3.91-4.00 (m, 1H, C H N ) , 4.35-4.50 (m, 2H,
CH 2 0), 7.12 (d, J=7.4 Hz, lH a r o m ), 7.33 (t, J=7.4 Hz, l H a r o m ) , 7.59 (d, J=7.4 Hz,
lHarom)- 13 C-Nmr (D20) 8: 9.4 (2 x C H ^ H s ) , 16.7 (COCH3), 24.1 (2 x CH 2 CH 3 ),
28.3 (CH2Ar), 52.0 (2 x C H 2 N ) , 54.6 (CHN), 62.6 (CH 2 Q), 117.2 (ArC), 120.9

(ArC), 124.2 (ArC), 127.3 (ArC), 136.5 (ArC), 153.2 (ArC), 205.0 (COCH 3 ). Ms

(CI) m/z (%): 276 (52, M+l), 246 (2), 175 (2). Anal. Calcd for Ci7H25N
C, 65.48; H, 8.40; N, 4.49. Found: C, 65.65; H, 8.62; N, 4.49.

Preparation of 5-(3-Nitrophenyl)-3,4-dihydro-3-(di-n-propylamino)-2
benzopyran (167)

INWo

As described for (146). 5-(3-Nitrophenyl)-3,4-dihydro-3-(di-npropylamino)-2H-l-benzopyran (167) (7%, 51% based on the recovered

starting material) was obtained as yellow crystals, mp 83-85 °C (EtO
lH-Nmr (CDCI3) 8: 0.85 (t, J=7.4 Hz, 6H, 2 x CH2CH3), 1.35-1.46 (m,

CH2CH3), 2.46 (t, J=7.5 Hz, 4H, 2 x CH2N), 2.50-2.60 (m, 1H, CHAr), 2.

(m, 1H, CHAr), 3.07-3.18 (m, 1H, CHAr), 3.92 (t, J=10.2 Hz, CHO), 4.3

1H, CHO), 6.84 (d, J=7.4 Hz, lHarom), 6.92 (d, J=7.4 Hz, lHar0m), 7.21 (
lHar0m), 7.59-7.72 (m, 2 Harom), 8.24-8.27 (m, 2Har0m)-
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C-Nmr (CDCI3) 8:

(2 x CH2CH3), 21.8 (2 x CH2CH3), 27.5 (CH2Ar), 52.7 (2 x CH2N), 53.5 (CHN)

67.6 (CH20), 116.7 (ArC-H), 119.5 (ArC), 121.9 (ArC-H), 122.1 (ArC-H), 124
(ArC-H), 127.3 (ArC-H), 129.2 (ArC-H), 135.2 (ArC-H), 140.7 (ArC), 142.7

148.1 (ArC), 154.8 (ArC). Ms (CI) m/z (%): 355 (95, M+l), 325 (10), 234 (1
Starting material recovered was 1.3 g from 1.5 g, 87%.

Preparation of 5-(3-Aminophenyl)-3.4-dihvdro-3-(di-n-propylamino)-2
benzopyran (168)

'O
i) As described for (146). 5-(3-aminophenyl)-3,4-dihydro-3-(di-npropylamino)-2H-l-benzopyran (168) (10%, 2 5 % based on the recovered
starting material) was obtained as a pale yellow oil. Starting material
recovered was 467 m g from 767 mg, 61%. (Note: the aminophenylboronic
acid was dissolved in ethanol before addition)
ii) To a stirred solution of (167) (91 mg, 0.257 mmol) were added glacial
acetic acid (0.5 ml) and zinc powder (85 mg, 1.32 mmol) at room temperature.
The solution was then allowed to continue stirring for 2h. The p H was then
adjusted to 6 by addition of dilute solution of N a O H and the solution was
extracted with D C M (3 x 10 ml). The combined organic extracts were dried,
evaporated and chromatographed (LP: EtOAc, 65:35 v/v) to give 5-(3aminophenyl)-3,4-dihydro-3-(di-n-propylamino)-2H-l-benzopyran (168)
mg, 36%). !H-Nmr (CDC13) 8: 0.86 (t, 1=7.4 Hz, 6H, 2 x CH 2 CH3), 1.38-1.47 (m,
4H, 2 x C1T2CH3), 2.47 (t, 1=7.6 Hz, 4H, 2 x C H 2 N ) , 2.70-2.74 (m, 2H, CH 2 Ar),
3.05-3.17 (m, 1H, C H N ) , 3.73 (s, 2H, N H 2 ) , 3.89 (t, 1=10.1 Hz, 1H, CHO), 4.294.34 (m, 1H, C H O ) , 6.66-6.86 (m, 5H a r 0 m), 7.12-7.25 (m, 2H a r 0 m).
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C-Nmr

(CDCI3) 8:11.7 (2 x C H ^ H s ) , 21.8 (2 x CH2CH3), 27.3 (CH2Ar), 52.7 (2 x CH 2 N),
53.7 (CHN), 67.8 (CH 2 0), 113.8 (ArC-H), 115.4 (ArC-H), 115.8 (ArC-H), 119.5
(ArC-H), 119.9 (ArC), 121.9 (ArC-H), 126.8 (ArC-H), 129.0 (ArC-H), 142.2 (ArC),
143.6 (ArC), 146.2 (ArC), 154.5 (ArC). M s (CI) m/z (%): 325 (68, M+l), 283 (4),
224 (3).

Preparation of 5-(3-Azidophenyl)-3,4-dihydro-3-(di-n-propylamino)-2H-lbenzopyran (169)

(168) (63 mg, 0.195) was dissolved in water (2 ml) and 7 drops of
sulphuric acid and was then placed in an ice bath. To this stirred

was added a solution of NaN02 (15 mg, 0.214 mmol) in water (2 ml). T

solution was then allowed to continue stirring for 30 min. A soluti
NaN3 (23 mg, 0.351 mmol) in water (2 ml) was added thereafter. The

solution was stirred for further 40 min. The pH was adjusted to 10 b

addition of dilute solution NaOH and the resulting solution was ext

with DCM (5 x 10 ml). The combined organic extracts were dried, eva

and chromatographed (LP:EtOAc, 90:10, v/v) to give 5-(3-azidophenyl)
dihydro-3-(di-n-propylamino)-2H-l-benzopyran (169) (38 mg, 56%) as

yellow solid, mp 60-61°C (EtOAc/LP). iH-Nmr (CDC13) 8: 0.86 (t, 1=7.

2 x CH2CH3), 1.35-1.50 (m, 4H, 2 x CH2CH3), 2.46 (t, 1=7.5 Hz, 4H, 2 x C

2.60 (ddd, 1=18.2, J=5.6, J=2.0 Hz, 1H, CHAr), 2.73 (dd, J=18.2, J=10.

CHAr), 3.04-3.16 (m, 1H, CHN), 3.90 (t, J=10.2 Hz, 1H, CHO), 4.30-4.

CHO), 6.80-6.90 (m, 2Har0m), 7.01-7.29 (m, 4Har0m), 7.42 (t, 1=7.8 Hz, lH

13C-Nmr (CDCI3) 8: 11.7 (2 x CH2CH3), 21.9. (2 x CH2CH3), 27.5 (CH2Ar), 5

x NCH2), 53.6 (CHN), 67.7 (CH20), 116.0 (ArC-H), 117.7 (ArC-H), 119.5 (ArC)

119.6 (ArC-H), 121.8 (ArC-H), 125.7 (ArC-H), 127.0 (ArC-H), 129.5 (ArC-H)

139.9 (ArC), 142.3 (ArC), 142.8 (ArC), 154.6 (ArC). Ir (Neat)umax: 2102 (
cm-1.

Preparation of 5-Cyano-3.4-dihydro-3-(di-n-propylamino)-2H-l-benzopyran
{147}

CN [

ay^
A stirred mixture of (141) (845 mg, 2.218 mmol), tetrakis
(triphenylphosphine)palladium (0) (2.563 g, 2.218 mmol) and zinc cyanide
(156 mg, 1.331 mmol) in D M F (20 ml) under argon was heated at 90°C
overnight. The solvent was removed in vacuo and the residue was extracted
with D C M (40 ml). The organic phase was then washed with saturated
solution of N a H C 0 3 (2 x 10 ml), dried, evaporated and chromatographed (LP:
EtOAc, 95:5 and then 90:10) to give 5-cyano-3,4-dihydro-3-(di-npropylamino)-2H-l-benzopyran (147) (406 mg, 71%) as a colourless oil. ! H N m r (CDC13) 8: 0.92 (t, J=7.4 Hz, 6H, 2 x CH2CH3), 1.42-1.56 (m, 4H, 2 x
CH2CH3), 2.46-2.64 (m, 4H, 2 x CH 2 N), 2.93 (dd, J=16.6, J=10.7 Hz, 1H, CHAr),
3.11 (ddd, J=16.6, J=5.1, J=1.9 Hz, 1H, CHAr), 3.15-3.27 (m, 1H, C H N ) , 3.88 (t,
J=10.3 Hz, 1H, CHO), 4.30-4.37 (m, 1H, CHO), 7.04 (dd, J=7.9, J=1.6 Hz, lHar0m),
7.18 (t, 1=7.9 Hz, lH ar0 m), 7.24 (dd, 1=7.9,1=1.6 Hz, lHar0m)-
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C-Nmr (CDCI3)

8: 11.7 (2 x C H 2 C H 3 ) , 21.9 (2 x CH2CH3), 26.8 (CH2Ar), 52.5 (CHN), 52.7 (2 x
C H 2 N ) , 68.3 (CH 2 0), 113.5 (CN), 117.5 (ArC), 121.3 (ArC-H), 125.0 (ArC-H),
125.5 (ArC), 127.7 (ArC-H), 155.0 (ArC). M s (CI) m/z (%): 259 (95, M+l), 244
(80), 222 (60), 217 (85). Ir (Neat) vmax- 2228 (CN)cm'1.

Preparation of 5-Amido-3.4-dihydro-3-(di-n-propylamino)-2H-l-benzop

am

A stirred solution of (147) (50 mg, 0.194 mmol) and N a O H (9 pelletes)

in a mixture of ethanol and water (4 ml, 1:1) was refluxed overnight

was adjusted to 6 by addition of hydrochloric acid (2M) and the sol
then extracted with DCM (3 x 10 ml). The combined organic extracts

dried and evaporated to give 5-amido-3,4-dihydro-3-(di-n-propylamin

1-benzopyran (148) (40 mg, 75%) as a pale yellow oil. XH-Nmr (CDC13)

(t, J=7.4 Hz, 6H, 2 x CH2CH3), 1.44-1.59 (m, 4H, 2 x CH2CH3), 2.56-2.

x CH2N), 3.07-3.11 (m, 2H, CH2Ar), 3.18-3.28 (m, 1H, CHN), 3.94 (t, J=

1H, CHO), 4.31-4.37 (m, 1H, CHO), 6.93 (dd, 1=8.0,1=1.4 Hz, lHar0m), 7.
J=8.0, J=1.4 Hz, lHarom), 7.15 (t, J=8.0 Hz, lHarom), 7.22 (s, 2H, NH2).
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C-

(CDCI3) 8: 11.7 (2 x CH2CH3), 21.3 (2 x CH2CH3), 52.5 (2 x CH2N), 53.2 (CHN

67.6 (CH20), 119.1 (ArC-H), 119.2 (ArC-H), 120.3 (ArC), 127.1 (ArC-H), 136

(ArC), 155.0 (ArC), 171.9 (CO). Ms (CI) m/z (%): 227 (95, M+l), 259 (8), 17
Ir (Neat) umax: 3392 (NH), 3202 (NH), 1646 (CO) cm4.

Preparation of 5-Aminomethyl-3,4-dihydro-3-(di-w-propylamino)-2H-lbenzopyran (149)

.NH,

To a stirred solution of (147) (355 mg, 1.376 mmol) in absolute ethanol
(10 ml) was added lithium aluminium hydride (209 mg, 5.504 mmol). The
solution was stirred for 5 h at room temperature. Water (15 ml) was then
added and the solution was extracted with ethyl acetate (4 x 20 ml). The
combined organic extracts were dried, evaporated to give 5-aminomethyl-3,4-

dihydro-3-(di-n-propylamino)-2H-l-benzopyran (149) (342 mg, 95%) as a pa
yellow oil. lH-Nmr (CDC13) 8: 0.92 (t, J=7.4 Hz, 6H, 2 x CH2(j:H3), 1.43-1.57 (m,
4H, 2 x CIHCH3), 2.41 (s, 2H, N H 2 ) , 2.57 (t, 1=7.8 Hz, 2H, C H 2 N ) , 2.58 (t, 1=7.8
Hz, 2H, C H 2 N ) , 2.67-2.89 (m, 2H, CHCH^Ar), 3.18-3.24 (m, 2H, C H N ) , 3.78-3.83
(m, 1H, C H O ) , 3.86 (s, 2H, CH2NH 2 ), 4.29-4.36 (m, 1H, CHO), 6.76 (d, J=8.6 Hz,
lHarom), 6.94 (d, J=8.6 Hz, lHarom), 7.13 (t, J=8.6 Hz, lH ar0 m). 13C-Nmr (CDCI3)
8: 11.8 (2 x CH2CH3), 22.0 (2 x C H 2 C H 3 ) , 25.2 (CHCH 2 Ar), 43.2 (CH 2 NH 2 ), 52.7
(2 x C H 2 N ) , 53.4 (CHN), 67.3 (CH 2 0), 115.4 (ArC-H), 119.1 (ArC-H), 119.7
(ArC), 127.1 (ArC-H), 142.2 (ArC), 154.7 (ArC-H). M s (CI) m/z (%): 263 (95,
M+l), 243 (4).

Preparation of 5-ChloroacetamidomethyI-3,4-dihydro-3-(di-H-propyIamino)2H-l-benzopyran (175)

O ^ ^CH2C1

?

NH

To a stirred solution of (149) (336 mg, 1.282 mmol) in DCM (8 ml)
under argon, in an ice bath, were added potassium carbonate (195 mg, 1.41
mmol) and then chloromethylchloride (0.11 ml, 1.41 mmol). The solution
was then stirred overnight Water (20 ml) was added and the two phase
were separated. The aqueous phase was extracted with further D C M (2 x 20
ml) and the combined extracts were dried, evaporated and chromatographed

(EtOAc: LP, 40:60, v/v) to give 5-chloroacetamidomethyl-3,4-dihydro-3-(d
propylamino)-2H-l-benzopyran (175) (290 mg, 67%) as colourless crystals, m p
78-80OC (EtOAc/LP). lH-Nmr (CDC13) 8: 0.91 (t, J=7.4 Hz, 6H, 2 x CH2CH3),
1.41-1.56 (m, 4H, 2 x CH^CHs), 2.54 (t, J=6.9 Hz, 2H, C H 2 N ) , 2.55 (t, J=6.9 Hz,
2H, C H 2 N ) , 2.69 (dd, J=16.2, 10.8 Hz, 1H, CHCHAr), 2.84 (ddd, J=16.2,1=5.8,
J=1.8 Hz, 1H, CHCHAr), 3.15-3.27 (m, 1H, C H N ) , 3.82 (t, J=10.3 Hz, 1H, CHO),
4.41 (s, 2H, CH 2 C1), 4.29-4.36 (m, 1H, C H O ) , 4.48 (dd, J=21.4, J=15.1 Hz, 1H,
C H N H ) , 4.50 (dd, J=21.4, J=15.1 Hz, 1H, C H N H ) , 6.83 (d, J=8.0 Hz, lH ar0 m), 6.86
(d, J=8.0 Hz, lH arorn ), 7.13 (t, J=8.0 Hz, lH a r o m )-
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C-Nmr (CDCI3) 8: 11.7 (2 x

C H ^ H s ) , 21.9 (2 x C H 2 C H 3 ) , 25.4 (CHCH 2 Ar), 41.4 (CH 2 NH), 42.6 (CH2C1),
52.7 (2 x C H 2 N ) , 53.2 (CHN), 67.5 (CH 2 0), 116.6 (ArC-H), 120.3 (ArC-H), 120.5
(ArC), 127.3 (ArC-H), 136.2 (ArC), 155.0 (ArC), 165.6 (CO). M s (CI) m/z (%):
341 (32, M+l, 37C1), 339 (95, M+l, 35C1), 305 (33), 263 (2), 204 (2). Ir (Near)umax:
3264 (NH), 1654 (CO) cm"1.
Photolysis of 5-Chloroacetamidomethyl-3,4-dihydro-3-(di-n-propylamino)2H-l-benzopyran (175)

A solution of (175) (135 mg, 0.399 mmol) in benzene (350 ml) was

irradiated for 30 min at room temperature using 500 W mercury lamp
solvent was then evaporated and the remaining crude residue was

chromatographed (LP:EtOAc, 50:50 and then 20:80, v/v) to give (176)

7%) as a pale yellow solid, mp 93-95°C (EtOAc/LP). lH-Nmr (CDCI3) 8

(t, J=7.3 Hz, 6H, 2 x CH2CH3), 1.40-1.55 (m, 4H, 2 x CH2CH3), 2.50 (

2H, CH2N), 2.51 (t, J=6.8 Hz, 2H, CH2N), 2.57-2.80 (m, 2H, CHQfcAr), 3
(m, 1H, CHN), 3.67 (s, 2H, COCH2Ar), 3.76 (t, J=10.3 Hz, 1H, CHO),

(m, 1H, CHO), 4.34-4.48 (m, 2H, CFT2NH), 5.55 (s, 1H, NH), 6.70 (d,

lHarom), 6.77 (d, J=7.5 Hz, lHarom), 7.06 (t, 1=7.5 Hz, lHar0m), 7.31-7.42 (
5Har0m).
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C-Nmr (CDCI3) 8: 11.7 (2 x CH2CH3), 21.9 (2 x CH2CH3), 25.1

(CHCH2Ar), 41.2 (CH2NH), 43.9 (COCH2Ar), 52.7 (2 x CH2N), 53.2 (CHN), 67.5

(CH20), 116.1 (ArC-H), 119.8 (ArC-H), 120.5 (ArC), 127.1 (ArC-H), 127.5 (

H), 129.1 (2 x ArC-H), 129.4 (ArC-H), 134.7 (ArC), 137.1 (ArC), 154.8 (Ar
170.7 (CO). Ms (CI) m/z (%): 381 (95, M+l), 303 (35).

(176)

Preparation of 5-Hydroxy-3,4-dihydro-3-amino-2H-l-benzopyran (150)

OH
l^^NH

2

.HBr

OCT
A solution of 5-methoxy-3,4-dihydro-3-amino-2H-l-benzopyran
(135) (2.145 g, 9.954 mmol) in hydrobromic acid (48%, 13 ml) and acetic acid
45

(glacial, 20 ml) was heated at 138°C for 6 h. The solution was then
evaporated to give

5-hydroxy-3,4-dihydro-3-amino-2H-l-benzopyran

hydrobromide (150.HC1) (2.28 g, 100%) as yellow crystals, m p 256-258°C (H20).
iH-Nmr (D 2 0) 8: 2.82-2.91 (m, 1H, CHAr), 3.12 (dd, J=18.0, J=5.8 Hz, 1H,
CHAr), 4.04-4.07 (m, 1H, C H N ) , 4.19-4.40 (m, 2H, C H 2 0 ) , 6.55 (d, J=8.3 Hz,
lH ar0 m), 6.60 (d, 8.3 Hz, lH ar0 m), 7.13 (t, 1=8.3 Hz, lH ar0 m). 13 C-Nmr (D20) 8:
23.4 (CH2Ar), 44.2 (CH 2 N), 65.6 (CH 2 0), 106.3 (ArC), 108.5 (ArC-H), 109.0 (ArCH), 128.7 (ArC-H), 154.4 (ArC), 155.2 (ArC). M s (CI) m/z (%): 166 (95, M+l),
148 (5).

Preparation of 5-Hydroxy-3,4-dihydro-3-ffert-butoxycarbonylamino)-2
benzopyran (151)

NHBoc
O
To a solution of (150) (1.9 g, 7.72 mmol) in THF (20 ml) were added a
solution N a O H (1M, 18 ml) and (Boc)20 (97%, 2.122 g, 9.43 mmol). The
solution was stirred overnight and the two phases were then separated. The
p H of the aqueous phase was adjusted to 7 by addition of HC1 (1M) and the
solution was then extracted with D C M (3 x 20 ml). The combined organic
extracts were dried, evaporated and chromatographed (LP:£tOAc, 77:23, v/v)
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to give 5-hydroxy-3,4-dihydro-3-(tert-butoxycarbonylamino)-2H-lbenzopyran (151) (2.0 g, 98%) as a colourless solid, m p 158-160°C (EtOAc/LP).
!

H - N m r (CDC1 3 ) 8: 1.44 (s, 9H, C(CH 3 ) 3 ), 2.64-2.75 (m, 1H, CHAr), 2.90 (dd,

J=17.3, J=5.8 H z , 1H, CHAr), 4.01-4.23 (m, 3H, C H N , C H 2 0 ) , 4.98 (d, J=7.6 Hz,
1H, N H ) , 6.05 (s, 1H, O H ) , 6.42 (d, 1=7.4 Hz, l H a r o m ) , 6.46 (d, J=7.4 Hz, lH a r 0 m),
6.97 (t, J=7.4 H z , lH a rom), 6.97 (t, J=7.4 Hz, lH ar om).

13

C-Nmr (CDCI3) 8: 26.0

(CH 2 Ar), 28.4 (C(CH 3 ) 3 ), 43.0 (CHN), 68.0 (CH 2 0), 107.4 (2 x ArC-H), 108.9
(ArC), 127.4 (ArC-H), 155.0 (2 x ArC), 155.6 (CO). M s (CI) m / z (%): 266 (5,
M+l), 227 (12), 210 (95), 195 (5), 166 (60), 148 (8).

Preparation of 5-Triflate-3,4-dihydro-3-fferf-butoxycarbonylamino)-2H-lbenzopyran (152)
OTf

1 ^ ^ ^ NHBoc

ay
As described for (141). The crude product was chromatographed
(LP:EtOAc, 90:10, v/v) to give 5-triflate-3,4-dihydro-3-(tertbutoxycarbonylamino)-2H-l-benzopyran (152) (93% from 4.615 g of starting
material) as colourless crystals, m p 82-84°C (EtOAc/LP). iH-Nmr (CDCI3) 8:
1.43 (s, 9H, C(CH 3 ) 3 ), 2.84 (dd, J=18.4,1=4.9 H z , 1H, C H A r ) , 3.07 (dd, J=18.4,
1=4.9 H z , 1H, C H A r ) , 4.13-4.26 (m, 3H, C H N , C H 2 0 ) , 4.85 (d, 1=7.6 H z , 1H,
N H ) , 6.89 (2d, J=8.5 H z , 2Harom), 7.19 (t, 1=8.5 Hz, lH ar om).

13

C-Nmr (CDCI3) 8:

26.5 (CH 2 Ar), 28.3 (C(CH 3 ) 3 ), 42.3 (CHN), 68.3 (CH 2 0), 113.6 (ArC-H), 113.9
(ArC), 117.0 (ArC-H), 121.1 (CF3), 128.1 (ArC-H), 148.6 (ArC), 155.1 (ArC), 155.4
(CO). M s (CI) m / z (%): 398 (3, M+l), 359 (96), 342 (32), 298 (94).

Preparation of 5-Vinyl-3.4-dihvdro-3-(fprf-butoxycarbonylamino)-2H-lbenzopyran (153)

,NHBoc
O
As described for (142). The crude residue was chromatographed
(Lp:EtOAc,

85:15, v/v)

to

give 5-vinyl-3,4-dihydro-3-(tert-

butoxycarbonylamino)-2H-l-benzopyran (153) (75% from 3.0 g of starting
material) as colourless crystals, m p 106-108°C (EtOAc/LP). X H-Nmr (CDCI3) 8:
1.47(s, 9H, C(CH3)), 2.75-2.83 (m, 1H, CHAr), 3.06 (dd, 1=16.9, T=5.6 Hz, 1H,
CHAr), 4.11-4.27 (m, 3H, C H N , CH 2 0), 4.93 (d, J=7.6 Hz, 1H, N H ) , 5.35 (dd,
J=11.0, J=1.3 Hz, 1H, Ar-CHCH 2 ), 5.67 (dd, J=17.4, J=1.3 Hz, 1H, Ar-CHCH),
6.76-6.87 (m, 2H, Ar-CHCH, lH ar0 m), 7.11-7.19 (m, 2H ar0 m).

13

C-Nmr (CDCI3)

8: 28.4 (C(CH3)), 29.2 (CH2Ar), 43.3 (CH 2 N), 67.8 (CH 2 0), 116.3 (Ar-CHCH2),
116.5 (ArC-H), 117.3 (ArC), 118.6 (ArC-H), 127.3 (ArC-H), 133.5 (ArCHCH 2 ),
138.6 (ArC), 154.0 (ArC), 155.4 (CO). M s (CI) m/z (%): 276 (5, M+l), 237 (35),
220 (95), 176 (45).

Preparation of 5-Ethyl-3,4-dihydro-3-(fgr£-butoxycarbonylamino)-2H
benzopyran (154)

NHBoc
"O
As

described

for

(143).

5-Ethyl-3,4- dihydro-3-(tert-

butoxycarbonylamino)-2H-l-benzopyran (154) was obtained as colourless
crystals (87% from 1.53 g of starting material), m p 98-99°C (EtOAc/LP). *HN m r (CDCI3) 8: 1.20 (t, J=8.4 Hz, 3H, CH2CH3), 1.42 (s, 9H, C(CH3)3), 2.54 (q,

1=8.4 Hz, 2H, C H 2 C H 3 ) , 2.66-2.77 (m, 1H, CHCHAr), 2.96 (dd, J=16.8, J=5.9 Hz,

1H, CHCHAr), 4.04-4.25 (m, CHN, CH20), 5.97 (d, J=7.6 Hz, 1H, NH), 6.

1=8.3 Hz, lHarom), 6.81 (d, f=8.3 Hz, lHar0m), 7.08 (t, J=8.3 Hz, lHar0m
Nmr (CDC13) 8: 14.2 (CH2CH3X, 25.3 (CH2CH3), 28.4 (C(CH3)3), 28.6

(CHCH2Ar), 43.4 (CH2N), 67.9 (CH20), 114.6 (ArC-H), 117.7 (ArC), 120.7 (A

H), 127.3 (ArC-H), 144.2 (ArC), 154.0 (ArC), 155.3 (CO). Ms (CI) m/z (%)
(8, M+l), 239 (20), 222 (95), 178 (45).

Preparation of 5-ethyl-3,4-dihydro-3-amino-2H-l-benzopyran (159a)

To a stirred solution of (154) (1.23 g, 4.62 mmol) in DCM (5 ml),

argon, was added trifluoroacidic acid (4 ml). The solution was all

continue stirring for 1 h. The solvent was then evaporated and the
was extracted with DCM (40 ml). The organic phase was washed with

saturated solution of NaHCOs (2 x 10 ml). The combined wash layers

extracted with EtOAc (30 ml). The combined organic extracts were d

evaporated to give 5-ethyl-3,4-dihydro-3-amino-2H-l-benzopyran (1

mg, 90%) as a colourless oil. iH-Nmr (CDCI3) 8: 1.24 (t, 1=7.6 Hz,

CH2CH3), 1.43 (s, 2H, NH2), 2.50 (dd, 1=16.3,1=7.3 Hz, 1H, CHCHAr), 2

J=7.6 Hz, 2H, CH^CHs), 3.04 (dd, J=16.3,1=4.7 Hz, 1H, CHCHAr), 3.36
1H, CHNH2), 3.79 (ddd, J=10.4, J=7.4, J=0.7 Hz, 1H, CHO), 4.15 (ddd,

J=3.0, J=1.6 Hz, 1H, CHO), 6.74 (d, 1=8.1 Hz, lHar0m), 6.82 (d, 1=8.1 Hz,
7.10 (t, J=8.1 Hz, lHarom)-
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C-Nmr (CDCI3) 8: 14.2 (CH2CH3), 25.4 (CH

32.0 (CHCH2Ar), 44.4 (CHNH2), 114.3 (ArC-H), 118.5 (ArC), 120.3 (ArC-H),

127.1 (ArC-H), 143.8 (ArC), 154.0 (ArC). Ms (CI) m/z (%): 178 (95, M+l).

Preparation of 8-|N-(5-Ethyl-3,4-dihydro-2H-l-benzopyran-3-yl)aminopropyn-8-azaspiro[4.5]decane-7,9-dione (159b)

(159b)
To a stirred solution of (159a) (556 mg, 3.41 mmol) in D M F (13 ml),
under

argon, were

added

a

solution

of

8-(4-bromobutyl)-8-

azaspiro[4.5]decane-7,9-dione45 (948 mg, 3.41 mmol) in D M F (2 ml),
potassium carbonate (868 mg, 6.28 mmol) and then a catalytic amount of
sodium iodide. The mixture was allowed to continue stirring at 35°C for 24
h. The solvent was then removed and the crude residue was extracted with
D C M (30 ml). The extract was washed with water (2 x 10 ml), dried,
evaporated and chromatographed (MeOH:EtOAc, 3: 97 and then 15:85) to
give three fractions. The first fraction was rechromatographed (EtOAc: Lp,
35:65, v/v) to give (162) (246 mg, 18%, 24% based on the recovered starting
material) as a colourless gum. iH-Nmr (CDCI3) 8: 1.22 (t, 1=7.6 Hz, 3H,
C H 2 C H 3 ) , 1.48-1.76 (m, 12H, 6 x CH 2 ), 2.53-2.60 (m, 6H, CHsCH^Ar, 2 x
C H 2 C O ) , 2.70-2.80 (m, 1H, N C H C H A r ) , 3.01 (dd, 1=16.8, J=5.5 Hz, 1H,
NCHCHAr), 3.80 (t, 1=6.0 Hz, 2H, C H 2 N C O ) , 4.05-4.16 (m, 4H, 2 x CH 2 0), 4.224.33 (m, 1H, C H N H ) , 5.10 (d, 1=7.6 Hz, 1H, N H ) , 6.75 (d, 1=8.1 Hz, lHarom), 6.83
(d, J=8.1 Hz, lHarom), 7.11 (t, J=8.1 Hz, lH a r o m )- M s (CI) m/z (%): 443 (14,
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M+l), 240 (95), 204 (4). The solvent in the second fraction was evaporated to

give 8-[N-(5-ethyl-3,4-dihydro-2H-l-benzopyran-3-yl)amino-propyl]azaspiro[4.5]decane-7,9-dione (159b) (648 mg, 52%, 7 0 % based on the
recovered starting material) as a colourless oil. iH-Nmr (CDCI3) 8: 1.20 (t,
J=7.3 Hz, 3H, C H 2 C H 3 ) , 1.46-1.74 (m, 12H, 6 x C H 2 ) , 2.48-2.61 (m, 7H,
CH 3 CH2Ar, C H C H A r , 2 x C H 2 C O ) , 2.75 (t, J=7.0 Hz, 2H, CH2NH), 2.94 (dd,
J=15.6 Hz, J=5.2 Hz, 1H, CHCHAr), 3.07-3.17 (m, 1H, N H ) , 3.73-3.85 (m, 3H,
C H 2 N C O , C H O ) , 4.15-4.22 (m, 1H, CHO), 6.69 (d, J=7.8 Hz, lH ar0 m), 6.77 (d,
J=7.8 Hz, lHarom), 7.05 (t, J=7.8 Hz, lH ar0 m)- M s (CI) m/z (%): 399 (45, M+l).
The third fraction was the starting material (142 mg, 26%).

j

Preparation of 8-f4-N-Propyl-N-(5-ethyl-3,4-dihydro-2H-l-benzopyran-3yl)amino-propyll-8-azaspirof4.5]decane-7,9-dione (159)

(159)

(

y

°y°

O

To a stirred solution of (159b) (600 mg, 1.508 mmol) in D M F (10 ml),
under argon, were added potassium carbonate (569 mg, 4.117 mmol) and
then iodopropane (0.4 ml, 4.10 mmol). The mixture was allowed to stir at

60°C overnight. The solvent was then evaporated and the crude residue was

extracted with DCM (40 ml). The extract was washed with water (2 x
dried, evaporated and chromatographed (EtOAc: LP, 25:75 and then

EtOAcMeOH, 99:1, v/v) to give two fractions. The solvent in the fi

fraction was evaporated and the remaining oil was treated with eth

oxalic acid. Crystals were collected and then treated with saturat

of NaHC03- Extraction with DCM, followed by evaporation gave 8-14

propyl-N-(5-ethyl-3,4-dihydro-2H-l-benzopyran-3-yl)amino-propyl]-8

azaspiro[4.5]decane-7,9-dione (159) (220 mg, 33%, 49% based on rec
starting material) as a colourless oil. ^-Nmr (CDC13) 8: 0.91 (t,

CH3CH2CH2N), 1.25 (t, 7.6 Hz, 3H, CH3CH2Ar), 1.44-1.75 (m, 14H, 7 x C

2.51-2.71 (m, 11H, 2 x CH2CO, 2 x CH2N, CHCHAr, CH3CH2Ar), 2.90 (dd,

J=15.6, J= 5.2 Hz, 1H, CHCHAr), 3.10-3.22 (m, 1H, CHN), 3.73-3.83 (

CH2NCO, CHO), 4.27-4.31 (m, 1H, CHO), 6.70 (d, 1=8.1 Hz, lHarom), 6.7
1=8.1 Hz, lHarom), 7.07 (t, 1=8.1 Hz, lHarom)- Ms (CI) m/z (%): 441 (95,

399 (3), 381 (5), 232 (8). Anal. Calcd for C27H4oN203.C2H204: C, 65.64

N, 5.28. Found: C, 65.50; H, 7.99; N, 5.32. The mother liquor was e

to give (165) (138 mg, 19%, 26% based on the recovered starting mat
1H-Nmr (CDCI3) 8: 0.95 (t, 1=7.6 Hz, 3H, CH2CH2CH3), 1.22 (t, 1=7.4

ArCH2CH3), 1.42-1.73 (m, 14 H, 7 x CH2), 2.51-2.62 (m, 6H, CHsCH^Ar

CH2CO), 2.82-2.98 (m, 2H, CHCFfcAr), 3.24 (t, 1=6.4 Hz, 2H, CH2NCO), 3

J=6.4 Hz, 2H, CH2N(CO)2), 4.04 (t, 1=6.8 Hz, 2H, CH2OCO), 4.13-4.20 (

CH2OAr, CHN), 6.71 (d, J=7.7 Hz, lHar0m), 6.79 (d, ]=7.7 Hz, lHar0m), 7.0

}=7.7 Hz, lHarom)- Ms (CI) m/z (%): 485 (11, M+l). The second fracti
the starting material (155 mg, 26%).

Preparation of 5-Acetyl-3,4-dihydro-3-(fgrf-butoxycarbonylamino)-2Hr-lbenzopyran (157)

NHBoc

O
As described for (145). The crude product was chromatographed

(EtOAc:LP, 10:90 and then 25:75, v/v) to give 5-acetyl-3,4-dihydro

butoxycarbonylamino)-2H-l-benzopyran (157) (1.164 g from 2.0 g of

starting material, 79%), mp 106-107 (EtOAc/LP). ^-Nmr (CDC13) 8: 1.

9H, C(CH3)), 2.59 (s, 3H, COCH3), 3.01 (dd, J=18.1,1=5.0 Hz, 1H, CHAr)

(dd, J=18.1, J=5.5 Hz, 1H, CHAr), 4.40-4.19 (m, 3H, CH20, CHNH), 4.7

Hz, 1H, NH), 7.04 (dd, 1=8.2,1=1.2 Hz, lHar0m), 7.23 (t, 1=8.2 Hz, lHar0m
(dd, 1=8.2 Hz, 1=1.2 Hz, lHarom).
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C-Nmr (CDCI3) 8: 28.4 (s, C(CH3)3)

(COCH3), 30.6 (CH2Ar), 43.2 (CHNH), 68.0 (CH20), 119.9 (ArC-H), 121.0 (A

H), 122.9 (ArC), 127.1 (ArC-H), 138.5 (ArC), 154.8 (ArC), 155.1 (NHCO),
(COCH3). Ms (CI) m/z (%): 292 (3), 253 (30), 236 (60), 192 (95). Ir
3366 (NH), 1688 (CO) cm"1.

Preparation of 5-Acetvl-3.4-dihydro-3-amino-2H-1-benzopyran (160a

CCT
As described for (159a). 5-Acetyl-3,4-dihydro-3-amino-2H-lbenzopyran (160a) was obtained as a colourless oil (703 m g from 1.107 g of
starting material, 97%). lH-Nmr (CDCI3) 8: 1.47 (s, 2H, N H 2 ) , 2.57 (s, 3H,

CH 3 ), 2.82 (dd, 1=18.8,1=9.0 Hz, 1H, CHAr), 3.25-3.36 (m, 2H, CHAr, C H N H 2 ) ,

3.80-3.89 (m, 1H, CHO), 4.15 (ddd, 1=10.8,1=2.5,1=2.5 Hz, 1H, CHO

J=8.1, 1=1.0 Hz, lHarom), 7.19 (t, J=8.1 Hz, lHar0m), 7.35 (dd, 1=8.1, J=1.
lHarom)-
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C-Nmr (CDC13) 8: 31.1 (COCH3), 35.3 (CH2Ar), 45.3 (CHNH2), 72

(CH20), 122.1 (ArC-H), 124.0 (ArC-H), 128.3 (ArC-H), 131.8 (ArC), 139.9 (
156.2 (ArC), 202.7 (CO). Ms (CI) m/z (%): 192 (95, M+l), 150 (11).

Preparation of 8-rA/-(5-Acetyl-3,4-dihydro-2H-l-benzopyran-3-yl)am
propyll-8-azaspiro[4.5]decane-7,9-dione (160b)

(160b)
Method i) As described for (159b). Reaction was carried out at 60°C.

The crude product was chromatographed (EtOAc:MeOH, 97:3, v/v) to g
three fractions. The solvent in the first fraction was evaporated

(240 mg from 294 mg starting material, 34%, 55% based on the recov

starting material) as a colourless gum. iH-Nmr (CDCI3) d: 1.49-1.
2 x CH2), 2.597 (s, 4H, 2 x CH2CO), 2.604 (s, 3H, COCH3), 3.02 (dd,
Hz, 1H, CHAr), 3.37 (1=18.7, J=5.3 Hz, 1H, CHAr), 3.79 (t, J=6.2 Hz,

CH2N(CO)2), 4.05-4.23 (m, 5H, 2 x CH20, CHNH), 4.93 (d, J=7.8 Hz, NH)

(dd, J=7.6, J=1.2 Hz, lHarom), 7.24 (t, J=7.6 Hz, lHarom), 7.41 (dd, 1=7.

lHarom). M s (CI) m / z (%): 457 (50, M+l), 240 (95), 174 (14). The second

fraction contained 8-[N-(5-acetyl-3,4-dihydro-2H-l-henzopyran-3-yl)amino-

propyl]-8-azaspiro[4.5]decane-7,9-dione (160b) (135 m g from 294 m g starting
material, 21%, 3 5 % based on the recovered starting material) as a pale yellow
oil after evaporation of the solvent. iH-Nmr (CDC1 3 ) 8: 1.46-1.74 (m, 12H, 6 x
C H 2 ) , 2.57 (s, 3H, C O C H 3 ) , 2.58 (s, 4H, 2 x C H 2 C O ) , 2.73 (t, J=6.5 H z , 2H,
CFT2NH), 2.87 (dd, J=17.3,1=7.3 Hz, 1H, CHAr), 3.08 (m, 1H, C H N H ) , 3.27 (dd,
1=17.3, J=4.8 Hz, 1H, CHAr), 3.76 (t, 1=7.3 Hz, 2H, CH 2 N(CO) 2 ), 3.88 (dd, 1=10.6,
1=7.3 Hz, 1H, C H O ) , 4.20 (ddd, 1=10.6,1=1.9,1=1.9, 1H, C H O ) , 6.99 (d, 1=7.8 Hz,
lHarom), 7.18 (t, 1=7.8 Hz, l H a r o m ) , 7.34 (d, L=7.8 Hz, l H a r o m ) . Ms(CI) m / z (%):
413 (95, M+l), 371 (10).
Method ii) To a solution of (160a) (416, 2.178 m m o l ) in acetonitrile (20
ml) under argon were added potassium carbonate (903 m g , 6.53 mg), a
solution of 8-(4-bromobutyl)-8-azaspiro[4.5]decane-7,9-dione45 (720 m g , 2.38
mmol) in acetonitrile (2 ml) and a catalytic amount of sodium iodide. The
mixture was refluxed for 48 h. The solvent was then evaporated and the
residue was extracted with D C M (40 ml). The organic extract was washed
with water (10 ml), dried, evaporated and chromatographed (EtOAc: M e O H ,
97:3, v/v) to give (160b) (368 mg, 41%) as a pale yellow oil.

Preparation of 8-f4-N-Propyl-N-(5-acetyl-3,4-dihydro-2H-l-benzopyran-3yl)amino-propyl]-8-azaspiro[4.5]decane-7,9-dione (160)

Method i) As described for (159). 8-[4-N-Propyl-N-(5-acetyl-3,4-

dihydro-2H-l-benzopyran-3-yl)amino-propyl]-8-azaspiro[4.5]decane-7
(160) was obtained as a pale yellow oil (50 m g from 125 m g of starting
material, 36%) after column chromatography (EtOAc: LP, 35:65, v/v). lHN m r (CDC13) 8: 0.88 (t, 1=7.3 Hz, 3H, CH 2 CH3), 1.40-1.75 (m, 14H, 7 x CH 2 ),
2.46-2.68 (m, 11H, 2 x C H 2 C O , 2 x C H 2 N , COCH3), 2.99-3.12 (m, 3H, CH 2 Ar,
C H N ) , 3.75-3.88 (m, 3H, CH 2 N(CO) 2 , C H O ) , 4.25-4.30 (m, 1H, C H O ) , 6.98 (d,
J=7.8 Hz, lHarom), 7.18 (t, J=7.8 Hz, lH a r o m ), 7.31 (d, J=7.8 Hz, lH ar0 m). M s (CI)
m/z (%): 455 (96, M+l). Anal. Calcd for C 2 7H 38 N20 4 .C 2 H20 4 : C, 63.95; H, 7.40;
N, 5.14. Found: C, 63.32; H, 7.20; N, 5.13. Compound (166) was a colourless
gum (80 m g from 125 m g of starting material, 53%). ^ - N m r (CDCI3) 8: 0.96
(t, J=7.3 Hz, 3H, CHCH3), 1.45-1.75 (m, 14H, 7 x CH 2 ), 2.59 (s, 3H, COCH3), 2.61
(s, 4H, 2 x C H 2 C O ) , 3.13-3.41 (m, 4H, C H 2 N C O , CH 2 Ar), 3.77 (t, 1=6.8 Hz, 2H,
CH 2 N(CO) 2 ), 4.07 (t, 1=6.7 Hz, 2H, C H 2 O C O ) , 4.17-4.25 (m, 3H, C H N , CH 2 OAr),
7.03 (d, 1=7.8 Hz, lHarom), 7.24 (t, 1=7.8 Hz, lHarom), 7.39 (d, 1=7.8 Hz, lH arom )Ms (CI) m/z (%): 498 (94, M+l), 546 (6).

Method ii) To a stirred solution of (160b) (360 mg, 0.874 mmol) i
acetonitrile (10), under argon, were added potassium carbonate (362 mg, 2.62
mmol) and idodopropane (0.26 ml, 2.62 mmol). The mixture was allowed to
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reflux for overnight. The solvent was then evaporated and the remaining
residue was extracted with D C M . The organic extract was dried, evaporated
and chromatographed (EtOAcLP, 35:65) to give (160) (151 m g , 35%) as a pale
yellow oil.

Preparation of (177)

To a stirred solution of 5-hydroxy-3,4-dihydro-3-amino-2H-lbenzopyran (370 m g , 2.07 mmol) in D M F (20 ml), under argon, were added
potassium carbonate (858 m g , 6.21 m m o l ) and 8-(4-bromobutyl)-8azaspiro[4.5]decane-7,9-dione45 (625 m g , 2.07 mmol). The mixture was then
allowed to continue stirring at 60°C overnight. Iodopropane (0.61 ml, 6.21
mmol) was added thereafter and the mixture was stirred for further 24 h at
this temperature. The solvent was removed in vacuo and the remainig
residue was extracted with D C M (30 ml). The organic extract was washed
with water (2 x 10 ml), dried, evaporated and chromatographed (EtOAcLP,
40:60, v/v) to give two fractions. The first fraction was (141) (389 m g , 43%).
The solvent in the second fraction was evaporated to give (177) (302 m g ,
33%) as a colourless solid, hygroscopic. iH-Nmr (CDCI3) 8: 1.49-1.74 (m, 12H,
6 x C H 2 ) , 2.58 (s, 4H, 2 x C H 2 C O ) , 2.70 (dd, 1=17.3, J=2.7 Hz, 1H, CHAr), 2.89 (dd,

J=17.3,1=5.6 Hz, 1H, CHAr), 3.75-3.82 (m, 5H, CH3O, CH 2 N(CO) 2 ), 4.04-4.21 (m,
5H, 2 x C H 2 0 , C H N H ) , 5.08 (d, 1=7.9 Hz, 1H, N H ) , 6.45 (d, 1=8.2 Hz, lH ar0 m),
6.50 (d, 1=8.2 Hz, lH ar0 m), 7.08 (t, J=8.2 Hz, lHar0m)- M s (CI) m/z (%): 445 (48,
M+l), 240 (95), 206 (74).

Preparation of 5-Phenyl-3.4-dihydro-3-(ferf-butoxycarbonylamino)-2
benzopyran (156)

J^^~K^S

NHBoc

As described for (146) (Note: The phenyl bromic acid was dissolved
ethanol before addition; the solution was refluxed for overnight). The crude
product was chromatographed (LP:EtOAc, 95:5 and then 80:20) to give a solid
residue. This was then recrystallised from EtOAc/LP to give 5-phenyl-3,4-

dihydro-3-(tert-butoxycarbonylamino)-2H-l-benzopyran (156) (1.30 g, fr
2.485 of the starting material, 64%, 8 0 % based on the recovered starting
material), m p 116-118°C (EtOAc/LP). iH-Nmr (CDCI3) 8:1.44 (s, 9H, C(CH3)3),
2.58 (dd, 1=16.9, J=4.3 Hz, 1H, CHAr), 3.01 (dd, 1=16.9,1=4.3 Hz, CHAr), 4.144.21 (m, 3H, C H 2 0 , C H N H ) , 4.80 (s, 1H, N H ) , 6.87-6.92 (m, 2H a r 0 m), 7.22 (t,
J=7.6 Hz, lH ar0 m), 7.29-7.47 (m, 5H ar0 m).

13

C-Nmr (CDCI3) 8: 28.3 (C(CH3)3),

30.4 (CH2Ar), 43.3 (CHNH), 68.1 (CH 2 0), 116.0 (ArC-H), 117.2 (ArC), 122.6
(ArC-H), 127.2 (ArC-H), 127.3 (ArC-H), 128.2 (2 x ArC-H), 129.0 (2 x ArC-H),
140.5 (ArC), 143.7 (ArC), 154.1 (ArC), 155.1 (CO). M s (CI) m/z (%): 326 (10,
M+l), 270 (95), 226 (27). The mother liquor was evaporated to give the
starting material (0.5 g, 20%).

Preparation of 5-phenyl-34-dihydro-3-amino-2H-l-benzopyran (158a)

As described for (159a). 5-Phenyl-3,4-dihydro-3-amino-2H-l-

benzopyran (158a) was obtained as a colourless oil (0.80 g from 1
starting material, 100%). lH-Nmr (CDC13) 8: 2.47 (dd, 1=16.5,1=6.9
CHAr), 2.84-2.93 (m, 1H, CHAr), 3.26-3.38 (m, 1H, CHNH2), 3.85 (dd,

Hz, 1H, CHO), 4.19 (d, 1=10.1 Hz, 1H, CHO), 6.84-6.89 (m, 2Harom), 7.2
Hz, lHarorn), 7.29-7.46 (m, 5Harom).

13

C-Nmr (CDCI3) 8: 30.9 (CH2Ar), 44.1

(CH2NH2), 71.2 (CH20), 115.6 (ArC-H), 118.0 (ArC-H), 122.2 (ArC-H), 125.

(ArC), 127.1 (ArC-H), 128.1 (2 x ArC-H), 129.1 (2 x ArC-H), 140.8 (ArC),
(ArC), 154.0 (ArC). Ms (CI) m/z (%): 226 (95, M+l).

Preparation of 8-[N-(5-phenyl-3,4-dihydro-2H-l-benzopyran-3-yl)am
propyl]-8-azaspiro[4.5]decane-7,9-dione (158b)
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As described for (159b). Reaction was carried out at 60°C. The crude

product was chromatographed (EtOAcLp, 60: 40 and then 100:0) to gi

fractions. The solvent in the first fraction was evaporated to giv

mg, 23%) as a colourless gum. iH-Nmr (CDC13) 8: 1.42-1.73 (m, 12H,

2.49-2.60 (m, 5H, 2 x CH2CO, CHAr), 2.98 (dd, 1=18.8, J=7.3 Hz, 1H, C

(t, 1=6.0 Hz, 2H, CH2N(CO)2), 4.00-4.18 (m, 5H, CHNH, 2 x CH20), 5.03

Hz, NH), 6.79-6.88 (m, 2Harom), 7.18 (t, 1=8.0 Hz, lHarom), 7.26-7.45 (m,

5Har0m). The second fraction contained 8-[N-(5-phenyl-3,4-dihydro-2H-

benzopyran-3-yl)amino-propyl]-8-azaspiro[4.5]decane-7,9-dione (158

mg, 57%) as a colourless oil. lH-Nmr (CDCI3) 8: 1.42-1.75 (m, 12H

2.50-2.72 (m, 7H, 2 x CH2CO, CH^NH, CHAr), 2.80 (dd, 1=17.2, 1=6.3 H

CHAr), 3.00-3.05 (m, CHNH), 3.67-3.92 (m, 3H, CH2N(CO)2, CHO), 4.23-4

(m, 1H, CHO), 6.83-6.88 (m, 2Harom), 7.17 (t, 1=7.6 Hz, lHar0m), 7.29-7.
5Har0m). Ms (CI) m/z (%): 448 (75, M+l), 280 (25), 240 (95).

Preparation of 8-f4-N-Propyl-N-(5-phenyl-3,4-dihydro-2H-l-benzopyr
yl)amino-propyl]-8-azaspiro[4.5]decane-7,9-dione (158)

As described for (159);
EtOAcLP, 40:60, v/v.

chromatography was performed using

8-[4-N-Propyl-N-(5-phenyl-3,4-dihydro-2H-l-

benzopyran-3-yl)amino-propyl]-8-azaspiro[4.5]decane-7,9-dione (158
obtained as a colourless oil (471 m g from 775 m g of starting material, 53%).
iH-Nmr (CDC13) 8: 0.83 (t, 1=7.3 Hz, 3H, CH 3 ), 1.29-1.76 (m, 12H, 6 x CH 2 ), 2.332.78 (m, 8H, C H 2 N , 2 x C H 2 C O , CH 2 Ar), 3.02-3.13 (m, 1H, C H N ) , 3.75 (t, J=7.2
Hz, 2H, CH 2 N(CO) 2 ), 3.88 (t, 1=10.2 Hz, 1H, CHO), 4.30 (ddd, f=10.2, J=3.2,1=2.0
Hz, 1H, CHO), 6.84 (d, 1=7.8 Hz, lH a r o m ), 6.85 (d, 1=7.8 Hz, lH a r o m ), 7.17 (t, 1=7.8
Hz, lH ar0 m), 7.33-7.48 (m, 5H ar0 m). M s (CI) m/z (%): 489 (77, M+l), 268 (95).
Anal. Calcd for C3iH4oN203: C, 68.49; H, 7.31; N, 4.84. Found: C, 67.86; H, 7.23;
N, 4.84; H20,1.20. (164) was obtained as a colourless gum (130 mg, 14%) after
evaporation of solvent. iH-Nmr (CDC13) 8: 0.93 (t, 3H, 1=7.4 Hz), 1.34-1.72 (m,
14H, 7 x CH 2 ), 2.40-2.71 (m, 5H, 2 x C H 2 C O , CHAr), 3.00-3.20 (m, 3H, CHAr,
C H 2 N C O ) , 3.70-3.78 (m, 2H, CH 2 N(CO) 2 ), 3.99-4.26 (m, 5H, C H N , 2 x CH 2 0),
6.81-6.88 (m, 2H ar0 m), 7.16 (dd, }=7.6 Hz, lH ar0 m), 7.29-7.47 (m, 5H ar0 m).

Preparation of 5-Methoxy-3,4-dihydro-3-chloroacetamido-2H-l-benzo
(170)
H
N > ^^CH 2 C1

OCT T
0
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To a stirred solution of 5-methoxy-3,4-dihydro-3-amino-2H-lbenzopyran (135)45 (1.075 g, 6.00 mmol) in D C M (30 ml), in an ice bath and
under argon, was added chloroacetyl chloride ( 0.54 ml, 6.741 mmol). The
solution was allowed to continue stirring overnight. Water (30 ml) was then
added and the two layers were separated. The aqueous phase was extracted
with further D C M (3 x 20 ml). The combined organic extracts were dried and
evaporated to give 5-methoxy-3,4-dihydro-3-chloroacetamido-2H-lbenzopyran (170) (1.504 g, 98%) as a pale yellow solid. iH-Nmr (CDC13) 8: 2.77
(dd, 1=17.6,1=2.4 Hz, 1H, CHAr), 2.96 (dd, 1=17.6,1=5.75 Hz, 1H, CHAr), 3.84 (s,
3H, OCH3), 4.06 (s, 2H, CH 2 C1), 4.12-4.16 (m, 2H, CH 2 0), 4.49-4.55 (m, 1H,
C H N H ) , 6.50 (d, J=8.1 Hz, lH ar0 m), 6.56 (d, 1=8.1 Hz, lH ar0 m), 6-82 (broad s, 1H,
N H ) , 7.14 (t, 1=8.1 Hz, Harom).

Photolysis of 5-Methoxy-3,4-dihydro-3-chloroacetamido-2H-l-benzopy
(170) in Benzene
A solution of (170) (500 mg, 1.966 mmol) in benzene (350 ml) was
irradiated for 3 h using 500 W

mercury lamp. The solvent was then

evaporated and the remaining crude residue was chromatographed
(EtOAcLP, 75:25 and then EtOAc:LP:MeOH, 75:23:2, v/v) to give two
fractions. The first fraction was the starting material (110 mg, 22%). The
solvent in the second fraction was evaporated to give 5-methoxy-3,4-

dihydro-3-acetamido-2H-l-benzopyran (171) (110 mg, 26%) as a pale yellow
oil. iH-Nmr (CDCI3) 8:1.99 (s, 3H, COCH3), 2.75 (d, 1=17.5 Hz, 1H, CHAr), 2.89
(dd, J=17.5,1=5.5 Hz, 1H, CHAr), 3.83 (s, 3H, CH3O), 4.03-4.19 (m, CH 2 0), 4.504.55 (m, C H N H ) , 5.88 (broad s, 1H, N H ) , 6.49 (d, J=8.2 Hz, lHarom), 6.54 (d,
1=8.2 Hz, lHarom), 7.13 (t, J=8.2 Hz, lHarom)-

OCH

Photolysis of 5-Methoxy-3,4-dihydro-3-chloroacetamido-2H-l-benzopyran
(170) in a Mixture of Acetonitrile and Water
A solution of (170) (627 m g , 2.454 m m o l ) in a mixture of acetonitrile
and water was irradiated for 2 h using 500 W

mercury lamp. The solvent

was then evaporated and the remaining crude residue was extracted with
D C M (30 ml). The extract was washed with water (10 ml), dried, evaporated
and chromatographed (EtOAcLP, 80:20 and then 100:0) to give 5-methoxy3,4-dihydro-3-hydroxyacetamido-2H-l-benzopyran (172) (116 m g , 20%) as a
pale yellow oil. iH-Nmr (CDC13) 8: 2.72 (dd, J=17.4,1=3.4,1H, CHAr), 2.92 (dd,
J=17.4, J=7.0 Hz), 3.80 (s, 3H, C H 3 O ) , 4.03 (s, 2H, C H 2 O H ) , 4.07-4.10 (m, 2H,
C H 2 0 ) , 4.45^.49 (m, 1H, C H N H ) , 6.47 (d, 1=8.0 H z , lH ar om), 6.51 (d, 1=8.0 Hz,
lHarom), 7.01 (d, 1=7.9 Hz, 1H, N H ) , 7.09 (t, 1=8.0 Hz, l H a r o m ) -

OCH

Equipments and Methods for Bindings to 5HT? Receptors
Products to be tested or reference compounds (eleven concentrations,
10"5 M to 10'12 M ) were incubated with membrane preparation. Radioligand,
non specific binding, cloned receptors, reference products, protein
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concentration, buffer, incubation time and temperature are indicated in the
table below.

Receptor

5HT7

Reference
products

Radioligand

[3H]-Lysergic acid
diethylamide
N E N batch 3235-049
S.A = 88 Ci/mmol
3.3 n M

Prot.

mL 1

Metergoline

16 ug
Methiothepin

Non-specific
binding

10" 5 M
Methiothepin

Binding
buffer
TrisHCl 50mM
pH 7.4 +
MgS0 4 lOmM +
EDTA 0.5 m M

Cloned
receptor

Human 5HT7
Biosignal batch
692203
cloned receptor

Incubation
time,
temperature

120 minutes
27°C

Methiothepin w a s from Tocris Cookson (Langford, Bristol U.K.) and
Metergoline from Virbac (Carros, Nice Fr).

-Competition experiments were analysed using the interactive non linear
least-squares curve fitting program, "inplot4, graphed". Kj were determined
using the method of Cheng and Prussof.

Equipments and Methods for Bindings to 5HTi A Receptors
Products to be tested or reference compounds (eleven concentrations,
10"5 M to 10"11 M ) were incubated with membrane preparation. Radioligand,
non specific binding, structure, reference products, protein concentration,
buffer, incubation time and temperature are indicated in the table below.

Receptor

5HT1A

Reference
products

Radioligand

[3H] -8-OH-DPAT
N E N batch 2923-137
S.A.= 143.8 Ci/mmol
0.5 n M
+ 0.1% ascorbic acid

Prot.
ml"1

Buspirone
0.6 m g
WB4101

Non-specific
binding

10*5M

Structure

Bovine
Hippocampus

Buspirone

Binding
buffer

TrisHCl 5 0 m M
p H 7.4 +
CaCl 2 4 m M +
Pargyl. 10 ug

Incubation
time,
temperature

40 minutes
23°C

Buspirone was from Sigma (St Louis.MO) and WB4101 from R.B.I. (Natick,

MA).

-Competition experiments were analysed using the interactive non linear

least-squares curve fitting program, "inplot4, graphed". Kj were determine
using the method of Cheng and Prussof.
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Appendix 1

Non-hydrogen atom coordinates and equivalent isotropic thermal
parameters of the cyclophane (64). y(c(l)) defines the origin.

Atom

C(l)
0(2)
C(3)
C(4)
C(5)
0(5)
N(6)
C(7)
C(71)
0(71)
0(72)
C(72)
C(8)
C(9)
C(10)
C(ll)
C(12)
0(12)
C(121)
C(13)

x

0.039(2)
0.087(1)
-0.049(2)
0.052(2)
-0.054(2)
-0.294(1)
0.129(1)
0.079(2)
0.167(2)
0.090(2)
0.331(2)
0.417(3)
0.213(2)
0.113(2)
-0.093(2)
-0.224(2)
-0.169(2)
-0.299(1)
-0.479(2)
0.191(2)

y

1.0(-)
0.938(1)
0.785(2)
0.643(2)
0.643(2)
0.662(1)
0.616(1)
0.674(2)
0.559(2)
0.572(2)
0.450(1)
0.334(2)
0.844(2)
0.962(2)
1.070(2)
1.150(2)
1.109(1)
1.166(1)
1.294(2)
0.938(1)

z

0.8501(5)
0.9282(3)
0.9379(5)
0.8865(5)
0.7979(5)
0.7816(3)
0.7429(4)
0.6598(5)
0.5958(6)
0.5260(4)
0.6215(4)
0.5612(6)
0.6477(5)
0.7077(5)
0.6897(5)
0.7507(5)
0.8307(5)
0.8954(3)
0.8824(6)
0.7896(5)

102UPnA2

0.041(4)
0.050(3)
0.051(4)
0.044(3)
0.035(3)
0.044(2)
0.035(3)
0.044(3)
0.058(4)
0.127(5)
0.087(4)
0.103(6)
0.042(4)
0.040(4)
0.049(4)
0.048(4)
0.038(3)
0.056(3)
0.061(4)
0.036(3)
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Appendix 2

Non-hydrogen positional and isotropic displacement parameters of
oxazolobenzazepinone (88).

atom

0(1)
C(2)
C(3)
0(3)
N(4)
C(5)
C(6)
C(6a)
C(7)
C(8)
0(8)
C(81)
C(9)
0(9)
C(91)
C(10)
C(10a)
C(ll)
C(lla)
0(lla)
C(l')
C(2')

x/a

0 .66213
0 .6272(4)
0 .6040(3)
0 .5671(3)
0..6319(3)
0 .6148(3)
0 .5577(4)
0..5000(3)
0..4166(3)
0 .3630(3)
0..2799(2)
0..2461(4)
0 .3953(3)
0 .3382 (2)
0..3661(5)
0 .4788(3)
0 .5317(3)
0 .6238(3)
0..6683 (3)
0 .7497(2)
0..8041(4)
0..8874(4)

y/b

0..8901(4)
0..7441(7)
0..6160(6)
0..4775(5)
0..6829(4)
0..6017(7)
0..7149(9)
0..8334(6)
0..8048(7)
0 .9142(5)
0 .8984(4)
0 .750(1)
1 .0607(5)
1 .1648(4)
1 .3214(9)
1 .0865(6)
0 .9754(5)
1 .0016(7)
0 .8564(5)
0 .8607(4)
0..7331(8)
0 .764(1)

z/c

0 .35882
0 .2867(5)
0..3581(4)
0 .3267(4)
0..4621(4)
0..5532(5)
0 .5918(5)
0..5000(4)
0 .4572(4)
0 .3761(4)
0 .3309(3)
0 .3656(8)
0 .3388(4)
0 .2617(4)
0 .2293(8)
0 .3809(4)
0 .4614(4)
0 .5072(5)
0 .4701(4)
0 .5451(3)
0 .5247(6)
0 .6023(7)

U(eq) A**2

0 .059(1)
0 .062 (2)
0 .056(2)
0 .083(2)
0..051(1)
0..062(2)
0..073(2)
0..053(2)
0..056(2)
0 .048(2)
0 .062(1)
0 .092 (3)
0 .048(2)
0 .067(1)
0 .091(3)
0 .051(2)
0 .048(2)
0 .058(2)
0 .050(2)
0 .061(1)
0 .083 (3)
0 .082(3)
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Appendix 3

NOVASCREEN receptor selectivity report on the hexahydropyrano
isoquinoline (123).

Initial
Percent
Inhibition
(Average; N=2)
Receptor/
Selectivity

Reference
Compound

Reference Ki(nM)

10"5M

Verification
Percent
Inhibition
(Average; N=2)

10-5M

Heurotr ansmi 11 er s
Adenosine
Alpha 1
Alpha 2
Beta
Dopamine 1
Dopamine 2
GABAA
GABAB
Serotonin 1
Serotonin 2
Nicotinic
NMDA
Kainate
Quisqualate
Glycine (stry sens.)

NECA
Prazosin
RX 821002
Alprenolol
SCH 23390
Sulpiride
Muscimol
Baclofen
Serotonin
Methysergi< de
Nicotine Sulfate
NMDA
Kainic Aci(i DME
Quisqualic Acid
Strychnine Nitrate

7.25
14.15
12.42
12.42
4.59
7.53
6.56
100.32
4.60
5.50
1.87
6358.47
1471.56
49.81
197.22

2.1
5.5
4.4
4.3
0.4
24.5
4.9
198.2
2.1
-0.9
13.4
7.7
-9.5
1.9
28.3

R0-151788
Glycine
MK-801
MK801

0.66
0.00
26.82
2.36

0.9
-44.4
6.1
0.5

Angiotensin II
Angiotensin II
arg-Vasopressin
CCK
CCK
Substance P

13.01
0.05
1.59
1.27
0.26
12.99

3.2
-2.6
4.5
4.3
5.9
-5.8

Regulatory Sites
Benzodiazepine (centrl)
Glycine (stry insens.)

PCP
MK-801
Brain/Gut Peptide s
Angiotensin Ty 1
Angiotensin Ty 2
Arg-Vasopressin V 1
CCK Central
CCK Peripheral
Substance P

du lic te t
P
a a "^!ched
Values are expressed as the percent inhibition of specific binding .and represent the average of
;ent innib
inhibition of fifty percent or greater (see attached
5L???h oi the concentrations tested. Bolded values represent
Verification Report) .
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Receptor/
Selectivity

Reference
Compound

Reference Ki(nM)

Initial
Percent
Inhibition
(Average; N=2)

Verification
Percent
Inhibition
(Average; N=2)

10"5M

10-5M

Brain/Gut Peptides
Substance K
NPY
Neurotensin
Somatostatin
VIP

3.77
0.45
6.34
0.62
0.20

9.3
14.4
9.1
2.4
47.0

EGF

0.29
0.87

•7.3
4.7

w-Conotoxin
Nifedipine
TBPS
Apamin

0.01
0.99
1.63
0.04

0.0
1.5
9.6
-3.2

20.71
12.01
17.67

-13.0
-6.7
-3.8

513 .81
801 .04
32 .81
1938,.73

6 .2
24 .4
18 .4
20 ,7

Neurokinin A
Neuropeptide
Neurotensin
Somatostatin
VIP
,^

Growth Factors & Peptides
ANF1 ANP
EGF
Ion Channels
Calcium (Type N)
Calcium (Type T & L)
Chloride
Potassium (low conduct)
Second Messengers
Forskolin
Phorbol Ester
Inositol Triphosphate

Forskolin
PDBU
IP3

Uptake Sites
Dopamine Reuptake
Norepinephrine Uptake
Serotonin Uptake
Choline Uptake

RS Bupropion
Desmethylimip ramine
Imipramine
Choline

nt the
the average
average of
duplicate tubes
^ues are expressed as the percent inhibition of specific binding and represent
of dup
ift-„ ra.rcmf nr nrparsr see attacneu
5[ each of the concentrations tested. Bolded values represent inhibition of fifty percent
or great:
'erification Report) .
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